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Chapter 1: General Introduction 
The research reported in this thesis was prompted by a series of studies in which a test battery 
for use in pharmacological research comprising a wide range of psychomotor and cognitive 
tests was evaluated. The test battery was used in all the studies presented here and includes 
tests of memory, attention, response speed and other motor-output measures, problem solving 
and planning, and several additional aspects of neuropsychological functioning. An account of 
WKHGHYHORSPHQWRIWKHWHVWEDWWHU\DQGWKHWHVWV¶GHVFULSWLRQVDUHJLYHQLQDSSHQGL[,$OOWKH
current studies investigated the acute effects of clinically relevant (neuro)psychiatric drugs in 
healthy volunteers. Because the results on memory performance were the most prominent and 
LQWULJXLQJPHPRU\EHFDPHWKHFHQWUDOWKHPHRIWKLVWKHVLVZLWKWKHGUXJV¶HIIHFWVRQ
psychomotor processes taking a back seat.  
 
Memory - background 
Memory is one of the most essential cognitive functions in everyday life and critical for our 
identity as individuals in how we recollect and interpret past experiences and act upon and 
anticipate present and future experiences (Curran and Mintzer 2006). With a growing elderly 
population, age-associated memory loss and dementia pose an increasing burden for health 
care. There is also an increasing awareness that psychiatric populations frequently 
concomitantly suffer from memory impairments, either related, as in schizophrenia, or 
unrelated, as in depression, to the core symptoms of the disease, which further hamper the 
patients in their daily lives. Conversely, sometimes the pharmacological treatments for these 
syndromes can negatively affect memory functions, with benzodiazepines and drugs with 
anticholinergic properties being most notable. 
With this in mind, it is evident why in the field of (psycho)pharmacology memory 
research is so important: we urgently need to find clinically effective drugs that have fewer or 
no adverse effects like impaired memory. It is essential that both in drug development and in 
patient care we disentangle the cognitive side effects (memory deficits) from those on 
alertness. They often occur simultaneously whereas only one is wanted, e.g. sedation in very 
anxious or agitated patients, and the other is not as memory impairments, for instance, may 
lead to an inability to attend other therapies. Hence, the first research question posed in this 
thesis is: Can we separate alertness effects from memory effects in existing drugs? 
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As stated above, (psycho)pharmaca-based memory research is of the utmost 
importance because we have a growing number of elderly people in our community that are 
all at risk of developing a dementia for which there are, as yet, few truly effective 
psychopharmacological treatments. Cholinesterase inhibitors were the first to be developed 
and have been applied since 1997 (Birks 2006). Although they have a moderately positive 
effect on global cognitive functioning, they have not been proven to enhance the autonomy of 
HOGHUO\SDWLHQWVVXIIHULQJIURP$O]KHLPHU¶VGLVHDVH$'9DQ+DOWHUHQHWDODFFHSWHGIRU
publication in Neuropsychology Review). In a Cochrane review on the placebo-controlled 
effects of the first registered cholinesterase inhibitor rivastigmine on the cognition of AD 
patients, a moderate but significant increase of 0.8 points was found on the Mini Mental State 
([DPLQDWLRQ006(DQGDQLQFUHPHQWRISRLQWVRQWKH$O]KHLPHU¶V'LVHDVH$VVHVVPHQW
Scale (ADAS-Cog;(Birks et al. 2003). Newer drugs like donepezil and galantamine also 
reduced cognitive impairments in AD patients, but again the improvements failed to 
significantly improve their daily lives (Takeda et al. 2006). The search for more effective 
drugs continues with studies exploring the working mechanism of both known and new drugs 
forming part of the quest. 
With memory problems in psychiatric populations receiving growing attention, the cry 
for more effective treatments for patients with schizophrenia, major depression, bipolar 
depression and ADHD has also become stronger. The second major goal of the current thesis 
was to more closely investigate drugs that are designed to improve cognitive performance, 
more specifically memory. 
Finally, the collected studies were also prompted by the relative lack of randomized, 
placebo-controlled trials in humans that focus on memory functions. A combined Medline, 
PsychInfo, Embase search conducted in March 2007 yielded only 410 hits with the tag 
TREATMENT-OUTCOME-CLINICAL-TRIAL and the search term µPHPRU\¶DVFRPSDUHG
to 295.985 hits for memory without the tag.  
 Next, the state of the art in drug-based memory research is discussed, highlighting the 
aspects we sought to answer by our studies.  
 
Memory and the influence of other cognitive processes 
By targeting different stages of memory processing, drugs can differentially affect memory 
performance.  
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Figure 1. Schematic overview of memory and other memory-related cognitive processes 
(adapted from Milner, 1998) with the stars indicating processes that can be affected by 
(psycho)pharmacological agents. 
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They can, for instance, impinge on the encoding, consolidation or retrieval stages, as the stars 
in the model for memory processes and related processes depicted in Figure 1 indicate. 
Benzodiazepine studies in which the drug administration times were manipulated showed that 
the agents only affected performance when they were taken before a wordlist needed to be 
memorized and not when they were taken  prior to word retrieval after the list had been 
learned. This implies that benzodiazepines alter the information-encoding process and not 
directly consolidation and retrieval of the information, which is attributable to a true memory 
HIIHFWDQGQRWRQO\WRWKHDJHQWV¶HIIHFWVRQDOHUWQHVVWKDWDUHDOZD\VSresent as well (Buffett-
Jerrott et al. 1998).  
Some drugs, like ampakines, for example, affect the consolidation process due to their 
cellular effect on long-term potentiation (LTP). Ampakines are positive allosteric modulators 
of the AMPA-type glutamate receptors (Lynch 2002) that are being developed to improve 
memory in several neuropsychiatric disorders (Lynch et al. 2003).  
Another type of drug that will feature in this thesis is a cholinesterase inhibitor that has 
specifically been developed for the treatment of AD (on which more in a later section). Like 
benzodiazepines, these compounds have an effect on the encoding stage but they do so by 
improving a signal-to noise ratio and therefore affect the encoding process through attention-
related actions rather than memory-dependent processes (Lucas-Meunier et al. 2003).  
 
Memory and alertness 
How to separate sedative from amnesic effects  
Memory performance is dependent on more than memory processes alone. Below, we 
summarize the main issues in memory research that pertain to alertness states (decreased 
DOHUWQHVVXVXDOO\WHUPHGµVHGDWLRQ¶DQGLQFUHDVHGDOHUWQHVVRUDURXVDODQGDWWHQWLRQDV
mediators of memory performance. 
The verbal memory test (VMT) is widely used to assess the effects of drugs on 
memory since they measure declarative, episodic memory: immediate and delayed free recall 
of words, as well as word recognition are evaluated. The immediate recall of words reflects 
WKHVXEMHFW¶VFDSDFLW\IRUVKRUW-term memory storage and the delayed recall condition his or 
her capacity for long-term storage. As both recall conditions are sensitive to distractions and 
fluctuations in alertness and attention, impaired performance does not necessarily indicate an 
impaired memory capacity. As word recognition is less sensitive to such fluctuations, the 
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recognition trial directly follows the delayed recall condition, whose outcome are always 
compared. Impaired free recall in the absence of impaired recognition may still indicate a 
memory problem, i.e. a retrieval problem, although it might also reflect deficient arousal or 
attention (Baddeley 1998; Lezak 2006).   
In order to separate memory from alertness effects we need to ascertain that none of 
WKHGUXJ¶VHIIHFWVGXULQJDPHPRU\WHVWDUHGXHWRVHGDWLRQEXWUDWKHUWR a specific effect on 
memory. Unfortunately, almost all amnesic drugs used in memory research also have sedative 
effects (Ghoneim 2004) which are known to confound the memory-function assessment 
(Curran et al. 1998; Curran and Birch 1991; Fluck et al. 1998; Huron et al. 2002; Lucchesi et 
al. 2003). Curran et al. (1991; 1998) proposed a variety of strategies to help differentiate the 
sedative from the amnesic effects (also see the review by Ghoneim, 2004) and the studies that 
used the recommended approaches reported the following results:  
1. After covarying for sedation, using a statistical method in which scores on a sedation 
measure become covariates, memory effects remained present (Curran 1991; Ghoneim 
and Mewaldt 1990; Veselis et al. 1997).  
2. Drugs showed a differential pattern of tolerance to sedation and memory when they were 
taken repeatedly (Curran et al. 1994; Ghoneim et al. 1981; Lucki et al. 1986; Tata et al. 
1994).  
3. Dose-effect curves for sedation and memory differed per drug (Rich and Brown 1992; 
Roache and Griffiths 1985; Weingartner et al. 1995).  
4. Drugs showed a differential reversal of the sedative and/or amnesic effects when a 
selective antagonist was added (Curran and Birch 1991; Hommer et al. 1993). 
5. Different drugs showed similar sedation effects but different memory effects or vice versa 
(Curran et al. 1998; Green et al. 1996).   
 
We used the first and the last of these differentiating approaches in two of our studies. In 
Chapter 2 we covaried for sedation to evaluate the sedative impact of an acute dose of 
haloperidol and olanzapine on memory. The earlier studies by Rich and Brown, Roach and 
Griffiths, and Weingartner entailed drugs targeting the GABAergic systems, and we wished to 
find out whether the approach would also hold for antipsychotic drugs that target other 
receptors systems like the histamine-1 receptors.  
Although both Curran (1998) and Green (1996) had demonstrated the usefulness of the 
fifth approach , with the exception of a visual analogue scale (VAS), they used different types 
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of sedation measures. In Chapter 3 we investigated the effects of four drugs known to have 
both memory and sedative side effects using the fifth comparative approach but now with a 
fixed and larger set of memory and sedation measures. We were keen to find out whether the 
sedative patterns on the subjective rating scales (VAS) and objective tests -among which a 
symbol digit substitution task (SDST), tests assessing reaction time (SRT, CRT), and saccadic 
eye movements (EOG)- would be similar for the different drugs because sedation may depend 
on more than one single pharmacological mechanism of action (Bourin and Briley 2004). In 
addition to simple drug-placebo differences, we also looked into the strength of the drug-
LQGXFHGHIIHFWVE\FDOFXODWLQJ&RKHQ¶VGHffect sizes (Cohen 1988; Snyder et al. 2005). 
Irrespective of the overlap between sedation and memory, and assuming that some drugs 
specifically induce more sedation and others tend to affect memory more, we expected the 
different drugs to show a different profile of effects across measures.  
 
Memory and sedation: Which drugs and hence which neurotransmitter systems cause 
which effects? 
In Chapters 2 and 3 the effects of haloperidol, olanzapine and in Chapter 3 the effects of 
mirtazapine were studied as these drugs have in part an anti-histaminergic effect on central 
KLVWDPLQH+UHFHSWRUVZKLFKLVWKHSUREDEOHFDXVHIRUWKHGUXJV¶XQZDQWHGVHGDWLYHDQG
sometimes amnesic side effects (Bourin and Briley 2004). Two reviews on the effects of anti-
histamines that are used to treat allergies show that the anti-histaminergic effect causes 
impairments in both objective measures of cognitive functioning (psychomotor speed, 
attention, memory, etc.) and subjective measures (self-evaluations) (Hindmarch and Shamsi 
1999; Shamsi and Hindmarch 2000).  
$VWKHSUHYLRXVLQYHVWLJDWLRQVWKDWWHVWHG&XUUDQDQG*KRQHLP¶VILYHGLIIHUHQWLDWLQJ
approaches all studied drugs targeting the GABAergic system (benzodiazepines), we decided 
to also include lorazepam as a reference drug in our study described in Chapter 3. Apart from 
an anxiolytic effect, lorazepam has known, distinct effects on both memory and attention and 
also causes sedation. Lorazepam is a benzodiazepine with a non-selective affinity profile for 
GLIIHUHQWĮ-receptor subtypes (Pompeia et al. 2005). Pharmacological studies in knock-out 
mice have shown that explicit memory performance appears to be affected through GABAA 
UHFHSWRUVFRQWDLQLQJWKHĮDQGĮVXEXQLWVZKHUHDVWKHHIIHFWVRQSURFHGXUDOPHPRU\
appears to be mainl\PHGLDWHGE\WKHĮVXEXQLW&UHVWDQLHWDO0RKOHUHWDO
6DYLFHWDOD6DYLFHWDOE7KHĮVXEXQLWSUHVHQWLQRIDOO*$%$A 
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UHFHSWRUVLVDOVRUHVSRQVLEOHIRUWKHVHGDWLYHDQGDQWLFRQYXOVDQWVLGHHIIHFWV7KHĮUHFHSWRUV
are responsible for anxiolytic actions, they represent 15-20 % of all GABAA receptors and are 
the major GABAA receptors found in the amygdala (McKernan et al. 2000; Mohler et al. 
2004).  
 
Memory and arousal 
If decreasing alertness impairs memory performance, does increasing alertness improve it? In 
general, there is an optimal relationship between arousal and performance that follows the 
Yerkes Dodson Law (1908), which they discovered while studying brightness discrimination 
learning in mice: increased electrical shocks enhanced performance, but only up to a point. 
After that point, further increases of shocks tended to impair performance. The relationship 
between shock intensity and performance followed an inverted U-shaped function. 
Subsequent studies demonstrated that the principle also applied to arousal induced by other 
stressors (Schmidt and Lee 1999) or arousal-enhancing substances like dopamine (Cohen et 
al. 2002) and ChEis (Braida and Sala 2001).  
Task complexity was also identified as a factor in this function, as is shown in Figure 
2. The level of arousal needed to maintain an optimal level of performance proved dependent 
on task complexity: for simple tasks the optimal level of arousal is higher than for more 
complex tasks.  
  
 
Figure 2. Yerkes Dodson law relating task complexity and arousal to task performance. 
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Surprisingly, pharmacological studies into increased arousal and memory are far fewer than 
those studying decreased arousal (sedation) and memory, which is why we conducted an 
effect study of d-amphetamine.  
 
Does d-amphetamine enhance performance in depressive patients? 
Dopamine, a neurotransmitter with arousing properties, is not a direct modulator of memory 
performance in general, but as it increases the overall arousal level in subjects, it can have an 
indirect effect by increasing the resources needed to perform an usually effortful memory test. 
Dopaminergic drugs designed to improve performance in patients are sometimes used for the 
same purpose by healthy people. Army pilots, for example, take d-amphetamines during long 
flight operations to combat fatigue (Caldwell et al. 2003; Caldwell and Caldwell 1997; 
Emonson and Vanderbeek 1995; Kenagy et al. 2004). In addition, there are reports (Butcher 
2003) that academic students in the USA are also using drugs originally indicated for ADHD 
(methylphenidate and d-amphetamine) to enhance their ability to focus and study. 
For our arousal study we opted for 15mg d-amphetamine as positive effects were 
earlier demonstrated for free recall of episodic memory measures and working memory in 
both depressed patients and patients with schizophrenia or schizophrenia spectrum personality 
disorders and in healthy volunteers (Barch and Carter 2005; Kirrane et al. 2000; Reus et al. 
1979; Soetens et al. 1993; Soetens et al. 1995). However, there is also evidence to suggest that 
d-amphetamine has effects on other cognitive measures than memory (Goldberg et al. 1991). 
The latest findings are that dopaminergic drugs like d-amphetamine follow an inverted U-
shaped dose-response function with respect to cognitive performance and that they especially 
affect working memory, the more executive part of memory (see Figure 1;(Cohen et al. 2002; 
Mattay et al. 2000; Tipper et al. 2005).  
So far, only one study relating alertness to memory was performed. Mintzer and 
Griffiths (2003) used d-amphetamine to reverse sedation caused by triazolam to investigate 
the role of benzodiazepine-induced sedation on memory processes. They found that d-
amphetamine reversed the effects of triazolam on all subjective sedation and psychomotor 
SHUIRUPDQFHUDWLQJVDQGVHOHFWLYHO\UHYHUVHGWKHDJHQW¶VPHPRU\-impairing effects on 
working memory and free recall of an episodic memory task (the more complex of memory 
functions), but not on recognition in an episodic memory task and digit recall (a less effortful 
task). 
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Prefrontal dopaminergic dysfunction and psychomotor slowing  
D-amphetamine enhances dopamine (DA) and noradrenalin (NA) levels especially in the 
prefrontal cortex (PFC). Several psychiatric syndromes and symptoms are linked to 
diminished prefrontal dopaminergic functioning of which psychomotor slowing, an 
objectively observable slowing in the cognitive and motor behaviour of patients suffering 
from a major depressive episode (DSM IV), is an example. 
The symptom is important for both the diagnosis and treatment of depression: two 
studies reported psychomotor slowing to be a predictor of non-response to treatment with a 
selective serotonin reuptake inhibitor (SSRI) in both younger and elderly depressed patients 
(Kalayam and Alexopoulos 1999; Taylor et al. 2006). The observed SSRI non-response was 
assumed to be associated with dopaminergic dysfunction in the prefrontal cortex (PFC) and 
subcortical areas, a dysfunction not directly targeted by SSRIs. These results led to the 
conclusion that treatment strategies in refractory patients exhibiting signs of psychomotor 
slowing should include enhancement of dopaminergic neurotransmission (Taylor et al. 2006). 
It were these results that underlined the importance of studying psychomotor performance in 
relation to dopaminergic enhancement and prompted our study presented in Chapter 4. 
Various techniques have been applied to study psychomotor slowing (Sabbe et al. 
1998a; Sabbe et al. 1998b; Sobin and Sackeim 1997). Several researchers used tasks primarily 
gauging visuomotor processes because such tasks tap both cognitive processes (speed of 
information processing) and motor abilities (movement speed) and previous research had 
found slowing in both processes in depressed patients with severe psychomotor slowing (Pier 
et al. 2004a; Pier et al. 2004b; Sabbe et al. 1999). Many of the tests we incorporated in our 
present test battery have been exploited to measure various aspects of psychomotor 
functioning. 
With the study described in Chapter 4 we wished to investigate whether dopaminergic, 
or to be more precise, catacholaminergic enhancement by d-amphetamine would facilitate 
information-processing or motor performance, or both, in depressive patients. Being able to 
differentiate the effects of dopaminergic compounds on the various cognitive processes is 
crucial because it might provide insight into how drugs might improve psychomotor slowing 
and possibly other cognitive processes in depression and other syndromes characterized by 
prefrontal dopaminergic dysfunction.  
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Improving memory 
Pharmacotherapy for dementia: Acetylcholine and memory 
7KHWKHVLV¶VHFRQGREMHFWLYHFRQFHUQHGPHPRU\-enhancing agents. Pharmacotherapy for mild 
to moderate AD is new, having started in 1997 with the cholinesterase inhibitors rivastigmine, 
donezepil and galantamine (Birks 2006). 
Originally, insight into the major role the central cholinergic system plays in memory 
arose from the finding that cognitive deficits are correlated with extensive cholinergic cell 
ORVVLQWKHEUDLQLQ$O]KHLPHU¶VGLVHDVH3KDUPDFRORJLFDOVWXGLHVLQERWKDQLPDOVDQGKXPDQV
demonstrated impaired cognitive performance after central cholinergic pathways had been 
blocked by use of anticholinergic drugs. Subsequent studies showed the process could be 
reversed by enhancing the cholinergic function with a treatment of cholinesterase inhibitors 
(ChEis;(Blokland 1995; Everitt and Robbins 1997; Muir 1997). The proposed memory-
enhancing working mechanism of acetylcholine (ACh) is that it enhances the signal-to-noise 
ratio (Lucas-Meunier et al. 2003). 
These new insights led to the development of drugs for AD and recently a Cochrane 
review compared the results of 13 randomized, double-blind, placebo-controlled trials with 
rivastigmine, donezepil and galantamine. It was found that for patients with dementia due to 
AD treatment at the recommended doses lasting 6 and 12 months produced moderate 
improvements in cognitive functioning as measured using the ADAS-Cog Scale (on average -
2.7 points (95%CI -3.0 to -2.3), in the midrange of the 70-point ADAS-Cog Scale). Clinicians 
rated the global clinical state and measures of activities of daily living and behaviour of 
cholinesterase inhibitor-treated patients more positively than they did for non-treated patients. 
Unfortunately, none of the treatment effects were large and the extent of adverse events, i.e. 
nausea, vomiting and diarrhoea, was substantial (Birks 2006). 
The search for better, more effective drugs continues by exploring the working 
mechanism of known drugs for clues. As most studies into the effects of cholinesterase 
inhibitors have been in clinical populations, the exact effect of these drugs on memory 
performance remains unknown. As the patients with manifest AD are often already 
considerably impaired in their cognitive functioning, the standard, sophisticated tests used to 
gauge the different processes associated with memory performance cannot be administered. 
Moreover, comprehensive and systematic evaluations of the cognitive effects of these agents 
in healthy volunteers are as yet lacking. 
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There are, however, studies in healthy volunteers for other types of cholinergic drugs. 
Concurrently with the development of drugs for AD, the discovery of the relationship 
between acetylcholine and memory generated a complete line of more fundamental memory 
research as well. Most of the human research in healthy, testable volunteers focused on 
learning and memory performance and looked into the actions of the anticholinergic drug 
scopolamine and the ChEi physostigmine. Imaging studies showed that cholinergic 
modulation in combination with memory performance caused activation changes in two types 
of functional anatomical areas: the learning- and memory-related areas like the hippocampus, 
inferior temporal cortex, prefrontal cortex and anterior cingulate, but also the information-
processing areas like the fusiform gyrus and other extrastriate areas (Ernst et al. 2001; Furey 
et al. 2000; Furey et al. 1997; Rosier et al. 1999; Sperling et al. 2002). 
Because in animal studies new, highly selective toxins for the cholinergic system often 
did not cause impairments in memory performance but selectively in attention and 
visuospatial performance, the focus in this line of research shifted from memory to attention 
(Baxter and Gallagher 1996; De Rosa et al. 2001; Everitt and Robbins 1997; Gutierrez et al. 
1999; Torres et al. 1994).  
In the study presented in Chapter 5 we investigated two cholinergic drugs with an 
opposite effect on the cholinergic system in healthy, elderly volunteers: the effects of 
biperiden, an anticholinergic drug, were compared to the effects of rivastigmine, a 
cholinesterase inhibitor, to asses which memory processes are affected by acetylcholine 
modulation. Both drugs are relatively selective for the CNS (Enz et al. 1993) and biperiden is 
also rather selective for the muscarinic 1 (M1) receptor (Bymaster et al. 1993; Jones and 
Shannon 2000). The main question in the study was whether in humans selective cholinergic 
drugs would show similar results as the very selective cholinergic lesioning did in animals, 
i.e. would they affect memory less and attention and visuospatial processing more when 
compared to non-selective cholinergic modulations? 
  
Pharmacotherapy for other neuropsychiatric disorders: Glutamate and ampakines 
:LWKWKHLQFUHDVLQJDZDUHQHVVWKDWEHVLGHV$O]KHLPHU¶VSDWLHQWVRWKHUQHXURSV\FKLDWULF
populations, e.g. patients diagnosed with schizophrenia, are suffering from cognitive and 
memory impairments as well, the need for effective treatments for these patient groups has 
also grown. One line in drug development research focuses on ampakines, positive allosteric 
modulators of the AMPA-type glutamate receptors (Lynch 2002) that have a positive effect 
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on LTP, an important mechanism by which memories are formed. It is proposed that at a 
molecular level glutamate, which is the major excitatory transmitter in the hippocampus, 
binds with NMDA or AMPA receptors, which leads to the unblocking of magnesium ions 
(Mg2+) when the membrane is depolarized. This means that these receptors are transmitter- 
and voltage-dependent. When these two conditions have been met, calcium (Ca2+) can enter 
the cell, which is critical for LTP. Ca2+ is an intracellular messenger giving the signal that 
changes enzyme activities that influence synaptic strength. A mechanism for improving 
memory would then be to facilitate depolarization and thereby enhance the effects of the 
transmitter on the AMPA receptors, which is what ampakines do.  
Since animal studies corroborated the expected effects (Arai et al. 1994; Staubli et al. 
1994), phase-I studies in healthy humans were performed with the ampakine CX516, which 
revealed improvements in the performance of various memory tasks (Lynch 2002).  
Ampakines are now being developed to help enhance memory and cognitive functioning in 
both AD and schizophrenia, with farampator specifically targeting patients with 
schizophrenia. But why develop such drugs for schizophrenia? The notion is based on the 
glutamate balance theory in which the potentiation of glutamatergic transmission is seen as 
having a potentially antipsychotic effect (Johnson et al., 1999). Evidence for glutaminergic 
involvement in schizophrenia comes from imaging and post-mortem studies, which found 
abnormalities in brain regions that are connected by glutaminergic circuits. Accordingly, if 
reduced excitatory (glutamatergic) activity should underlie some of the symptoms observed in 
schizophrenic patients, drugs that enhance glutamatergic transmission might correct the 
imbalance in this system. 
In Chapter 6 the acute effects of farampator, a new ampakine, are discussed as 
observed in healthy, elderly volunteers. As this drug is specifically being developed for the 
treatment of cognitive decline in schizophrenia, we looked into its effects on different types of 
memory measures as well as measures of information processing.  
 
Outline of the thesis 
In this thesis five papers are discussed that were prompted by the results of three studies 
originally set up to evaluate a test battery for use in pharmacological trials.  
 
For the first two studies we had selected psychiatric drugs with known effects on cognition to 
allow a comparison of sedation and activation. We had opted for drugs on the sedation-
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activation axis since thHVHZRXOGDIIRUGDQLQVSHFWLRQRIWKHWHVWEDWWHU\¶VVHQVLWLYLW\LQ
detecting bidirectional changes in performance. Lorazepam, mirtazapine and d-amphetamine 
were contrasted in the first and haloperidol, olanzapine and paroxetine in the second study. 
The effects were studied in healthy young volunteers aged between 18 and 40 years. The third 
study was aimed at detecting changes in memory performance. To this end the effects of 
biperiden, rivastigmine and the ampakine farampator were assessed in healthy, but now 
elderly volunteers (age range: 60-75). The first (present) chapter thus highlights the 
importance of memory and which questions might be answered by these studies.  
The second chapter looks into the acute effects of the antipsychotics haloperidol and 
olanzapine on psychomotor functioning and memory. To investigate whether the sedative 
effects of the drugs could be separated from memory effects, we employed one of the 
methods offered by Curran (1991) and Ghoneim and Mewaldt (1990): we used the scores of a 
sedative measure as a covariate variable in the analyses of drug-placebo effects on memory. 
In the third chapter the results of two placebo-controlled, randomized, four-way cross-
over studies are presented and the effects of lorazepam, mirtazapine, olanzapine and 
haloperidol, all agents known to cause both impaired memory and sedation, are discussed. 
The focus is on the amnesic and sedative effects and the possibility to distinguish between the 
two types of side effects. For this purpose we exploited a of &XUUDQ¶VPHWKRGVZKRVXJJHVWHG
that different drugs will show a similar effect on sedation, but different effects on memory or 
vice versa (Curran et al. 1998; Green et al. 1996).  
The fourth chapter reports the effects d-amphetamine, an activating drug, had on 
psychomotor, memory and information-processing measures. This study was not memory-
based but specifically designed to test whether dopaminergic drugs would help ameliorate 
psychomotor processes from the perspective of ameliorating symptoms of psychomotor 
retardation in patients suffering from major depression.  
Chapter 5 features two drugs that both target the cholinergic system but in two different ways. 
The cholinesterase inhibitor (ChEi) rivastigmine is a drug designed to combat the effects of 
AlzhHLPHU¶V'LVHDVH$'DQGVXSSRVHGO\LPSURYHVPHPRU\ZKLOHWKHDQWLFKROLQHUJLF
biperiden is used to alleviate extrapyramidal symptoms caused by antipsychotic agents. The 
acute effects of the two agents were investigated in healthy, elderly volunteers.  
The final study comprising the sixth chapter discusses the effects of the ampakine 
farampator on memory. Ampakines act as positive allosteric modulators of AMPA-type 
glutamate receptors and have been shown to facilitate hippocampal long-term potentiation 
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(LTP), a mechanism associated with memory formation and storage. As farampator has 
specifically been developed for the treatment of cognitive decline in schizophrenia, we 
studied its effects on various memory measures as well as on measures of information 
processing.  
Finally, in Chapter 7 the results are summarized, discussed and placed into 
perspective.  
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Abstract 
Rationale: Impaired psychomotor function has been shown to be associated with clinical and 
functional outcome in schizophrenia. However, few studies have investigated the short-term 
effects of antipsychotics on the cognitive and psychomotor functions of this patient group. 
Because many confounding factors tend to influence the test results in patient research, this 
VWXG\LQYHVWLJDWHVWKHGUXJV¶HIIHFWVLQKHDOWK\YROXQWHHUV 
Objectives: The short-term effects of haloperidol (2.5 mg), olanzapine (10 mg), and 
paroxetine (20 mg) on psychomotor function in 15 healthy volunteers are compared with 
placebo and each other. Methods: In a crossover design, the subjects completed a battery 
of psychomotor tasks assessing psychomotor speed, sensorimotor accuracy, visuospatial 
monitoring, and speed of information processing. In addition, peak velocity of saccadic eye 
movements and subscales of the visual analog scales were analyzed as the objective and 
subjective measures for sedation, respectively. Finally, the verbal memory test was used to 
DVVHVVWKHGUXJV¶HIIHFWVRQPHPRU\ 
Results: Apart from affecting the pursuit task where visuospatial monitoring, sensorimotor 
speed, and sensorimotor accuracy are measured simultaneously, haloperidol has been proven 
to be not associated with sedative nor with impairing effects on psychomotor function or 
verbal memory. In contrast, olanzapine had significant sedative effects. Moreover, the 
subjects displayed a significant impairment on all measures of psychomotor function and 
YHUEDOPHPRU\ZKLFKZDVQRWDWWULEXWDEOHWRWKHGUXJ¶VVHGDWLYHHIIHFWV$IWHUDGPLQLVWUDWLRQ
of paroxetine, no effects were found, with the exception of a single improvement in eye 
movement velocity.  
Conclusions: Short-term administration of olanzapine, and not of haloperidol, impedes 
several aspects of psychomotor function and verbal memory in healthy volunteers.  
 
 
Introduction 
Information processing speed is one of seven domains of cognitive functioning that were 
shown to be impaired in schizophrenia (1). What is more, slowing of psychomotor 
functioning in schizophrenics was demonstrated to be a predictor of poor prognosis and 
poorer clinical and functional outcome (2-7). 
Although many clinical studies focused on the effects of antipsychotic treatment on 
cognitive functioning, very few addressed the effects of these compounds on psychomotor 
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speed. There are some reports in the literature that do describe impeding effects but the 
findings are inconsistent and, to our knowledge, only one study (8) was primarily aimed at the 
pharmacological effects on processing speed. 
 Some studies claimed that the observed psychomotor slowing in schizophrenia is 
merely a side effect of the antipsychotic treatment (9-12) while others even demonstrated a 
mild improvement of psychomotor functioning in this patient group after treatment with both 
conventional (13) and atypical antipsychotics (14). Several explanations can be suggested for 
these contrasting results and views. The study into the effects of antipsychotic drugs on 
psychomotor functioning in schizophrenic patients is hampered by numerous confounding 
factors that may affect the test results, such as the course of the disease and momentary, 
symptomatic performance enhDQFHPHQWWKHSDWLHQW¶VPRWLYDWLRQRUFRQFRPLWDQWPHGLFDWLRQ
To get round these predicaments, we chose to investigate the effects of antipsychotics in 
healthy volunteers. Indeed, both the effects of typical and atypical antipsychotics on the 
psychomotor skills of healthy controls have been documented before. Thus, haloperidol has 
repeatedly been demonstrated to impair the psychomotor performance of healthy controls (15-
19) although studies using doses of less than 3 mg of haloperidol did not find any impairing 
effects (20-22). Olanzapine, on the other hand, was also shown to affect psychomotor 
functioning in healthy volunteers but only in the first few days after intake (18), as opposed to 
the continuing deterioration of psychomotor functioning observed after repeated dosages of 
haloperidol (16, 18).  
Antidepressants are also often used agents in the treatment of schizophrenic patients. 
However, these agents have effects on psychomotor and cognitive functioning as well. 
Selective serotonin reuptake inhibitors (SSRI) have been shown to improve speed of 
information processing and psychomotor speed in both healthy subjects (Van Laar et al., 
2002, Furlan 2001, Loubinoux et al. 2002, 2005) and depressed patients (Sabbe et al., 1996). 
Therefore, we decided to include an SSRI in the present study as well. 
Clinical studies assessing psychomotor functioning also tend to be incompatible 
through the multitude of different, complex task paradigms, where no distinction is made 
between tasks that assess basic psychomotor processes, i.e. the processes involved in 
initiation and execution of actions (e.g. finger tapping or simple drawing tasks), and more 
multifactorial tasks that also address higher-order cognitive processes (e.g. the symbol digit 
substitution test or the Stroop). However, it has been demonstrated that slowing of 
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sensorimotor and the more higher-order cognitive processes may occur independently (23-
26). Moreover, concurrent cognitive and sensorimotor slowing was associated with poor 
treatment outcome (27). This suggests that psychotropic agents might affect the various 
processes involved in slowing differently. If so, task paradigms sensitive to higher-order 
cognitive processes would generate different results than those that mostly address basic 
psychomotor processes. Hence, in our current investigation of the effects of antipsychotic and 
antidepressant agents on psychomotor functions we not only included tests assessing more 
complex forms of processing speed, but also several simple psychomotor tests. 
In addition, the diversity in pharmacological properties of the investigated agents may 
lead to differential effects on cognitive and sensorimotor functioning. SSRIs mainly affect the 
serotonergic system and were found to have modulatory effects on striatal dopaminergic 
neurotransmission (Penttila, Kajander et al., 2004). Conventional antipsychotics, on their part, 
primarily have an antagonizing effect on D2-receptors, with a high affinity for striatal D2-
receptors, which might be associated with sensorimotor dysfunctioning (23, 28). Atypical 
antipsychotics, on the other hand, have a high affinity for several different receptors, and 
therefore may have conflicting psychomotor effects. Olanzapine, for example, has an affinity 
for striatal D1, D2 and D4 receptors, which might cause sensorimotor dysfunctions while its 
high 5-HT2 affinity as well as its anticholinergic and 5-HT1a agonist activity may protect 
against striatal dysfunction, although the impact of these affinities on sensorimotor and 
cognitive functioning are not well understood (18, 29). Finally, olanzapine also has sedative 
effects possibly attributable to its affinity for histaminergic receptors. Considering this 
receptor profile, and contrary to conventional neuroleptics like haloperidol, it seems plausible 
that olanzapine affects both sensorimotor and cognitive processes. Moreover, due to the 
affinities of atypical agents for multiple receptor types acute and chronic administration of the 
drugs may affect psychomotor performance differently. 
To investigate these potentially divergent effects of both atypical and typical 
antipsychotics as well as antidepressants on cognitive and sensorimotor processes after acute 
administration, fifteen healthy volunteers entered a double-blind, cross-over design in which 
they were subjected to a battery of tasks assessing different aspects of psychomotor 
functioning as well as verbal memory after administration of haloperidol, olanzapine, 
paroxetine or placebo. The psychomotor tasks were administered on a writing tablet to 
facilitate separate scrutiny of the cognitive and sensorimotor processes involved. To our 
knowledge, this is the first study to directly compare the effects of acute administration of 
these compounds on the psychomotor performance of relatively young, healthy volunteers. 
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Due to its multiple receptor affinity we expected psychomotor skills to be more affected by 
olanzapine than by haloperidol. In addition, we expected a lack of impairing effects if not the 
presence of improving effects of paroxetine on psychomotor functioning. 
 
Materials and Methods 
Participants 
Participants were healthy volunteers (n=15; 7m, 8f) with a mean age of 22.3 years (SD=5.2; 
range: 19-40 years) with the educational level ranging from higher to academic. All 
participants were in good mental and physical health as established by their medical histories 
and medical, ECG and laboratory examinations. 
Prior to participation all subjects gave their informed consent. The study was carried out in 
accordance with the latest version of the Helsinki Declaration and was approved by the local 
medical ethics committee. 
 
Design and procedure 
The study has a double-blind, placebo-controlled, four-way crossover design. The four drug 
conditions were placebo, olanzapine 10mg, haloperidol 2.5mg and paroxetine 20mg. The 
H[SHULPHQWDOGRVDJHVPDWFKWKHDJHQWV¶DYHUDJHVWDUWLQJGRVHVLQWKHFOLQLFDOSUDFWLFH
Assessments of sedation were carried out for olanzapine three hours and thirty minutes after 
drug-intake and for haloperidol and paroxetine two hours and thirty minutes after drug-intake. 
The difference in time of drug-intake was achieved by a double-dummy administration.  
Assessment of memory and psychomotor measures were carried out at T-max 
(Farmacotherapeutisch Kompas), i.e. at five hours after administration of haloperidol and 
paroxetine and at six hours after administration of olanzapine. The washout period between 
consecutive assessments was kept at one week. 
To familiarize the participants with the tests and procedures, they were invited to the hospital 
for a practice session within the week preceding the first actual test day. Five modified 
versions of the Verbal Memory Test (VMT) and the Symbol Digit Substitution Test (SDST) 
were used for the practice sessions and the actual four assessment days. 
 
Apparatus and tests 
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Apparatus 
Writing Tablet 
The psychomotor tasks were all executed on a digitizing tablet (WACOM1218RE) and a 
special pressure-sensitive pen both connected to a standard personal computer. The X and Y 
co-ordinates of the pen-tip, both on and up to 5 mm above the digitizer, were sampled with a 
frequency of 200 Hz and a spatial accuracy of 0.2 mm (30). 
2.3.1.2. Saccadic Eye Movements 
Target stimuli were generated by the Nihon Kohden Nystagmo Stimulator (SLE-5100) on a 
LED display. The saccadic eye movements were recorded via Ag/AgCl electrodes that were 
placed laterally to both eyes and on the mastoid and connected to a bioelectric input box 
(Nihon Kohden ENG Input Panel (PN-640G)). The signals were amplified by the Nihon 
Kohden Polygraph Amplifier Console (RMP6004) and filtered by the Nihon Kohden AN-
601G. The high-pass filter was set at 3.0 Hz and sensitivity at 4 x 6 dB. The eye movements 
were recorded and analyzed using the Cambridge Electronics Design Intelligent Interface 
(CED 1401). 
 
Tests 
Visual Analogue Scale (VAS) 
The VAS, a questionnaire of 16 visual analogue scales from which the three factors subjective 
drowsiness, calmness and contentment can be derived, was completed by the participants. In 
this study the factor drowsiness was used as a measure for subjective sedation. 
 
Saccadic Eye Movements (SEM) 
The participants, whose heads were kept stationary during test performance, were asked to 
visually track as accurately as possible a target that jumped to lateral positions (+20° or ±20°) 
while their SEMs were recorded by use of an electrooculogram (EOG). The target consisted 
of a light-emitting diode moving horizontally with a lateral angle of 40 degrees, which was 
presented on a screen placed 50 cm in front of the participants. The mean peak velocity was 
used as a measure for objective sedation. 
 
Pointing Test 
All subjects were instructed to hold the pen in a steady position above the paper on the 
writing tablet keeping within the confines of a small circle for the duration of one minute. The 
median distance was entered into the analysis as a measure for fine motor control. 
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Pursuit Test 
Based on the classical rotary pursuit task (31, 32) our continuous sensorimotor task required 
subjects to follow the movements of a target circle (2.0 cm in diameter) on the computer 
screen with a cursor they could control by manipulating the pen on the writing tablet. The 
target rotated along a predictable circular path with a radius of 8 cm. The speed of the target 
was gradually increased with 5% every 0.5 s as long as the cursor was kept on the target and 
decreased with 30% as soon as the subject failed to keep track of the target. The mean number 
of target rotations in one minute was taken as reflecting the level of visuospatial monitoring, 
sensorimotor speed and sensorimotor accuracy. 
 
Symbol Digit Substitution Test (SDST) 
The Symbol Digit Substitution Test (SDST), a subtest of the Wechsler Adult Intelligence 
Scale-Revised (33), is widely used to assess processing speed. A series of symbols is 
presented that has to be decoded as fast as possible within a preset 90-s limit by use of a key 
translating the nine different symbols into the digits 1±9. Twelve different forms were used, 
each presenting the same symbols but with their order in the key being randomized over the 
different test forms. 
 In addition to the general performance measure, i.e. the number of correctly 
substituted digits within the time limit, two additional variables were calculated to 
differentiate the cognitive and sensorimotor components: matching time, representing the 
time the subject needed to find the correct digit, and writing time, reflecting the time the 
subject used to write down the digit.  
 
Line-copying Task  
Participants were instructed to copy a series of stimuli consisting of straight horizontal, 
vertical or  diagonal (2 orientations) lines that were randomly presented on a computer screen 
as fast as possible in designated boxes on a sheet of paper placed on the writing tablet.  
 
7KH)LWWV¶7DVN 
In this line-drawing task (34-36) participants had to connect two circles, one placed above the 
other at a distance of 1 cm, starting the connecting line in the centre of the top circle and 
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ending it in the centre of the lower circle. Sensorimotor accuracy was manipulated by 
alternatinJWKHFLUFOHV¶GLDPHWHUVHLWKHUFPRUFP 
 
Verbal Memory Test  
Unlike the classical Auditory Verbal Learning Test (37) on which it was founded, our verbal 
memory test consisted of 18 instead of 15 words to prevent ceiling effects. The list is orally 
presented to the participants three times. After each presentation (immediate recall) and after 
an interval of 20 minutes (delayed recall) they are asked to recite as many words as they can 
remember. The total number of words recollected over the three immediate-recall conditions 
was used as measure of short-term verbal memory and the total of recited words after the 20 
minutes-interval as a measure for delayed recall. 
  
Analysis 
SPSS (version 12.0) for Microsoft Windows was used for the statistical analysis. 
Multivariate General Linear Model (GLM) Repeated Measures analyses were performed on 
the sedation and psychomotor functioning data. When significance was attained, additional 
contrast analyses were performed to investigate differences in performance between placebo 
and the two drug conditions.  
 
Results 
Table 1 lists the descriptive statistics of the four drug conditions for all measures together 
with the results of the GLM analyses for repeated measures that were carried out to compare 
all performance results of the four drug conditions.  
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Table 1: Descriptive statistics for all measures of all participants (n=15) in the four drug 
conditions and the GLM repeated measures (F(df, N-1)) for all drug conditions 
SDST= Symbol Digit Substitution Test; SDST - n= number of correct substitutions; MT= 
matching time; WT=writing time; IT= Initiation time; DT= drawing time; VAS= Visual 
Analogue Scales; SEM - pv=Saccadic eye movements -  peak velocity; VMT=verbal memory 
test 
 
 
All significant overall drug effects were attributable to performance differences between 
placebo and olanzapine. All haloperidol performance measures proved unimpaired apart from 
the pursuit-rotation results, representing visuospatial monitoring, sensorimotor accuracy and 
sensorimotor speed. In the olanzapine condition pursuit performance had been significantly 
affected, as were the outcomes on the pointing task, assessing fine motor control, and the 
SDST, writing time more than matching time. In addition, in the line-copying test initiation 
WLPHVEXWQRWGUDZLQJWLPHVZHUHSURORQJHGDQGQHLWKHUZHUHWKHGUDZLQJWLPHVRQWKH)LWWV¶
task. Finally, VMT performance was highly significantly impeded in all recall conditions. 
Similar to the haloperidol condition, all paroxetine measures proved unimpaired apart from 
the initiation time in the Line Copying Task, which was mildly impaired. In addition, writing 
 Placebo Haloperidol Olanzapine Paroxetine F(3,14) p-value 
Pointing - median 
distance 
.450 (.164) .496 (.185) .607 (.276) .461 (.172) 3.981 .035 
Pursuit rotations 18.40 (3.05) 16.44 (3.63) 12.39 (4.23) 18.74 (1.72) 13.265 <.001 
SDST - n 59.93 (9.70) 57.73 (9.04) 53.47 (9.72) 58.07 (10.10) 4.782 .020 
SDST - MT 1.207 (.434) 1.229 (.307) 1.310 (.270) 1.205 (.273) 2.161 .146 
SDST - WT .363 (.060) .375 (.061) .431 (.110) .397 (.091) 2.863 .081 
Line-copying IT .695 (.101) .739 (.118) .819 (.142) .754 (.100) 8.896 .002 
Line-copying DT .230 (.066) .220 (.060) .251 (.081) .224 (.084) 1.484 .269 
Fitts - Big Target .147 (.128) .110 (.086) .114 (.082) .126 (.079) .427 .738 
Fitts - Small Target .148 (.100) .127 (.114) .152 (.109) .171 (.114) .015 .997 
VAS - Drowsiness 48.23 (3.06) 49.59 (3.83) 53.56 (7.24) 49.01 (2.74) 2.475 .111 
SEM - pv 353.89 (20.29) 359.25 (22.99) 334.68(26.62) 371.84 (25.85) 12.898 <.001 
VMT - direct recall 10.49 (2.01) 9.93 (1.73) 8.13 (1.75) 10.04 (2.34) 28.451 <.001 
VMT - delayed recall 9.67 (3.27) 9.20 (3.08) 6.20 (2.91) 9.93 (3.63) 5.449 .013 
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time on the SDST almost reached significance. It should be noted that peak velocity on the 
SEM was significantly reduced as well in the paroxetine condition. 
Since 13 repeated measure ANOVA analyses were carried out, p values should be 
adjusted for multiple comparisons. Even when applying a severe bonferroni correction (p-
value cut-off = 0.05/13 = 0.004), the subjects in the olanzapine condition still had 
significantly impaired performance compared to the placebo condition on the following 
measures: the pursuit task, the initiation time in the Line Copying Task, both memory 
measures and the SEM-peak velocity. Performance on the pointing task and writing time in 
the SDST reached significance. In the haloperidol condition, no measure remained significant, 
whereas in the paroxetine condition only the SEM-peak velocity was the only measure that 
remained  significantly impaired. 
Additional analyses were conducted to check whether sedation was responsible for the 
performance detriment in the olanzapine condition. Both the subjective (VAS drowsiness) and 
the objective sedation measure (SEM peak velocity) were significantly impaired. Since of the 
two SEM peak velocity yielded the highest F-value, the difference in peak velocity between 
two conditions (pvol-pl) was calculated as a measure for sedation. GLM analysis was repeated 
for the placebo and olanzapine conditions with pvol-pl as a covariate. Results are presented in 
Table 3.  
Interestingly, even when sedation was treated as a covariate the olanzapine-placebo 
differences remained intact for all affected measures, except for the VAS drowsiness factor, 
which was expected, thus validating the use of pvol-pl as a measure for sedation. After 
bonferroni correction (p value cut-off = 0.004), subjects remained significantly impaired in 
their performance on the pursuit task, the initiation time on the Line Copying Task and both 
memory measures. 
 
Discussion 
The healthy volunteers of our study were not sedated after administration of 2.5 mg of 
haloperidol and, as our test battery demonstrated, did not display significant impairments in 
their psychomotor or memory functions. They did show a moderate performance reduction on 
the more demanding pursuit task. After intake of 10 mg of olanzapine, however, the subjects 
exhibited a highly significant reduction in memory capacity, fine motor control and motor 
accuracy, as well as significant increments in movement initiation but not movement 
execution. Moreover, none of the olanzapine-induced impairments could be attributed to the 
GUXJ¶VVHGDWLYHHIIHFWVAfter administration of 20 mg of paroxetine, the subjects were 
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objectively sedated, an effect they were not aware of. They were not impaired in their 
psychomotor or memory functioning, neither did they improve performance on any of the 
measures. One single measure in the line copying task was mildly affected. 
 
Table 2: Contrasts between placebo and the two drug conditions in GLM repeated measures 
(F(df, N-1). 
 
SDST= Symbol Digit Substitution Test; SDST ± n =number of correct substitutions; 
MT=matching time; WT= writing time; IT=initiation time; DT=drawing time; VAS=Visual 
Analogue Scales; SEM - pv=Saccadic eye movements - peak velocity; VMT=verbal memory 
test 
 
 Placebo vs. Haloperidol Placebo vs. Olanzapine Placebo vs. Paroxetine 
F(1,14) p-value F(1,14) p-value F (1 ,14 ) p-value 
Pointing - 
median 
distance 
2.444 .140 9.910 .007 <1 .622 
Pursuit 
rotations 
5.330 .037 22.773 < .001 <1 .611 
SDST - n 2.170 .163 8.891 .010 <1 .383 
SDST - MT <1 .679 1.564 .232 <1 .978 
SDST - WT 1.587 .228 9.286 .009 4.451 .053 
Line-copying - 
IT 
2.216 .159 24.329 <.001 5.945 .029 
Line-copying - 
DT 
<1 .579 1.234 .285 <1 .802 
Fitts - Big 
Target 
<1 .390 1.356 .265 1.279 .280 
Fitts - Small 
Target 
<1 .895 <1 .966 <1 .856 
VAS - 
Drowsiness 
1.448 .249 8.413 .012 <1 .536 
SEM - pv 1.056 .322 23.846 < .001 11.651 .004 
VMT - direct 
recall 
1.359 .263 58.608 <.001 <1 .368 
VMT - delayed 
recall 
<1 .620 12.636 .003 <1 .866 
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The largely unaffected psychomotor performance in our sample of healthy volunteers 
after intake of 2.5 mg of haloperidol is in line with previous findings. Although several 
authors reported psychomotor impairments with similar doses in older volunteers (18, 22) or 
with higher doses in healthy subjects within the same age range (17, 19), the absence of 
impeding effects (17; 21, 38) or even the presence of an improvement (20) with lower doses 
of haloperidol in younger subjects has been documented as well. Our volunteers did display a 
mild deterioration of performance on the more taxing pursuit task, which tests three 
psychomotor skills concurrently, i.e. visuospatial monitoring, sensorimotor speed and 
accuracy. The effect might be attributed to the nigrostriatal dopaminergic activity of 
haloperidol, which is known to be associated with motor impairment (39). Yet, no such 
impairment was found for the undemanding pointing task, which, by merely requiring the 
subjects to keep the raised pen stationary, only addressed motor accuracy and may have been 
insufficiently sensitive to record other potential changes in performance.  
Olanzapine (10 mg), on the other hand, had highly significant acute effects on both 
motor and memory functions in our sample. This is in line with Beuzen et al. (18) who 
observed slowed performance, impaired motor accuracy and reduced memory in older 
volunteers after intake of only 3 mg. Performance on the SDST, commonly used to measure 
processing speed, was only modestly affected and the slowing was predominantly restricted to 
the motor and, surprisingly, not the cognitive component. However, both basic psychomotor 
and higher-order cognitive processes are addressed in this task. Possibly olanzapine only 
affected a few of these processes. Since a clear-cut disentanglement of the cognitive and 
sensorimotor processes involved in the SDST is not possible, it is difficult to interprete these 
results. Our focus was on the psychomotor skills in this study, thus the findings resulting from 
the tasks that mainly address basic psychomotor processes, without tapping these higher-order 
FRJQLWLYHIXQFWLRQVDUHPRUHLQIRUPDWLYH6HQVRULPRWRUVSHHGZDVQRWLPSHGHGLQWKH)LWWV¶
and line-copying tasks, whereas the agent clearly affected the measures for movement 
initiation, fine sensorimotor control and accuracy as wells as short-term and delayed memory. 
It should be noted that most of these measures remained impaired after a rigorous bonferroni 
correction. 
In contrast to haloperidol, olanzapine has a high affinity for histaminergic receptors, 
which may explain its sedative profile on both the objective and subjective measures. Our 
results suggest that the sedative action of olanzapine could not account for the impairment on 
verbal memory (see also Wezenberg et al. 2006) or the motor functions. This is also in line 
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Table 3: GLM analysis for the differences between the placebo and olanzapine conditions 
with the difference in SEM (saccadic eye movements) peak velocity (pvol-pl) as a covariate. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
SDST= Symbol Digit Substitution Test; SDST - n: number of correct substitutions 
MT=matching time; WT= writing time; IT=initiation time; DT=drawing time; VMT=verbal 
memory test; VAS=Visual Analogue Scales. 
 
with the finding that in the present study paroxetine demonstrated sedative effects that 
were not accompanied by impairments in the memory and psychomotor measures. No 
sedative actions were found in the haloperidol condition nor could the one modest effect on 
WKHSXUVXLWEHDWWULEXWHGWRWKHDJHQW¶VVHGDWLYHIHDWXUHV3RVVLEO\WKHDIILQLW\RIRODQ]DSLQH
for, for instance, serotonergic, muscarinergic and adrenergic receptors, may have influenced 
the results as well. Indeed, anticholinergic action, for example, is known to be associated with 
memory impairment (40).   
Our findings seem to be in contrast with the improving effects on cognitive and 
psychomotor functioning that have been demonstrated in schizophrenic patients with atypical 
agents (14, Peuskens), and to a lesser degree on cognitive but not psychomotor functioning by 
conventional agents (Mishara, Goldberg, 2004). However, it should be emphasized that these 
improving effects are typically found after chronic administration in contrast with our 
measurements after one single intake. Indeed, it has been demonstrated in healthy subjects 
 F(1,14) p-value 
Pointing - median distance 8.667 .011 
Pursuit rotations 24.321 < .001 
SDST - n 4.121 .063 
SDST - MT <1 .505 
SDST - WT 6.151 .028 
Copying Lines - IT 11.816 .004 
Copying Lines - DT <1 .494 
Fitts - Big Target <1 .548 
Fitts - Small Target <1 .770 
VMT - direct recall 27.642 <.001 
VMT -delayed recall 20.028 .001 
VAS - Drowsiness <1 .681 
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that the initial impairing effects of olanzapine disappeared after a couple of days of 
administration (18). 
Finally, in our sample paroxetine did not improve nor did it impair psychomotor and 
memory functions. This is in contrast with a study that found improving effects on 
psychomotor functioning of  paroxetine after a single dose of 20 mg ( Loubinoux et al., 2002) 
in healthy volunteers. However, in the latter study the subjects were elder patients with an 
average age of 58 years in contrast with our younger sample, which might explain the 
different results. 
 Since we opted to investigate a fixed, prevalent dose for each drug and all participants, 
we cannot report dose-related changes of psychomotor functioning. Different doses of these 
drugs might have produced fewer or more deleterious effects on the outcome measures. 
Therefore, it is difficult to make overall general comparative statements about the investigated 
drugs based on our data. On the other hand, dosages used in the present study reflect often 
used dosages in clinical practice. Thus the present study may provide valuable information. 
Another limitation is that task performance was exclusively tested at peak time on the day the 
drug was administered. And finally, the results we found in our healthy volunteers may be 
different from the effects in schizophrenic patients because the neurobiological pathways of 
schizophrenic patients may differ from those of healthy individuals, resulting in differential 
effects of antipsychotics on cognitive and psychomotor functioning.  
 'HVSLWHWKHVWXG\¶V limitations we think the current findings might have several 
important clinical implications. Cognitive dysfunction and psychomotor slowing are 
important clinical features of schizophrenia and are known to be related to social and 
functional outcome (6, 41). Atypical antipsychotics have been found to enhance psychomotor 
speed and cognitive functioning in schizophrenic patients (14) after a few weeks. However, 
the results of this study suggest that olanzapine has an initial impairing effect on both memory 
and psychomotor functioning. Athough the initial sedating profile of olanzapine might be 
clinically interesting, one should also be aware of its early impeding effects on psychomotor 
functions. On the other hand, it should be noted that antipsychotic drugs are administered on a 
chronic basis. As suggested by data in both healthy volunteers (18) and schizophrenic patients 
(14), tolerance to the sedative and psychomotor-impairing effects of such drugs are likely, 
which may limit the clinical value of these impairments.  
 3RVVLEO\RODQ]DSLQH¶VSURWHFWLYHDFWLRQDJDLQVWVWULDWDOG\VIXQFWLRQZKLFKDFFRUGLQJ
to Paquet et al. (29) may result from high 5-HT2 relative to D2 receptor affinity, have to 
RYHUFRPHWKHGUXJ¶VLQLWLDOVHGDWLYHDQGLPSDLULQJDFWLRQ7KLVLs in line with Beuzen et al. 
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(18) who found an initial olanzapine-induced impairment in healthy subjects to decrease with 
repeated doses, in contrast to an augmenting impairment after repeated administration of 
haloperidol. We therefore hypothesize that atypical agents have conflicting effects on 
cognitive and motor functions over time due to their affinity for multiple receptors. This 
would explain the contrasting and confusing results reported in clinical studies investigating 
the effects of these agents on cognition in schizophrenia. 
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Abstract  
Objective: The study investigated whether four specified drugs would show similar patterns 
on tests considered to measure sedation. In addition, their drug-effect patterns on sedation and 
memory performance were compared to determine whether the sedative effects could be 
differentiated from the memory effects. 
Methods: Two double-blind, placebo-controlled, crossover studies, each with 16 healthy 
volunteers, were performed, one testing lorazepam (2.5 mg) and mirtazapine (15 mg) and the 
other olanzapine (10 mg) and haloperidol (2.5 mg). Subjective sedation was assessed by 
means of visual analogue scales (VAS) and objective sedation using a simple (SRT) and a 
choice-reaction-time task (CRT), code substitution (SDST) and the peak velocity of saccadic 
eye movements (SEM). A Verbal Memory Test (VMT) was administered to evaluate memory 
capacity.  
Results: Apart from haloperidol, all drugs proved to impair performance on all five sedation 
indices. Contrary to the VAS, the objective measures yielded different response profiles. Two 
types of drug-effect patterns emerged: one for greater impairments in response speed (SRT, 
SEM) and one for greater impairments in information processing (CRT, SDST). Lorazepam 
and olanzapine impeded memory performance, whereas mirtazapine did not. With the use of 
standardized scores it proved possible to differentiate between the size of the effects of the 
drugs on the sedation and memory tests. 
Conclusion: To accurately assess the level and nature of sedation and to differentiate sedation 
from memory impairments different types of sedation measures are required. Besides 
studying the subjective effects, it is recommended to also test psychomotor responses and 
information processing speed. 
 
Introduction 
,QGUXJUHVHDUFKWKHWHUPµVHGDWLRQ¶LVJHQHUDOO\XVHGWRGHVFULEHWKHGHSUHVVDQWHIIHFWVRI
drugs on the Central Nervous System (CNS). In the search for drugs with favourable side-
effect profiles, the sedation profiles allow a differentiation across and within drug classes. 
Many drugs that are currently prescribed in psychiatry are equally effective in the treatment of 
the core symptoms of the targeted disorders and therefore it is especially the sedative side-
effects profiles that play a major role in the development of new drugs or choice of 
prescripWLRQV5LGRXW0HDGRZVHWDO,QDGGLWLRQPRUHLQVLJKWLQWRDGUXJ¶VVHGDWLYH
effects will allow researchers to separate these from other (adverse) cognitive reactions to the 
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drug. Benzodiazepines, for example, have both amnesic and sedative effects and are 
FRPPRQO\XVHGIRUPHPRU\UHVHDUFK7KHSUREOHPLVWKDWWKHGUXJ¶VVHGDWLYHHIIHFWVDUH
known to confound the assessment of the effects the drug exerts on memory. (Curran 1991; 
Curran, Pooviboonsuk et al. 1998; Curran, Schifano et al. 1991; Fluck, File et al. 1998; 
Huron, Giersch et al. 2002; King 1992; Lucchesi, Pompeia et al. 2003).  
The verbal memory test (VMT) is widely used to assess the effects of drugs on 
memory since it gauges declarative episodic memory, i.e. knowledge people know they have 
acquired. Immediate and delayed free recall of words (number of words recollected from a 
verbally presented wordlist) are evaluated, as well as word recognition (where stimulus words 
are a part of the list and subjects have to indicate whether they heard an old or new word 
beIRUH7KHLPPHGLDWHUHFDOORIZRUGVUHIOHFWVWKHVXEMHFW¶VFDSDFLW\IRUVKRUW-term memory 
storage and the delayed recall condition the subMHFW¶VFDSDFLW\IRUORQJ-term storage.  
As both immediate and delayed free recall are sensitive to fluctuations in alertness and 
attention or to distractions, impaired performance does not necessarily indicate an impaired 
memory capacity. However, recognition is less sensitive to such fluctuations and therefore the 
recognition trial directly follows the free delayed recall condition, whose outcome is always 
compared to the free recall performance. Impaired free recall in the absence of impaired 
recognition may still indicate a memory problem, although it might also reflect deficient 
arousal or attention (Lezak 1995; Baddely 1998). For research purposes it is necessary to 
know that an effect on a memory test is not due to sedation and is a specific effect on 
memory, making a differentiation of the two crucial. 
The term sedation is another complex construct. It can be measured in multiple ways: 
e.g. by a description of the subjective,  self-observed, decreased level of arousal or drowsiness 
(Curran, Pooviboonsuk et al. 1998; Green, McElholm et al. 1996; Kay and Harris 1999; 
Shamsi and Hindmarch 2000; Starbuck, Kay et al. 2000; Young-McCaughan and Miaskowski 
2001) and by the more objective, measurable impairment of cognitive processes (Hindmarch 
and Shamsi 1999; Levander 2000). The instruments assessing the subjective level of arousal 
usually consist of a series of visual analogue scales (VAS) with which respondents can 
LQGLFDWHKRZµDOHUW-GURZV\¶RUµHQHUJHWLF-OHWKDUJLF¶WKH\IHHO$LWNHQ%RQGDQG/DGHU
1974;Norris 1971). The degree of cognitive impairment due to sedation is mostly tested by 
means of tasks measuring response speed in various designs that either focus more on 
cognitive functions or on motor components, such as (adaptations of) the Symbol Digit 
Substitution Test (SDST), Reaction Time Tasks (RTT) and the Finger Tapping Test (FTT). 
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Two additional widely-used psychophysiological techniques are the recording of the peak 
velocity of Saccadic Eye Movements (SEM) and the Critical Flicker Fusion Threshold 
(CFFT).  
That instruments measuring subjective and objective sedation appear to measure 
sedation differently follows from the observation that although respondents are usually quite 
able to report that they are sedated following the ingestion of a particular substance, they are 
not always very accurate in assessing the impact it has on their behaviour and response 
capabilities. This discrepancy between the subjective overrating of their response capacity and 
the actual performance level (which is significantly deteriorated) is frequently found to be the 
cause of traffic accidents. In addition, laboratory research has shown that subjects tend to 
underestimate the impairing effects of alcohol on their performance, especially when they 
have been given low doses that lead to only mild levels of sedation (Holdstock and de Wit 
1999; Roache and Griffiths 1987; Schuckit, Greenblatt et al. 1991; Yesavage and Leirer 
1986).  
Further experimental evidence of differential sensitivity of sedation tests comes from 
drug studies using other sedative compounds. Green et al. (1996), for instance, found similar 
effects for chlorpromazine (100 mg) and lorazepam (2 mg) on the VAS, but different scores 
on the SDST. Using a subjective sedation measure Curran et al. (1998) observed a 
comparable response for scopolamine (0.6 mg), lorazepam (2 mg) and the antihistaminergic 
drug diphenhydramine (25 mg, 50 mg), but found different responses for the various drugs 
when psychomotor performance was evaluated.  
Some studies that evaluated the effect of only one drug known to have sedative side 
effects also reported analogous discrepancies when the drug was administered in varying 
doses. Weingarter et al. (1995), and more recently Huron et al. (2002) and Pompeia et al. 
(2004a), noted that, in contrast to other sedation measures, the VAS failed to distinguish small 
differences in doses of triazolam (0.250, 0.375 and 0.500 mg), lorazepam (0.038 mg/kg and 
0.026 mg/kg) and zolpidem (5 and 10 mg), respectively.  
Since most of these studies used only one or two sedation measures to complement the 
VAS, we thought it worthwhile to compare drug effects on multiple sedation measures. We 
were curious whether the sedative patterns on the subjective and objective tests would be 
similar for the different drugs, because it is known that sedation does not correspond to a 
single pharmacological mechanism of action. Drug-induced sedation can result from a 
number of pharmacological mechanisms including facilitation of GABAergic transmission or 
blockade of central histamine H1 recHSWRUVDVZHOODVIURPDQWDJRQLVPRIĮRUĮ- 
The role of sedation tests in identifying sedative drug effects in healthy volunteers and their power  
to dissociate sedative-related impairments from memory dysfunctions          47                             
²²²²²²²²²²²²²²²²²²²²²²²²²²²²²²²²²²²²²²²²²²²²² 
 
adrenergic recepWRUVRUDJRQLVWDFWLRQRIȝ-opioid receptors (Bourin and Briley 2004; Young-
McCaughan and Miaskowski 2001).   
In addition, we also looked into the possibility of differentiating sedative effects from 
memory impairments by comparing the sedation data with the performance on an episodic 
memory task (VMT). In spite of the overlap between sedation and memory, some drugs might 
have stronger memory-impairing than sedative effects, whereas others might show a reverse 
pattern. Thus, different drugs were studied in a range of different tests that measure sedation 
and in three conditions of the VMT memory task.  If it is true that some drugs specifically 
induce more sedation and others tend to affect memory more, then those drugs should show a 
different profile of effects across measures.  
 
To this end, we conducted two placebo-controlled experiments with identical designs 
to compare the effects of four established drugs with known sedative side effects caused by 
different pharmacological actions. In the first experiment we compared lorazepam and 
mirtazapine to placebo and in the second experiment olanzapine and haloperidol to placebo. 
The sedative effect in lorazepam are mediated by facilitation of GABAergic functioning 
(Curran 1991) whereas in mirtazapine the sedative effect is principally due to antagonism of 
the histamine H-1 receptors (Holm and Markham 1999), which might also apply to 
olanzapine and haloperidol (Bymaster et al. 1996; Lawlor, 2004). The VAS was selected to 
assess subjective sedation. As objective measures we chose a simple and a choice-reaction-
time task (SRT and CRT, respectively), the Symbol Digit Substitution Test (SDST) and the 
peak Saccadic velocity of the Eye Movements (SEM). The VMT was selected to assess 
memory performance. In addition to the drug-placebo analyses we compared the magnitude 
of the drug effects using standardized scores. 
 
Methods and materials  
Participants 
In the first study 16 healthy volunteers (eight men, eight women) completed all measures. 
Mean age was 22.5 years (sd 5.09; range 18-39 years) and 14 volunteers were right-handed 
and two left-handed. The second study initially included 16 healthy volunteers but one 
participant left the study prematurely. The 15 participants that completed all trial conditions 
(seven men, eight women) had a mean age of 22.3 years (sd 5.21; range 19-40 years) and 13 
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were right-handed and two left-handed. The educational level of the participants in both 
studies varied from higher to university level and all were in good physical and mental health 
as based on their medical histories, a medical examination, an ECG and laboratory tests. The 
study was approved by the local Medical Ethics Committee and written informed consent was 
obtained from all volunteers. 
 
Design, drug administration and procedure 
Both studies had a double-blind, placebo-controlled, four-way crossover design. To achieve a 
balanced administration order, the drugs were randomized using a Latin-square design 
(repeated four times). In study 1 the four drug conditions were placebo, lorazepam 2.5 mg, 
mirtazapine 15 mg (and d-amphetamine 15 mg, not reported here). Testing took place two 
hours after drug intake, which approximated Tmax for all three drugs. All drugs were 
administered in single oral doses with a washout of one week. In study 2 the four drug 
conditions were placebo, olanzapine 10 mg, haloperidol 2.5 mg, and (paroxetine 20 mg, not 
reported here). Testing took place at around Tmax for all three drugs, which was achieved by a 
double-dummy administration of the drugs: for olanzapine assessment took place three hours 
and thirty minutes after drug intake and for haloperidol two hours and thirty minutes after 
drug-intake. To familiarize the subjects with the tests and procedures, they were invited to the 
hospital for a practice session during the week preceding the actual testing. We used five 
modified versions of the VMT and the SDST for the practice sessions and the four test days 
with the test versions counterbalanced over the test days.  
 
Tests 
Visual Analogue Scales (VAS) 
The VAS is a self-report measure of 16 items (Bond and Lader 1974) that are often used 
because of their simplicity, relative reliability and because they can be used repeatedly 
(Aitken 1969). Each scale consists of a 100-mm-long horizontal line with on each end two 
extremes of a mood. Subjects are asked to regard each line as a continuum where the middle 
RIWKHOLQHLQGLFDWHVµQRUPDO¶DQGWRUDWHWKHLUIHHOLQJVDWWKHWLPHRIWHVWLQJE\SODFLQJD
vertiFDOPDUNDFURVVHDFKOLQHHJVXEMHFWVUHSRUWHGKRZµDOHUW-GURZV\¶RUµHQHUJHWLF-
OHWKDUJLF¶WKH\IHOW%\PHDQVRIIDFWRUDQDO\VLVWKHWKUHHIDFWRUV$OHUWQHVV&DOPQHVVDQG
Contentment were derived. Only the mean result of the composite score of the Alertness items 
will be reported here, because the other scales were not significantly changed by the drugs. 
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The VAS items used for the composite score included: alert, attentive, lethargic, muzzy, 
coordination, slowing, strong, interested, and competent. 
 
Symbol Digit Substitution Test (SDST) 
The SDST is an adaptation of a subtest from the WAIS (Wechsler Adult Intelligence Scale; 
Wechsler (1981) ). Subjects are presented with nine different symbols and are requested to 
substitute as many symbols as possible by the digits 1-9 on the basis of a preset key within a 
set time frame. Subjects are presented with nine different symbols and are requested to 
substitute as many symbols as possible by the digits 1-9 on the basis of a preset key within a 
set time frame by writing down the digit that corresponds to a given symbol. The outcome 
measure is the number of correct digits entered within 90 seconds (Hege, Ellinwood, Jr. et al. 
1997;Lezak 1995). 
 
Simple Reaction Time task (SRT) 
The SRT comprised the presentation of a yellow square in the centre of a PC monitor at 
random intervals (range 0.5-1.5 seconds). Subjects were instructed to press the response 
button on the response module with the index finger of their dominant hand as soon as they 
saw the target. The outcome measure was the mean reaction time over a total of 20 targets. 
 
Choice Reaction Time task (CRT) 
'XULQJWKH&57WKHZRUGVµOHIW¶DQGµULJKW¶ZHUHSUHVHQWHGLQUDQGRPRUGHURQWKH3&
monitor and subjects were asked to press the corresponding buttons on the response module 
as fast as possible using the left index-ILQJHUIRUWKHZRUGµOHIW¶DQGWKHULJKWLQGH[-finger for 
WKHZRUGµULJKW¶$JDLQWKHRXWFRPHPHDVXUHZDVWKHPHDQUHDFWLRQWLPHRYHUDWRWDORI
stimuli. 
 
Saccadic Eye Movements (SEM) 
The participants whose heads were immobilized in a head-support during task performance 
were instructed to track a fast-moving target with their eyes as accurately as possible while 
their saccadic eye movements (SEM) were recorded by means of an electro-oculogram 
(EOG). The target consisted of a light-emitting diode (LED) moving on a horizontal bar on a 
VFUHHQWKDWZDVSODFHGFPLQIURQWRIWKHSDUWLFLSDQWV7KHVL]HRIWKHWDUJHW¶VODWHUDO
displacements was fixed at 20 or 40 degrees of visual angle (10 and 20 degrees from the 
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centre, respectively) with varying inter-stimulus-intervals. The participants first performed 7 
trials at 20 degrees, followed by 14 trials at 40 degrees and the test ended with 7 trials at 20 
degrees. Only the results of the 40-degree trials will be reported here as they showed the 
strongest response. The outcome measure was the mean peak velocity.  
 
Verbal Memory Test (VMT) 
 Contrary to the classical Auditory Verbal Learning Test (Vakil and Blachstein 1993) on 
which it was founded, our VMT consisted of 18 words instead of the original 15 words to 
prevent ceiling effects. The words are read out to the participants three times with the 
instruction to memorize as many words as possible each time. Under normal circumstances 
more words will be recalled after each presentation. The participants were asked to recite the 
words they could recollect immediately following each presentation (immediate recall or IR) 
and after an interval of 20 minutes (delayed recall or DR). After the DR condition a list of 36 
words was read out to them from which they were asked to identify the 18 words of the test 
list (word recognition or RC). The 18 distractor words resembled the correct words 
semantically or phonologically. The outcome measures are the number of correctly 
recollected words for the three immediate-recall conditions, the delayed-recall condition and 
the word recognition condition.  
 
Apparatus 
Saccadic Eye Movements 
The Nihon Kohden Nystagmo Stimulator (SLE-5100) generated the target stimuli on the LED 
display. The saccadic eye movements were recorded via Ag/AgCl electrodes that were placed 
laterally to both eyes and on the mastoid and connected to a bioelectric input box (Nihon 
Kohden ENG Input Panel (PN-640G)). The signals were amplified by the Nihon Kohden 
Polygraph Amplifier Console (RMP 6004) and filtered by the Nihon Kohden AN-601G. The 
high-pass filter was set at 3.0 Hz. The sensitivity was 4 x 6 dB. The eye movements were 
recorded and analyzed by the Cambridge Electronics Design Intelligent Interface (CED 
1401). 
 
Cognitive tests 
The SDST version used in this study belongs to a cognitive and psychomotor test battery 
ORGABAT (www.kikosoft.com; Wezenberg, Hulstijn et al. 2004). The SRT and CRT tests 
were recorded on a :LQGRZV3&E\WKHµ5WSV\FK¶SURJUDPZULWWHQLQ'HOSKL 
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Statistical analysis 
For statistical evaluation SPSS 11 for Windows was used.  
First, to verify if the drugs caused sedation two Multivariate General Linear Model 
(GLM) Repeated Measures Analyses of Variance (MANOVA) were performed, one for each 
VWXG\ZLWKµGUXJV¶DVZLWKLQ-subject factor and the sedation outcome measures as dependent 
variables. Contrasts of drugs to placebo were analyzed in the MANOVAs. Subsequent 
analyses were only performed if the drug generated significant impairments, i.e. sedative 
effects. 
To facilitate direct comparison of the tests and drugs the data were transformed into 
standardized scores by subtracting the mean of the drug data from the mean of the placebo 
data and dividing the outcome by the standard deviation of the placebo condition for each 
experiment: (mean drug ± placebo)/sd placebo. This procedure is used for the computation of 
&RKHQ¶VGZKLFKLVDQHIIHFWVL]HVFRUHWKDWDOORZVDFRPSDULVRQRIWKHVWUHQJWKRIGUug 
effects. An effect size between 0 and 0.2 is considered small, 0.3-0.7 is considered moderate 
and 0.8 is considered large (Cohen 1988;Snyder, Werth et al. 2005).  
Drug effects were analyzed for the VMT through GLM Repeated measures analysis using 
Drug-Placebo contrasts. Lastly, the VMT data were transformed to standardized scores to 
allow a visual comparison of the strength of the drug-effect patterns on the sedation measures 
versus the patterns on the memory measures.  
 
Results 
The descriptive statistics of the drug effects on the sedation tests, as well as on the memory 
test are presented in Table 1. 
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Table 1. Mean scores (M) and standard deviations (SD) for the sedation tests for the drug 
conditions. Lor = lorazepam; Mir = mirtazapine; Ola = olanzapine; Hal = haloperidol; 
Plac1 = placebo in study 1; Plac2 = placebo in study 2. 
 
      Plac1 Lor Mir   Plac2 Ola Hal 
                    
VAS (mm) M 43 59 62  48 54 50 
  SD 13 9 7  3 7 4 
SDST (completed) M 68 54 63  60 53 58 
  SD 7.2 8.4 8.4  9.7 9.7 9 
SRT (ms) M 238 277 290  243 325 256 
  SD 14 47 41  31 65 25 
CRT (ms) M 298 349 337  318 383 305 
  SD 23 59 50  75 73 23 
SEM (cm/sec) M 399 339 314  354 335 359 
    SD 43 49 47   10 27 23 
VMT (words)         
 
 
Immediate Recall 
M 31 21 29  31 24 30 
  SD 6.2 5.4 6.7  6 5.3 5.2 
 Delayed Recall M 11 5 10  10 6 9.20 
  SD 3.5 2.5 3.5  3.3 2.9 3.1 
 Recognition M 15 10 13  13 12 12 
  SD 2.1 2.9 2.8  3.1 3.7 3.4 
 
 
Drug effects on the sedation measures 
The results of the MANOVAs conducted for the two studies are presented in Table 2. 
As Table 2 shows, multivariate analysis of the standardized Drug-Placebo contrast on all 
sedation measures showed an overall drug effect in both study 1 and study 2. The results for 
the individual tests demonstrated significant impairments on both the subjective and objective 
tests for lorazepam and mirtazapine and olanzapine, but not for haloperidol. Haloperidol was 
therefore excluded from further analysis.   
The role of sedation tests in identifying sedative drug effects in healthy volunteers and their power  
to dissociate sedative-related impairments from memory dysfunctions          53                             
²²²²²²²²²²²²²²²²²²²²²²²²²²²²²²²²²²²²²²²²²²²²² 
 
Table 2. F statistics (Double Multivariate MANOVA); Lor = Lorazepam; Mir = Mirtazapine; 
Ola = Olanzapine; Hal = Haloperidol; Plac1 = Placebo in study 1; Plac2 = Placebo in 
study 2. Significance levels: 
#
 p = < .1, * p = < .05, ** p < .01; *** p < .001. 
 
  Multivariate Study 1: F(10,6) = 7.60*** Multivariate Study 2: F(10,5) = 11.08** 
  
Lor vs Plac1 
df (1,15) 
Mir vs Plac1 
df (1,15) 
Ola vs Plac2 
df (1,14) 
Hal vs Plac2 
df (1,14) 
VAS 9.18** 20.65*** 8.98** 1.44 
SRT 9.67** 30.94** 48.91*** 3.58
#
 
SDST 26.94*** 9.46** 8.89** 2.17 
CRT 11.68** 11.80** 28.93*** < 1 
SEM  48.59*** 75.29*** 23.85*** 1.06 
 
 
Differential Patterns of Sedation 
The standardized scores of the sedation measures are depicted in Figure 1. As mentioned in 
the previous paragraph, all drugs differed significantly from placebo. For reference: 
differences between drugs exceeding a half are meaningful and those close to one or 
exceeding one are large differences  (Cohen 1988; Snyder et al. 2005). 
It is evident from Figure 1 that compared to the objective sedation tests the differences 
between drugs in the subjective test are relatively small, and showed no difference between 
the drugs.  
The tests revealed two patterns of drug effects: on both the CRT and SDST lorazepam 
showed a markedly greater effect than olanzapine whereas on the SRT and SEM it was 
mirtazapine that had a strikingly greatergreater effect than olanzapine.  
Interestingly, the SRT revealed the strongest drug effects, thus proving to be the most 
sensitive of our sedation tests.  
 
 
Chapter 3                                                                                                                                                               54 
²²²²²²²²²²²²²²²²²²²²²²²²²²²²²²²²²²²²²²²²²²²²² 
 
Sedation Tests
-4.5
-4
-3.5
-3
-2.5
-2
-1.5
-1
-0.5
0
VAS SRT SEM CRT SDST
S
ta
n
d
a
rd
iz
e
d
 d
ru
g
-p
la
c
e
b
o
 
s
c
o
re
s
Lorazepam Mirtazapine Olanzapine
 
 
Figure 1: Standardized Drug-Placebo differences for lorazepam, mirtazapine and olanzapine 
on all sedation tests, with standard error bars. Larger bars indicate larger differences 
between drugs and placebo.  
 
With regard to the effects of the various drugs, lorazepam showed the strongest effect 
on the SRT, followed by the CRT and SDST, with the smallest effects on the SEM and VAS . 
Mirtazapine showed the largest effects on the SRT, followed by the CRT and SEM and much 
smaller effects on the SDST and the VAS scores. Olanzapine also induced the greatest 
impairment on the SRT, although this was the only objective sedation measure where the drug 
effects was greater than on the subjective measure. The drug effects on other sedation tests 
were all smaller compared to the drug effects on the VAS.  
In summary, the drugs generated similar levels of sedation on the VAS, but not on the 
other, objective sedation tests. In addition, there were two patterns of drug effects and the 
largest impairments were found in the SRT. 
 
Drug effects on the verbal memory test 
Lorazepam was found to impair VMT performance in all three conditions (IR: F(1,15) = 
36.46, p < .001; DR: F (1,15) = 40.5, p < .001; RC: F(1,15) = 43.6, p < .001). Olanzapine 
DIIHFWHGWKHSDUWLFLSDQW¶VLPPHGLDWHDQGGHOD\HGUHFDOOFDSDFLWLHVEXWQRWWKHLUUHFRJQLWLRQ
skill (i.e. the number of words correctly recognized as old or new) (IR: F(1,14) = 58.6, p < 
.001; DR: F(1,14) = 12.6, p = .003). Mirtazapine proved not to have reduced overall memory 
performance but did tend to impair word recognition non-significantly (RC: F(1,15) = 4.1, p = 
.062; see Table 1 for means and SD). 
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Differential drug effect patterns on sedation and memory measures 
To see whether the decrements in performance caused by sedation could be 
distinguished from memory impairments, we compared the drugs-placebo effects on the 
sedation and memory tests. Two drugs showed a different effect pattern on the sedation and 
memory measures: all drugs impaired performance on the sedation tests but olanzapine did 
not impede VMT word recognition and mirtazapine affected none of the memory measures. 
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Figure 2: Standardized Drug-Placebo differences on the VMT. IR = Immediate Recall sum 
score, DR = Delayed Recall score, RC = Recognition recall score. Larger bars indicate 
larger differences between drugs and placebo.  
 
The standardized scores offer additional information about the strength of the drug-
induced effects thus facilitating a further differentiation of the effects of the various drugs.  
Comparison of the two figures (1 and 2) demonstrates that lorazepam generated an 
equal decrement in memory and sedation-test performance, whereas mirtazapine induced a 
greater performance decline on the sedation tests and no impairment on any of the memory 
conditions. Lorazepam shows a relatively more impaired performance in the sedation tests 
and RC performance than olanzapine, but the VMT free recall results show a similar pattern 
for the two drugs. A comparison of mirtazapine and olanzapine shows that mirtazapine 
impaired the sedation measures relatively more than olanzapine, whereas olanzapine impaired 
the memory performance relatively more than mirtazapine. Only in word recognition is no 
difference found between mirtazapine and olanzapine performance.  
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Discussion 
With regard to the differentiation of drugs according to pharmacological profile, the 
analysis showed that all sedation tests proved sufficiently sensitive to detect drug-placebo 
effects at the dosages that were studied. The comparison of the standardized scores of the 
drugs and tests revealed that the objective sedation tests helped uncover differences in the 
severity of the sedative effects, whereas the VAS did not. In addition, one of the objective 
sedation tests, the SRT, proved to be the most sensitive test for all drugs in detecting sedation.  
 
The sedation tests were effective in revealing two patterns of drug effects: in the SRT 
and SEM mirtazapine had a much larger effect than olanzapine, and in the CRT and SDST, 
lorazepam had a markedly larger effect than olanzapine 
The difference in these effect patterns may be attributed to the difference in the relative 
cognitive effort required to perform a task. Both the SRT and SEM assess basic behavioural 
reactions and thus require less cognitive effort. In addition, they predominantly measure 
response speed rather than information processing. The simplest task, the SRT, merely 
requires a button-press with the dominant index finger in response to the detection of a target. 
The SEM only differs from the SRT in that the timed responses involve eye movements and 
require alternate left- and rightward motions. Alternatively, the CRT and SDST necessitate 
more information to be processed because in both tests the stimuli also contain the 
information about which response is required (Schmidt, 1999). This would warrant the 
conclusion that mirtazapine has a greater effect on response speed (motor processes), whereas 
lorazepam more strongly affects information processing (cognitive processes). We refrain 
from making assumptions about which pharmacological mechanisms could underlie these 
effects because that would require knowledge of the effect of other doses and the time course 
of the drugs. However, we can conclude that sedation is not a general endpoint of a drug-
induced state. 
The present results show similarities to the results of other studies. As was stated in 
the introduction, several studies had found that the VAS did not discriminate between drugs 
or dosages of the same drug whereas other sedation measures did (Green, McElholm et al. 
1996; Huron, Giersch et al. 2002; Pompeia, Lucchesi et al. 2004; Weingartner, Sirocco et al. 
1995). However, it should be noted that the results of two studies suggest that subjective 
ratings can discriminate better than the psychomotor measures (Mintzer and Griffiths 2002; 
Roache, Cherek et al. 1993). This may be explained by the fact that these two studies used 
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another type of subjective ratings than the other studies mentioned that might have been more 
discriminative than the VAS from Bond and Lader (1974), or that the psychomotor measures 
used by Roach et al or Mintzer and Griffiths were less sensitive to the ones used in the present 
study. Another explanation could be that at smaller doses there might be larger between-drug 
differences in subjective effects, whereas at larger doses the drugs may show, larger 
differences in psychomotor performance. What is new is that our comparative analyses 
suggest that the objective sedation measures appear to allow a distinction between two types 
of sedative effects: some predominantly measure response speed and others (speed of) 
information processing. 
 
Differential patterns on memory and sedation tests 
Standardized scores proved to be most helpful in evaluating differences in drug effects 
across the two studies.  Lorazepam showed an equal impairment on the memory and sedation 
measures whereas mirtazapine induced more sedative effects than memory impairment. 
Lorazepam caused more sedation and more impairment on word recognition than olanzapine, 
but equal memory impairments in the VMT free recall. The comparison of olanzapine and 
mirtazapine revealed that mirtazapine induced greater impairments on the sedation tests than 
olanzapine, whereas olanzapine caused more impairment on memory measures than 
mirtazapine. The findings clearly demonstrated that lorazepam had strong sedative effects as 
well as strong effects on memory, that olanzepine and mirtazapine also induced robust 
sedative effects and that mirtazapine did not affect memory in the measures used. 
Interpretation of the effects of olanzapine on memory, however, is less straightforward. Word 
recognition proved intact, which is indicative of preserved capacity for storage of information 
into memory (Lezak, 1995), suggesting that either changes in arousal or attention caused the 
impairments in the two free recall conditions. On the other hand, its sedative effects were less 
pronounced than they were for mirtazapine, which refutes the former explanation although it 
does not fully exclude changes in attentional functions. Although not significant, relative to 
its effects on some of the objective sedation tests the VAS scores for olanzapine were high, 
which might indicate that the perceived sedative effects caused subjects to be distracted or 
less motivated to perform optimally in the free recall trials of the memory test, but as 
distraction and motivation were not studied we can only speculate about this. 
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Table 3. Overview of the comparative VL]HVWUHQJWKRIWKHGUXJV¶HIIHFWVRQWKHFRJQLWLYH
sedation tasks and memory tests. 
 Tests Strength of drug effects 
SEM MIR > LOR > OLA 
SRT MIR >  LOR =  OLA 
CRT LOR =  MIR > OLA 
SDST LOR > MIR = OLA 
RC LOR > MIR = OLA 
IR LOR > OLA >  MIR 
DR LOR > OLA > MIR 
 
Another interesting observation is that when we arrange the cognitive sedation tests 
and memory conditions, i.e. from those requiring the least to those requiring the most 
cognitive effort, a pattern of drug effects emerges. As we have in part seen earlier in the 
section discussing the sedation tests only, for the SRT and SEM the effect of mirtazapine is 
larger than of lorazepam, whereas the reverse is true for the next three tasks: CRT, SDST and 
RC. For all five tasks the effect of olanzapine is smallest or smaller than the effects for 
mirtazapine in the first two tasks and lorazepam in the next three tasks. The last two, the free 
recall conditions IR and DR of the VMT are the most demanding tasks as they require the 
most cognitive effort to perform. Here the effect of lorazepam is again strongest, but now 
followed by olanzapine and the smallest effects are found for mirtazapine. Taken together, the 
effect of mirtazapine appears to diminish relative to the effects of the other drugs when task 
demands or cognitive effort increases. The effects of lorazepam, on the other hand, appear to 
become stronger with incremental task demands or cognitive effort. For olanzapine the effect 
is smallest on the least demanding tasks but it becomes larger in the two most demanding 
memory tasks. 
The effects of the three drugs on the SDST showed a remarkable resemblance to their 
effects on word recognition in the memory task. This does not appear to be a chance finding 
as the results of other studies corroborate this. Green et al. (1996) found similar levels of 
sedation for chlorpromazine (100 mg) and lorazepam (2 mg) on the VAS and SEM but not on 
the SDST. Both the SDST and the memory tests were affected by lorazepam only. 
Additionally, Curran and colleagues (1998) observed that lorazepam (2 mg), scopolamine (0.6 
mg) and diphenhydramine (50 mg) all induced subjective sedation and decreased speed on the 
Finger Tapping Test whereas other sedation tests, among which the SDST, and the memory 
test were only affected by lorazepam and scopolamine. 
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The present study has substantial relevance for future studies comparing drugs with regard to 
their (adverse) sedative effects. Our data show that it is ill-advised to solely base the 
evaluation on a single sedation test or a single memory condition. The use of standardized 
scores and the combination of multiple tests that differ in the amount of cognitive effort they 
require will facilitate the detection of differential patterns in drug effects. One limitation of 
the present study is that the drugs were compared at a single-dose level. This could very well 
be one of the reasons why we failed to find effects of haloperidol in the present study. 
Possibly, the dose we chose was too low or the timing too early as Beuzen et al (1999) did 
find sedative effects for haloperidol (3 mg) on the SRT six hours after administration. On the 
other hand, De Bruijn et al (2006), did find effects for 2.5 mg haloperidol in that it reduced 
error related negative processing in an ERN / ERP paradigm, thereby proving CNS activity 
for this dose.  
Future research should be conducted to see whether similar findings can be found with 
both lower and higher doses for each drug tested because it is, for example, known that higher 
doses of benzodiazepines will generate equal responses to various sedation measures (Buffett-
Jerrott and Stewart 2002). Although lorazepam and other benzodiazepines are known to show 
dose-related effects, such studies could clarify whether this is also the case for olanzapine and 
mirtazapine or haloperidol. It is known that high doses of mirtazapine are less sedative than 
lower doses due to the relative higher noradrenergic activation which overrides 
antihistaminergic activation which is limited in increase with dose (Fawcett et al 1998 and 
Nelson et al 1997). In addition, chronic administration studies might offer relevant 
information about differences in time course of tolerance patterns for the sedative drugs. 
Future studies might also want to investigate a larger group of subjects to allow for other 
statistical approaches like principal component analyses or regression analyses. These 
LQYHVWLJDWLRQVFRXOGKHOSFODULI\WKHIDFWRUVLQYROYHGLQDQGWKHQDWXUHRIWKHGUXJV¶VHGDWLYH
propensities. 
 
In conclusion, the results of the current study show that the effects of drugs vary in magnitude 
across different measures. Furthermore, the drug patterns showed that the SRT and SEM were 
more sensitive to increases in response speed, which were largest for mirtazapine. The CRT 
and SDST were most sensitive to identify impairments in information processing, caused by 
lorazepam. Also, the effect of lorazepam is greater in tasks demanding more cognitive effort. 
On the other hand, the effect of mirtazapine appears strongest in the least demanding tasks, 
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which diminishes when cognitive effort increases. For olanzapine the effect is relatively low 
in the least demanding tasks, i.e. the sedation tests, but it becomes greater in the two most 
demanding memory tasks. Based on our findings, we conclude that the use of multiple 
sedation tests affords a differentiation of the effect patterns in sedative drug.  
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CHAPTER 4 
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D-amphetamine enhances psychomotor speed and not 
information processing.  
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Abstract 
Introduction: Dopaminergic enhancement by d-amphetamine may be relevant for patients 
with a major depressive episode as the concomitant symptoms of psychomotor slowing 
affecting both motor and information-processing speed are thought to be associated with 
dopaminergic prefrontal dysfunction. It is hypothesized that d-amphetamine will augment 
motor speed rather than information processing.  
Method: In a double-blind study the acute effects of d-amphetamine (15 mg) are compared to 
placebo in sixteen healthy volunteers. Psychomotor speed is assessed using a simple and a 
choice-reaction-time task, an electrooculogram (EOG) of saccadic eye movements, a figure-
copying task, two rotor-pursuit tasks and a code-substitution task (SDST). Accuracy is 
evaOXDWHGZLWK(2* D )LWWV¶ DLPLQJ WDVN D WUDFNLQJ WDVN DQG D pointing task. Information 
processing is gauged using the SDST and the continuous trail-making test and memory by an 
episodic verbal-memory test. Subjective alertness, contentedness and calmness are rated with 
visual analogue scales.  
Results: After d-amphetamine overall psychomotor speed was enhanced while accuracy 
remained intact. Neither information processing nor memory were improved. Self-reported 
alertness and contentedness were augmented. 
Conclusion: D-amphetamine improved psychomotor speed but not information processing 
thus further corroborating the notion that the subgroup of depressed patients characterized by 
slowed psychomotor speed might benefit from psychopharmacological treatment enhancing 
dopaminergic functioning. 
  
Introduction 
Several psychiatric symptoms and diseases are linked to diminished prefrontal dopaminergic 
functioning. A number of imaging studies, for instance, have related psychomotor slowing, an 
objectively observable slowing in the motor and cognitive behavior of patients suffering from 
a major depressive episode (DSM IV), to decreased activation in loops connecting the frontal 
lobes, limbic system, basal ganglia, and cerebellum (Hickie, Ward et al. 1999; Videbech, 
Ravnkilde et al. 2002).  Another imaging study found striatal presynaptic dopaminergic 
functioning to be diminished in depressive patients exhibiting psychomotor slowing but not in 
impulsive depressives (Martinot, Bragulat et al. 2001). Psychomotor slowing is not only 
important for the diagnosis of depression but also for the choice of treatment as two studies 
showed that the symptom predicts nonresponse to treatment with a selective serotonin 
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reuptake inhibitor (SSRI) in both younger and elderly depressed patients (Kalayam and 
Alexopoulos 1999; Taylor, Bruder et al. 2006). SSRI nonresponse was thought to be 
associated with dopaminergic dysfunction in the prefrontal cortex (PFC) and subcortical 
areas, a dysfunction not directly targeted by SSRIs. These results led to the conclusion that 
treatment strategies in refractory patients with signs of psychomotor slowing should include 
enhancement of dopaminergic neurotransmission (Taylor, Bruder et al. 2006). Mentioned 
findings underscored the relevance of continued research into the relationship between 
psychomotor performance and dopaminergic enhancement and prompted the present study. 
Various techniques have been applied to measure and explain the mechanism and scope of 
psychomotor slowing (Sabbe, van Hoof et al. 1998a; Sabbe, van Hoof et al. 1998b; Sobin and 
Sackeim 1997), among which the assessment of the visuomotor processes implicated. In 
previous research into depressed patients with severe psychomotor slowing the tasks 
employed tapped into information processes as well as psychomotor performance and both 
processes were found to be slowed (Pier, Hulstijn et al. 2004a; Pier, Hulstijn et al. 2004c; 
Sabbe, Hulstijn et al. 1999). 
The aim of the present study is to investigate whether dopaminergic, or to be more precise, 
catacholaminergic enhancement by d-amphetamine facilitates motor performance or 
information-processing performance, or both. This has not been consistently investigated 
before. Only one small-scale study (Austin, Mitchell et al. 2000) explored the effects of 
apomorphine (2,5 mg subcutaneous) in seven melancholically depressed patients and five 
controls, but found no effects. Although the authors accordingly concluded that neither motor 
performance nor inIRUPDWLRQSURFHVVLQJZHUHPRGXODWHGE\GRSDPLQHWKHVWXG\¶VPDQ\
limitations do not allow such a conclusion. Its sample size was too small, patients and 
controls differed considerably in age causing significant differences in the baseline 
SV\FKRPRWRUPHDVXUHVDQGLWUHPDLQHGXQFOHDUWRZKDWH[WHQWWKHVXEMHFWV¶SHUIRUPDQFHKDG
been affected by the potential sedative side effects of apomorphine and even domperidon.  
To prevent the latter potential confounders, in the present study we investigated the effects of 
15 mg d-amphetamine, a catecholaminergic drug that enhances dopamine (DA) and 
noradrenalin (NA) especially in the prefrontal cortex (PFC). Although d-amphetamine is less 
selective for dopamine than apomorphine, it has substantially fewer side effects and has 
known therapeutic effects in patients where it attenuates depressive symptoms such as lack of 
energy and apathy (Brown and Gershon 1993; Feinberg 2004; Linet 1989). We, moreover, 
opted for healthy volunteers because we specifically wished to separate the effects of d-
DPSKHWDPLQHRQWKHVXEMHFWV¶FRJQLWLYHSHUIRUPDQFHIURPWKRVHRQWKHLUPRWRURXWFRPHDQG
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feared that in depressive patients exhibiting psychomotor slowing we might not be able to 
disentangle these effects from other disease processes. 
Another reason to choose d-amphetamine is that in contrast to other dopaminergic drugs, the 
DJHQW¶VVWLPXODWLQJHIIHFWVon overall cognitive functioning are well established (Solanto 
1998). In healthy volunteers d-amphetamine is known to increase subjective alertness and 
induces feelings like euphoria, elation and friendliness (de Wit, Enggasser et al. 2002; 
Feeney, Goodall et al. 1996; Fillmore, Kelly et al. 2005; Zacny, Bodker et al. 1992). In his 
review Koelega (1993) concluded that the effects of stimulants like d-amphetamine improve 
performance by both enhancing overall performance levels (speed and accuracy) and 
preventing a decrement of performance in time. More interestingly, three more recent reports, 
one being a review, concluded that d-amphetamine specifically enhances motor activation as 
opposed to stimulus activation, i.e. improved information processing (Cochran, Thorne et al. 
1992; Halliday, Gregory et al. 1990; Solanto 1998). It should, however, be noted that these 
studies only used a single test to assess these various performance aspects.  
The current study hence attempts to replicate the reported effects of d-amphetamine in healthy 
volunteers and in a wider range of tests assessing psychomotor performance and information 
processing that have earlier been used in depression research (Austin, Mitchell et al. 2000; 
Hickie, Ward et al. 1999; Pier, Hulstijn et al. 2004c). We hypothesized that psychomotor 
slowing measures are modulated by the dopaminergic enhancement induced by d-
amphetamine and that the effects on tasks manipulating motor speed will be more pronounced 
than those that rely more strongly on information processing. Memory and subjective 
evaluations were added as control measures. 
 
Materials and methods 
Participants 
Participants were 16 healthy volunteers (8 men, 8 women) with a mean age of 22.5 years (sd 
5.09; range 18-39 years) of whom 14 were right-handed and 2 left-handed. Educational status 
ranged from high school completers to university graduates. All volunteers were in good 
physical and mental health as determined by their medical history and medical, ECG and 
laboratory examinations. The study was approved by the local medical ethics committee and 
written informed consent was obtained from all volunteers prior to testing. 
 
Design, drug administration and procedure 
D-amphetamine enhances psychomotor speed and not information processing  67 
²²²²²²²²²²²²²²²²²²²²²²²²²²²²²²²²²²²²²²²²²²²²² 
 
We used a double-blind, placebo-controlled, randomized, four-way crossover design. The 
study originally comprised four drug conditions, i.e., placebo, d-amphetamine 15 mg, 
lorazepam 2.5 mg, and mirtazapine 15 mg. To achieve a balanced administration order, the 
drugs were randomized using a Latin-square design (repeated four times). The results 
concerning the d-amphetamine and placebo conditions are reported here; the lorazepam and 
mirtazapine effects have been reported elsewhere (Wezenberg, Sabbe et al. 2006). Testing 
took place two hours after drug intake, which was around Tmax. All drugs were administered 
in a single oral dose, with a washout of one week. 
To familiarize themselves with the tests and procedures, all participants were invited to the 
hospital for a practice session within the week preceding the actual trials. For the practice 
session and the four test days we had 5 equivalent versions of all tasks at our disposal with the 
versions being counterbalanced over the various test days.  
 
Tests 
Psychomotor tasks 
Simple reaction time task (SRT) 
The subjects were instructed to press a response button on a response module with the index 
finger of their dominant hand as soon as they saw a yellow square ± presented at random 
intervals (range 0.5-1.5 seconds) ± appear in the center of a PC monitor. The SRT outcome 
measure was the mean reaction time over a total of 20 targets. 
 
Choice reaction time task (CRT) 
7KHZRUGVµOHIW¶DQGµULJKW¶ZHUHSUHVHQWHGLQUDQGRPRUGHURQD3&PRQLWRUDQGVXEMHFWV
were asked to press the corresponding buttons on the response module as fast as possible 
using the left LQGH[ILQJHUIRUWKHZRUGµOHIW¶DQGWKHULJKWLQGH[ILQJHUIRUWKHZRUGµULJKW¶
Also the CRT outcome measure was the mean reaction time over a total of 20 stimuli. 
 
Electro Oculogram, peak velocity of saccadic eye movements  (EOGpv) 
The participants, whose heads were immobilized in a head support during task performance, 
needed to track a fast-moving target with their eyes as accurately as possible while their 
saccadic eye movements (SEMs) were recorded by means of an EOG. The target consisted of 
a light-emitting diode (LED) moving on a horizontal bar on a screen that was placed 50 cm in 
IURQWRIWKHSDUWLFLSDQWV7KHVL]HRIWKHWDUJHW¶VODWHUDOGLVSODFHPHQWVZDVIL[HGDWRU
degrees of visual angle (10 and 20 degrees from the center, respectively) with varying 
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interstimulus intervals. The trial sequence was: 7 trials at 20 degrees, 14 at 40 degrees and 7 
at 20 degrees. Because they showed the strongest response, we will only report the results of 
the 40-degree trials. The SEM outcome measures are the overall mean peak velocity, reaction 
times and movement accuracy. 
 
Pointing task 
In this simple motor-coordination test subjects have to hold a normally shaped, electronic 
ballpoint pen closely above a target dot on a sheet of paper that is placed on a digitizer and to 
WU\QRWWRPRYHWKHSHQIRUVHFRQGV:HXVHGWKLVµKDQG-VWDELOLW\¶WHVWZKLFKVRPHZKDW
resembles the body sway test that measures overall postural stability  (McClelland 1989), to 
FRQWUDVWWKHVXEMHFWV¶PRWRUFRRUGLQDWLRQWRWKHLUSHUIRrmance on the more complex pursuit 
tasks (see below). The pointing-WDVNRXWFRPHPHDVXUHLVWKHSHQ¶VPHGLDQGLVWDQFHWRWKH
target point; to facilitate comparison to the two pursuit measures, each score was transformed 
to a z-score. 
 
Pursuit task 1 
For this continuous motor task we used a computerized version of the classical rotary pursuit 
task (Ammons 1947;Siegel 1990). Subjects had to track the movements of a large target 
stimulus that followed a spatially predictable circular path across the computer screen with a 
cursor by moving the pen across an XY-tablet. The pursuit-1 outcome measure was 
percentage of time on target.  
 
Pursuit task 2  
In this second pursuit task, whose format was identical to that of pursuit task 1, attention load 
was manipulated in that the target speed gradually increased when the cursor was kept within 
the confines of the target and rapidly slowed down again when it was not. The pursuit-2 
outcome measure was the total number of rotations.  
 
)LWWV¶WDVN 
7KH)LWWV¶WDVNZHXVHG0DJill 1993) requires precise motor planning and programming. The 
centers of three open circles that are placed in a triangle have to be connected in a clock-wise 
GLUHFWLRQ3HUWULDOPRYHPHQWDFFXUDF\ZDVPDQLSXODWHGE\YDU\LQJWKHFLUFOHV¶GLDPHWHUV
or 1 cm) and the between-circle distance (3.5 or 7 cm), resulting in four different trials (1 = 
big target/short distance, 2 = big target/long distance, 3 = small target/long distance, 4 = small 
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target/short distance). Trial duration was 25 seconds. The task¶VRXWFRPHPHDVXUHZDVWKH
number of completed lines per trial. 
 
Tracking task 
We based our eye-hand co-ordination test on a maze task that was shown to be sensitive to 
drug effects (MeyerLindenberg, Gruppe et al. 1997). The subject has to move a cursor along a 
curved path up to its end without touching the borders. If a border is touched, the trial has to 
be repeated. The level of difficulty is increased in that in consecutive trials the path becomes 
narrower and the number of curves rises. The tracking-task outcome measures are the number 
of mazes completed, mean completion time and number of errors. 
 
Figure copying task (FCT) 
The task requires subjects to copy 20 patterns containing two, three or four line segments that 
are presented in a fixed random order on a computer screen in the designated, preprinted 
boxes on a form sitting on the digitizer. They start the trial by putting the pen in a circle 
printed below and left of the relevant box. The stimulus patterns disappear as soon as the pen 
is put on the paper. Subjects end the trial by putting the pen in a circle printed above and right 
of the relevant box. The FCT outcome measures are the time taken to start drawing the 
pattern, denoted as RTD (reation time pen down), i.e., the time elapsed between the moment 
the pen is lifted from the start-trial cirlce and is first placed inside de designated copy box) 
and the time taken to complete drawing the pattern, which was denoted as MT (motion time), 
i.e., the time between RTD and the moment the pen is lifted from the copy box for placement 
in the end-trial circle.  
 
Information-processing tasks 
Symbol Digit Substitution Test (SDST)  
In this variant of a subtest of the Wechsler Adult Intelligence Scale (WAIS; (1997) subjects 
have to substitute nine symbols with the digits 1 to 9 on the basis of a given key. The SDST 
outcome measure is the total number of digits completed within 90 seconds.  
According to Hege et al.(1995) and Lezak (Jogems-Kosterman, Zitman et al. 2001;Sabbe, 
Hulstijn et al. 1999;van Hoof, Jogems-Kosterman et al. 1998a) the SDST measures many 
cognitive components like visuospatial scanning, intermediate memory, perceptual motor and 
cognitive processing speed. To distinguish between these higher-order cognitive processes 
and the more automated motor action of noting down familiar digits, we adopted an analysis 
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method that has been used in previous studies (Jogems-Kosterman, Zitman et al. 2001; Sabbe, 
Hulstijn et al. 1999; van Hoof, Jogems-Kosterman et al. 1998b). Based on the pen-pressure 
data, movement trajectories are defined as either pen-up or pen-down periods, allowing the 
separate computation of mean matching time, i.e., the intervals spent on the predominantly 
cognitive processes, and mean writing time, the time spent on the actual motor component. 
 
Continuous Trail-Making Test (CTMT)  
7KH&707YDULDQWZHXVHGLVEDVHGRQ5HLWDQ¶VWUDLO-making test (Lezak 2006). Part A, the 
simplest section of the test, measures visual scanning, motor speed and agility while the more 
complex part B assesses executive performance, i.e., set-shifting, working memory and 
divided attention (Vakil and Blachstein 1993).  
In Part A subjects needed to connect as many letters in alphabetical order as they could in 120 
seconds. In Part B, and again in 120 seconds, they needed to connect as many numbers to 
their corresponding letters in the alphabet by alternating between the two sequences (e.g. 
1A2B). The CTMT outcome measures for Part A and Part B were the total number of 
correctly connected elements. 
 
Memory task 
Verbal memory test (VMT) 
Contrary to the classical Auditory Verbal Learning Test (1974) on which it was founded, our 
VMT consisted of 18 words instead of the original 15 words to prevent ceiling effects. The 
words were read out to the participants three times with the instruction to memorize as many 
words as possible each time. Under normal circumstances an increasing number of words will 
be recalled after each presentation. The participants were asked to recite the words they could 
recollect immediately following each presentation (immediate recall) and after an interval of 
20 minutes (delayed recall). Immediately following the delayed-recall condition a list of 36 
words was read out from which they were asked to identify the 18 words of the test list (word 
recognition). The other 18 words were distracters that resembled the correct words 
semantically or phonologically. The outcome measures for the five separate recall conditions 
were the number of correctly recollected words.  
 
Subjective measure 
Visual Analogue Scales (VAS) 
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:HRSWHGIRUWKHWKUHH9$6VXEVFDOHVµDOHUWQHVV¶µFDOPQHVV¶DQGµFRQWHQWPHQW¶WKDW%RQG
and Lader derived by factor analysis (Bond and Lader 1974). Each scale consists of a 10-cm 
horizontal line with on each end two extremes of a mood. Subjects are asked to rate their 
feelings at the time of testing by placing a vertical mark across each line with the middle of 
the scale taken to reflect a normal mood.  
 
Apparatus 
In the SEM test the Nihon Kohden Nystagmo Stimulator (SLE-5100) generated the target 
stimuli on the LED and Ag/AgCl electrodes were placed laterally to both eyes and on the 
mastoid. The electrodes were connected to a bioelectric input box (Nihon Kohden ENG Input 
Panel (PN-640G)). The signals were amplified by the Nihon Kohden Polygraph Amplifier 
Console (RMP 6004) and filtered by the Nihon Kohden AN-601G. The high-pass filter was 
set at 3.0 Hz. The sensitivity was 4 x 6 dB. The SEMs were recorded and analyzed using the 
Cambridge Electronics Design Intelligent Interface (CED 1401) and CED Spike2 software. 
The pointing task, both pursuit tests, the Fitts and Tracking tasks, and the FCT, CTMT and 
SDST formed part of an ORGABAT cognitive and psychomotor test battery 
(www.kikosoft.com) (Cochran, Thorne et al. 1992;Halliday, Gregory et al. 1990;Solanto 
7KH657DQG&57WHVWVZHUHUHFRUGHGRQD:LQGRZV3&XVLQJWKHµ5WSV\FK¶
program written in Delphi).  
 
Statistical analysis 
The tests were grouped and analyzed according to the following domains: psychomotor 
measures emphasizing speed and those focusing more on accuracy, speed of information 
processing, memory function and subjective evaluation. To assess whether d-amphetamine 
had improved performance, a Multivariate General Linear Model (GLM) Repeated Measures 
Analyses of Variance (MANOVA) was performed for each group of tests. We subsequently 
performed separate analyses for the single tests. For the tests that assessed both baseline and 
T-max measures, the T-max results were used for the group analyses. 
For statistical evaluation SPSS 12 for Windows was used.  
 
Results 
Both the descriptive statistics and the MANOVA results of the d-amphetamine effects on all 
measures are presented in Table 1. 
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Table 1: Results of the descriptive statistics and the MANOVAs on the two psychomotor, the 
information-processing, memory and self-report measures.    
 
m = mean; sd = standard deviation;  FCT MT, - RTD = Figure copying task motion time, reactiontime down; 
EOG RT, - PV, -Acc = Electro oculogram reaction times, peak velocity, accuracy of movement;  ERT = 
elementary reaction time; CRT = choice reaction time; SDST = Symbol digit substitution test; CTMT = 
continuous trail making test; VMT IR, -DR, -RC = verbal memory test immediate recall, delayed recall, 
recognition; VAS alert, - cont, - calm = Visual analogue scales alertness, contentedness, calmness. 
  
  
Placebo D-amphetamine   
m sd m sd F (1,15) p 
Psychomotor speed       Multivariate: F(7,9) = 6.67, p = .015 
Pursuit 1 (% in target) 96.46  2.01 96.28 2.32 < 1 ns 
Pursuit 2 (no. of rotations) 21.76 3.08 23.58 2.35 4.69 .047 
Fitts (no. of lines) 68.25 13.16 69.67 12.76 < 1 ns 
Tracking (no. of mazes) 11.38 1.50 11.94 1.12 3.46 .083 
FCT MT (m.sec) 549 115 547 105 < 1 ns 
FCT RTD (m.sec) 1103 214 1065 182 3.34 .088 
EOG RT 
(sec) 
 
Baseline 0.221 0.019 0.225 0.026 
4.39 .054 T-max 0.218 0.014 0.212 0.017 
EOG PV 
(sec/cm) 
Baseline 348.25 31.05 343.03 27.80 
20.43 <.001 T-max 345.02 28.35 361.51 26.02 
SRT (m.sec) 
 
Baseline 240.80 19.68 250.98 45.03 
< 1 ns T-max 238.39 14.42 241.60 26.23 
CRT (m.sec) 
 
Baseline 291.67 26.98 303.09 40.11 
< 1 ns  T-max 298.19 23.30 294.27 28.77 
Psychomotor accuracy  Multivariate F(3,13) = 1.19, p = .364 
EOG Acc 
ǻGHJUHHV 
Baseline 2.08 0.64 2.21 0.51 
< 1 ns T-max 2.09 0.51 1.89 0.46 
Pointing (cm) 0.41 0.07 0.38 0.07 3.19 .094 
Fitts (no. of errors) 10.05 6.16 8.80 4.71 3.48 .082 
Tracking (no. of errors)  1.75 1.34 1.68 1.96 < 1 ns 
Information processing Multivariate: F(4,12) < 1, p = ns 
SDST (no. of digits) 68.44 7.22 66.75 8.54 1.54 .233 
SDST MT (m.sec) 950 148 1001 204 3.34 .089 
CTMT Part A 79.8 11.1 79.4 11.1 < 1 ns 
CTMT Part B 67.6 12.3 68.7 14.2 < 1 ns 
 Memory         Multivariate: F(3,13) < 1, p = ns 
VMT IR  31.31 6.24 31.00 6.49 < 1 ns 
VMT DR 11.06 3.49 11.19 3.19 < 1 ns 
VMT RC 14.75 2.11 14.88 1.96 < 1 ns 
Subjective evaluation    Multivariate F(3,13) = 5.21, p = .014 
VAS alert Baseline 43.06 3.09 42.85 2.83 
9.15 .009 (less-more) T-max 42.83 3.28 32.91 3.53 
VAS cont Baseline 47.64 0.97 46.86 1.16 
5.25 .037 (less-more) T-max 46.25 1.07 49.78 1.24 
VAS calm Baseline 36.94 3.08 38.44 3.42 
1.39 .256  (less-more) T-max 42.09 2.80 46.06 3.71 
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The multivariate analysis of the drug-placebo contrast revealed an overall performance 
improvement after d-amphetamine on the psychomotor measures with an emphasis on speed. 
For the measures with an emphasis on accuracy neither and overall improvement nor an 
overall decrement was found.  
The results for the individual psychomotor-speed tests after d-amphetamine intake 
demonstrated significant improvements for the second pursuit test with variable performance-
dependent acceleration/deceleration, and EOG peak velocity. In addition, the drug tended to 
accelerate reaction times on the FCT and EOG, and to boost the number of mazes that were 
completed in the tracking test. And although the information-processing and memory data 
showed no drug-related effects, the subjective measures were significantly affected by d-
amphetamine: participants felt significantly more alert and content after drug intake. 
 
Discussion  
The results of the present study provide strong support for the hypothesis that psychomotor 
speed is mediated by catecholamine, i.e. dopamine and noradrenaline levels. With an acute 
dose of 15 mg d-amphetamine we found overall improvements in various psychomotor-speed 
measures, but not in measures with an emphasis on information processing. These results are 
in line with earlier inferences stating that d-amphetamine would specifically enhance motor 
activation and not the stimulus-activation processes that relate to information processing 
requirements (2004). We have now shown this to be true using a wide range of tests that 
gauge these processes in various ways. 
A more careful inspection of the results of two speed measures may clarify our findings 
further. It were the second pursuit task and the saccadic peak velocity of the EOG that yielded 
significant effects. In the pursuit test performance is constant and reliant on the continuous 
attention to a moving stimulus and a continuous adaptation of movements due to the 
performance-related increases and decreases in the speed of the moving target that are 
GHSHQGHQWRQWKHVXEMHFW¶VVXFFHVVLQUHPDLQLQJZLWKLQWKHWDUJHW7KHWDVN¶VUHTXLUHPHQWV
thus distinguish themselves from those of the other tasks where subjects needed to respond to 
targets in successive trials. Its properties hence seem to merit the conclusion that in addition 
to psychomotor speed it also measures action monitoring, which would be consistent with 
earlier evidence that d-amphetamine has a positive effect on this process (Griffiths, Marshall 
et al. 1984).  
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Performance on the EOG is different from that on the other measures in that especially the 
peak velocity of SEMs are not directly controlled by the cortex, where performance on the 
other tests is, but by the superior colliculus in the brainstem (Kato, Miyashita et al. 1995). The 
suppression and initiation of SEMs are in part innervated by the basal ganglia through the 
inhibitory connection from the substantia nigra pars reticulata to the superior colliculus and 
dopamine is known to have strong modulatory effects on the basal ganglia function (de 
Visser, van der Post et al. 2003). Therefore, drugs and in our case d-amphetamine may have a 
more direct and hence stronger effect on eye movements than on more cortically controlled 
motor actions. This assumption would be in accordance with the known sensitivity of the 
EOG measure to the (dose-dependent) sedative effects of drugs in general (Halliday, Gregory 
et al. 1990). 
Although pursuit task 2 and the EOG were the only speed tasks to show significant drug-
induced effects, all the other measures in this group yielded nonsignificant improvements in 
mean performance after d-amphetamine. However, it should be noted that performance on 
pursuit task 1, the test with invariable target speed, was optimal in both the placebo and the 
drug condition, which is very probably due to a ceiling effect.    
We evaluated the effects of d-amphetamine on the accuracy measures separate from those on 
the psychomotor-speed measures to control for possible shifts in the speed-accuracy trade-off. 
Although the changes did not reach significance, d-amphetamine did enhance mean 
performance in all the accuracy tasks. This underscores that the improvements in motor speed 
reflected a genuine performance enhancement that was not achieved at the cost of accuracy.  
The information-processing tests did not yield any significant drug-induced mean 
performance effects, which indicates that, contrary to what was hypothesized and previously 
found by others (Foster, Lidder et al. 1998) the present dose of d-amphetamine did not 
improve nor impair information processing in our healthy volunteers. This lack of effect may 
be attributable tRWKHVXEMHFWV¶SURFHVVLQJDELOLWLHVDOOZHUH\RXQJDQGKHDOWK\DQGWKHLU
performances may have been close to optimal and therefore not susceptible to (drug-induced) 
augmentation, which phenomenon has been reported in other studies using similar subjects 
(Brauer and de Wit 1996). As patients exhibiting psychomotor slowing are not performing at 
an optimum level, it may be conceivable that in this population d-amphetamine will enhance 
information-processing abilities.  
Subjective mood proved significantly affected by d-amphetamine, as was reflected by the 
elevated VAS scores for alertness and contentedness, which is in line with results from earlier 
studies (Pier, Hulstijn et al. 2004b;Sabbe, Hulstijn et al. 1999). 
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It would be interesting to see whether our findings can be replicated in studies in patient 
groups with prefrontal dopaminergic dysfunctions. Will the performance of patients 
diagnosed with a major depressive episode exhibiting varying levels of psychomotor slowing, 
for instance, be differentially affected by d-amphetamine? As both functions have been 
reported to be impaired in patients suffering from psychomotor slowing (Pier, Hulstijn et al. 
2004b; Sabbe, Hulstijn et al. 1999), will d-amphetamine enhance both psychomotor speed and 
information processing in this or other patient groups?  
 
Conclusion  
The present randomized controlled study demonstrated that catecholaminergic enhancement 
by 15 mg d-amphetamine affected performance in healthy volunteers in tasks that are also 
used to measure psychomotor slowing in patients diagnosed with major depression, a 
condition that is associated with prefrontal dopaminergic dysfunction. D-amphetamine 
LPSURYHGWKHVXEMHFWV¶VSHHGHGPRWRUSHUIRUPDQFHZLWKRXWQHJDWLYHO\DIIHFWLQJDFFXUDF\DQG
raised their self-reported alertness and contentedness, but had no impact on their information-
processing performance. The results are promising and offer favorable perspectives for 
studies examining the effect of dopaminergic treatment strategies aimed at the attenuation of 
psychomotor slowing symptoms in patients presenting with major depression. 
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biperiden and rivastigmine in elderly healthy subjects. 
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Abstract  
Rationale: The central cholinergic system is implicated in cognitive functioning. The 
dysfunction of this system is expressed in many diseases like Alzheimers Disease, Dementia 
RI/HZ\%RG\3DUNLQVRQ¶V'LVHDVHDQG9DVFXODU'HPHQWLD,QUHFHQWDQLPDOVWXGies it was 
found that selective cholinergic modulation affects visuospatial processes even more than 
memory function.  
Objective: In the current study we tried to replicate those findings. In order to investigate the 
acute effects of cholinergic drugs on memory and visuospatial functions, a selective 
anticholinergic drug, biperiden, was compared to a selective acetylcholinesterase-inhibiting 
drug, rivastigmine, in healthy elderly subjects. 
Methods: A double-blind, placebo-controlled, randomised, cross-over study was performed 
in 16 healthy, elderly volunteers (8 male, 8 female; mean age 66.1 sd 4.46 years). All subjects 
received biperiden (2 mg), rivastigmine (3 mg) and placebo with an interval of 7 days 
between them. Testing took place one hour after drug intake (which was around Tmax for both 
drugs). Subjects were presented with tests for episodic memory (wordlist and picture 
memory), working memory tasks (N-back, symbol-recall) and motor learning (Maze task, 
Pursuit rotor). Visuospatial abilities were assessed by tests with high visual scanning 
components (tangled lines and Symbol Digit Substitution Test (SDST)).  
Results: Episodic memory was impaired by biperiden. Rivastigmine impaired recognition 
parts of the episodic memory performance. Working Memory was non-significantly impaired 
by biperiden and not affected by rivastigmine. Motor learning as well as visuospatial 
processes were impaired by biperiden and improved by rivastigmine.  
Conclusions: These results implicate acetylcholine as a modulator not only of memory but 
also of visuospatial abilities.  
 
Introduction  
Insight into the major role of the central cholinergic system in memory arose from the finding 
that cognitive deficits are correlated with extensive cholinergic cell loss in the brain in 
Alzheimer Disease (AD). Pharmacological studies were able to show impaired cognitive 
performance after blocking central cholinergic pathways by use of anticholinergic drugs. 
Subsequent studies showed that this process could be reversed by enhancing cholinergic 
function with the treatment of cholinesterase inhibitors (Blokland 1995; Everitt and Robbins  
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1997; Muir 1997). The type of cognitive functions modulated by the acetylcholine (ACh) 
system varies from learning and memory to visuospatial abilities, attention and other cortical 
modulation of sensory information by changing the signal-to-noise ratio of neural 
transmission (Lucas-Meunier, Fossier et al. 2003). In contrast to animal research, human 
research mainly focused on the learning and memory modulating effects of acetylcholine, 
concentrating on the ACh receptor antagonist, scopolamine and the cholinesterase inhibitor, 
physostigmine. Generally, the findings indicate that encoding processes, and not retrieval 
processes of the declarative memory functions are negatively affected by scopolamine (Atri, 
Sherman et al. 2004; Mintzer and Griffiths 2003), and that the administration of 
physostigmine can restore the memory functioning back to normal (Flood and Cherkin 1986; 
Hammond, Meador et al. 1987; Mewaldt and Ghoneim 1979).  
In animal studies more specific methods can be used to disable the cholinergic system.  CNS 
cholinergic pathways can be totally destroyed by several exitotoxic lesioning methods (Everitt 
and Robbins 1997; Muir 1997; Robbins, McAlonan et al. 1997; Sarter and Bruno 1998a). 
Many of the early studies using exitotoxic lesions in the nucleus basalis of Meynert in rats 
showed a broad range of impaired performance on various learning paradigms like the Morris 
water maze, delayed-nonmatching-to-position and passive avoidance tasks (Dunnett, Everitt 
et al. 1991; Fibiger 1991; Muir 1997). These early toxins were not solely selective for 
cholinergic neurons, therefore it is interesting that most of the more recent studies using new 
highly selective toxin for ACh neurons, 192 IgG-saporin, could not reproduce the earlier 
findings. (Baxter, Bucci et al. 1995; Baxter and Gallagher 1996; De Rosa, Hasselmo et al. 
2001; Gutierrez, Gutierrez et al. 1999; Power, Vazdarjanova et al. 2003; Torres, Perry et al. 
1994; Wenk, Stoehr et al. 1994). This suggests that the selective decrease of cholinergic 
function might not impair learning and memory performance (Blokland 1995). Recent animal 
studies have shown that selective decrease of cholinergic function markedly impaired 
measures of attention and visuospatial performance (like a five-choice serial reaction time 
WDVNDFRQWLQXRXVSHUIRUPDQFHWHVWRIYLVXDODWWHQWLRQDQGDQDQLPDOYHUVLRQRI3RVQHU¶V
orientation task). Due to these findings the focus of interest in animal research has shifted 
from learning and memory to attentional and visuospatial functions. (Muir 1997; Voytko 
1996; Voytko, Olton et al. 1994).  
Data concerning the effects of cholinesterase inhibitors (ChEi) in patients suffering from AD, 
as well as Lewy Bod\'HPHQWLD/%'3DUNLQVRQ¶V'LVHDVH3'DQG9DVFXODU'HPHQWLD
(VaD) show that ACh not only influences memory, but also attention and neuropsychiatric 
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symptoms (Corey-Bloom 2002; Lucas-Meunier, Fossier et al. 2003; Poirier 2002; Sarter and 
Bruno 1998b). 
On the other hand, as mentioned before, in healthy volunteers studies relatively little attention 
has been paid to the effects of cholinergic modulation on other than memory related cognitive 
functions, like visuospatial and attentional abilities, and the studies that have, used non-
selective cholinergic drugs (scopolamine and physostigmine). Nevertheless, these few studies 
do seem to indicate that visuospatial processes can be impaired by anticholinergic compounds 
and facilitated by ChEi,  (Curran, Schifano et al. 1991b; Kopelman and Corn 1988; Meador, 
Moore et al. 1993; Mintzer and Griffiths 2003). In support of this view are the results of two 
patient studies: one study that looked into the effects of chronic co-administration of 
rivastigmine in schizophrenia, where it was found that rivastigmine lead to a significant 
improvement in spatial working memory (Sharma, Hughes et al. 2004). The other study 
looked into the effects of physostigmine on cognition in schizotypical personality disorder 
and found a positive effect also on spatial working memory (Kirrane, Mitropoulou et al. 
2001).The question arises as to whether the same results as in the animals can be reproduced 
in human healthy volunteers. We hypothesized that selective cholinergic drugs as compared 
to scopolamine and physostigmine, would show little effect on memory performance and 
more on visuospatial performance.  
A variety of memory and learning tests were selected, with and without visuospatial aspects. 
In addition, a set of tests with visuospatial elements was selected with and without memory 
components. The cholinergic drugs: biperiden and rivastigmine were chosen as study 
medication. Biperiden is a muscarinic receptor antagonist with much higher affinity for the 
muscarinic 1 (M1) receptor than scopolamine, which is rather non-selective (Guthrie, Manzey 
et al. 2000; Jones and Shannon 2000). M1 selectivity is relevant because the M1 receptors are 
primarily located in the hippocampus and cerebral cortex. They are associated with cognitive 
function and cell loss in AD (Bymaster, Heath et al. 1993; Everitt and Robbins 1997; Jones 
and Shannon 2000; Mash, Flynn et al. 1985).  
Theoretically a selective M1 agonist would have been the preferred choice as comparison-
drug, however most drugs that had been taken into clinical trials have now been discontinued 
due to lack of efficacy, unacceptable side effects and poor plasma pharmacokinetics (Eglen, 
Choppin et al. 2001). Therefore we have chosen for a registered  ChEi, rivastigmine that has 
proven to be effective in improving cognition in AD and has an acceptable side effects profile 
(Birks, Grimley Evans et al. 2003). In addition, it has a favourable pharmacokinetic profile. 
As opposed to physostigmine, it is relatively selective for the central nervous system. It 
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primarily affects the hippocampus and neo-cortex, the regions most affected by AD (Enz, 
Amstutz et al. 1993).  
Other reasons for choosing these drugs lie in their clinical relevance and in the general lack of 
knowledge of their cognitive effects. Biperiden is one of the drugs used to alleviate tremors in 
3DUNLQVRQ¶VGLVHDVHDQGH[WUDS\UDPLGDOV\PSWRPVFDXVHGE\DQWLSV\FKRWLFDJHQWV*XWKULH
Manzey et al. 2000). Rivastigmine is used to delay and reverse cognitive aspects of disease 
progress in AlzheimeU¶VGLVHDVHDQG/HZ\%RG\GHPHQWLD%LUNV*ULPOH\(YDQVHWDO 
Wild and Petit 2004). Both scopolamine and physostigmine, the drugs that are commonly 
used in this field of research, are mainly used for research purposes. Their cognitive effects 
are well known. 
 
Method 
Subjects 
The study was approved by the local Medical Ethics Committee. All subjects gave their 
informed consent before participating in the study. 
To prevent ceiling effects on cognitive measures, this study was performed in healthy 
elderly volunteers, because it is known that both cholinergic and cognitive functions decline 
with age and can be improved by AChE inhibitors. Sixteen healthy elderly volunteers 
completed this study, eight male and eight female. The mean age was 66.1 (sd 4.46; range 60-
75 years). They were all in good physical and mental health as determined by medical history, 
medical examination, ECG and laboratory examination. Mini Mental State Examinations 
scores were normal (mean = 28.13, sd = 1.73, range 25-30). Fifteen volunteers were right 
handed and one was ambidextrous. The education level varied from primary education to 
academic level (primary: 3, lower: 2, intermediate: 3, higher: 6, academic: 2).  
 
Drug administration 
A double-blind, placebo-controlled, randomised, four-way crossover study was performed 
with placebo, biperiden 2 mg and rivastigmine 3 mg, and Org24448 500 mg as drug 
conditions.  
For biperiden peak plasma concentrations are reached 1 to 2 hours after single dose 
administration followed by a rapid initial decline of the concentrations to 12% of the peak 
values after 6 hours, and subsequently followed by a slow terminal elimination phase with 
concentrations close to or below detection limit at 48 hours (Hollmann, Muller-Peltzer et al. 
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1987). In steady state, half-life is 26-40 hours in elderly subjects. For rivastigmine the time to 
reach maximum plasma concentration ranges from 0.8 to 1.2 hours. In elderly healthy 
volunteers, the plasma elimination half-life is 0.9 to 1.3 hours. Renal elimination of the dUXJ¶V
metabolites is rapid and essentially complete after 24 hours. Inhibition of ChE activity (in 
CSF) is significant by 1.2 hours, reaches a peak by 2.4 hours and declines slowly until approx. 
8.5 hours. (Jann, Shirley et al. 2002). Org 24448 is an Ampakine, which is known to enhance 
long-term potentiation, a mechanism associated with consolidation in memory (Staubli, 
Rogers et al. 1994). For Org24448 the time to reach maximum plasma concentration after oral 
administration of Org24448 500 mg is 1.2 hours. The terminal elimination half-life is 
approximately 6-8 hours. Because Org 24448 is not a cholinergic compound, the results on 
this drug will be reported elsewhere. 
All drugs were administered in single oral doses, with a washout of one week. To achieve a 
balanced administration order, the drugs were randomized using a Latin-square design 
(repeated four times). Testing took place one hour after drug-intake (which was around Tmax 
for all drugs).  
 
Tests, apparatus and procedure 
The tests that were used in this study belong to a cognitive and psychomotor test battery 
(Wezenberg, Hulstijn et al. 2004). In this paper only the results concerning memory and 
visuospatial performance are reported. The performance on all tests was recorded by means of 
a digitizing tablet (WACOM UD-1218-RE), a laptop computer, a pressure sensitive pen 
(which could also be used as a cursor) and test-forms. The x and y coordinates of the pen tip 
on and up to 5 mm above the digitizer were sampled with a frequency of 200 Hz and a spatial 
accuracy of 0.2 mm (de Jong, Hulstijn et al. 1996).  
To familiarize the subjects with the tests and procedures, they were invited to the hospital to 
perform a practice session within one week before the actual study days. All tests had 5 equal 
versions for 4 test-days and one practice day, test-versions were counterbalanced over test-
days. The order of the tests as well as the relative time to dose at the start of each test is 
displayed below in Table 1. 
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Tabel 1: Order of the tests and the relative time to drug administration at the start of each test. 
Only tests that will be reported in this paper are displayed. VMT = Verbal Memory 
Test, IR trials = immediate recall trials; DR 1
st
 = first delayed recall trial; DR 2
nd
 = 
second delayed recall trial; RC = recognition trial. SDST = Symbol Digit Substitution 
Test, SDRT 1
st
 = first recall trial of the SDST.  
 
Tests: 
Relative time  
after drug intake (minutes) 
VMT, IR trials 60 
SDST 67 
SDRT 1
st
 69 
VMT, DR1
st
 72 
Tangle 77 
Picture memory 90 
Figure Copying Task 95 
SDRT 2
nd
 98 
VMT, DR2
nd
 and RC 102 
Maze learning task 122 
N-back task 132  
 
 
Episodic memory tests 
Verbal Memory Test  
Based on the classical Auditory Verbal Learning Test (Vakil and Blachstein 1993), a variant 
was made consisting of a list of eighteen words. The classic test uses 15 words, however to 
prevent ceiling effects, and moreover to make the test very difficult and to resemble a state of 
dementia, a longer wordlist was chosen. The list was presented verbally three times and under 
normal circumstances subjects are supposed to remember more words after each trial. Directly 
after each presentation, and after an interval of 5 and 30 minutes subjects were asked to recall 
as many words as they could remember. After the last delayed recall trial a list of thirty-six 
words was presented from which they had to recognize the eighteen correct words. The 
incorrect words were distracters and resembled the correct words in a semantically or 
phonologically manner. The outcome measures are number correct scores for the three 
immediate recall trials, the two delayed recall trials and the delayed recognition trial.  
 
Picture Memory  
Visual memory or picture memory has been used widely as a measure of immediate and 
delayed memory for the detection of cognitive change in all sorts of conditions. 
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Figure 1: Example of Picture memory test. To the left are the sixteen pictures that need to be 
learned. To the right is where the sixteen correct ones need to be recognized. 
 
The Picture Memory task used in this study was modelled after a task used for the detection 
and localisation of brain damage by Petrides and Milner (1982). That visual memory tests are 
also sensitive for cholinergic (and other) drug effects has been shown by many studies 
(Kikuchi, Wada et al. 1999; Peretti, Danion et al. 1997; Rammsayer, Rodewald et al. 2000; 
Robbins, Semple et al. 1997).   
An example of the test is depicted in Figure 1. In the first part of this test (the immediate 
visual recognition part) a matrix of sixteen abstract visual designs was presented, which had 
to be memorized. Thereafter a matrix of forty-eight designs was presented and the sixteen 
original designs had to be identified by pointing them out. The second part of the test started 
with the presentation of the correctly remembered designs, which were interspersed among 
other designs (again together 48 designs). Subjects were asked again to learn these designs, 
and to recognize them out of 48 designs, but now only one at the time. After each choice the 
matrix was scrambled, containing the same 48 designs and subjects had to point out the next 
design. This continued until all designs had been recognized or until two mistakes in a row 
had been made. 
This test evaluates visual recognition and self-ordered retrieval and the outcome 
measures are number correct in part 1 and part 2. 
 
Working memory tests 
N-back task 
For the measurement of working memory an N-back task was chosen that is widely used for 
the detection of working memory deficits in schizophrenia (Meyer-Lindenberg, Poline et al. 
2001; Weinberger, Mattay et al. 1996). In the present version of this test subjects were 
presented with a starting circle and six possible target circles surrounding the starting circle 
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on the computer monitor, which reflects the same positions as on the paper form. In the 1-
back condition, subjects had to respond to the stimulus that was presented in the previous 
trial. In the 2-back condition, subjects had to respond to the stimulus that was presented two 
trials before. Both conditions had two parts with either 25 correct trials or the number that 
could be attained in 2 minutes duration. 
7KHRXWFRPHPHDVXUHLVµPRYHPHQWWLPHWRUHDFKWDUJHW¶ZKLFKLVIDVWHUZKHQ
working memory is improved and slower when working memory is impaired. The measure 
µGLVWDQFHFRYHUHGWRUHDFKWDUJHW¶ZDVDGGHGDVDFRQWUROYDULDEOHEHFDXVHPRYHPHQWWLPHLV
dependent of the distance needed to cover. One subject did not perform this test. 
 
Symbol Digit Recall Test (SDRT) 
This test comes directly after the Symbol Digit Substitution Test (SDST), which will be 
discussed in the last paragraph of this section. When subjects were finished with the SDST 
they were again presented with the symbols from the SDST, now one at the time, and asked to 
point out the corresponding numbers.  
This test is based on an extended procedure of the SDST by Kaplan et al. (1991) to measure 
incidental learning. The outcome measures are the number of correctly identified symbols and 
the response times. 
 
Motor learning tests (with visuospatial component) 
Maze learning task  
 
 
Figure 2: Example of the Maze test. 
 
To study the effect of cholinergic modulation on motor learning we used the Maze learning 
task from developed by van Mier et al. (1993). In several studies (among one PET study) it 
was shown that this task assesses motor learning without sight (van Mier, Hulstijn et al. 1993; 
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van Mier, Tempel et al. 1998b). For an example see Figure 2. The maze designs are cut-out 
designs, creating a path for the pen to traverse. The maze consists of 8 line segments, with a 
complete path of 24 cm, the width of the paths is 0.5 cm , the depth 0.15 cm. To simplify 
decision-making, the maze consists of straight lines with 90-degree angles. Only two opposite 
direction choices can be made at each intersection, one of which comes to a dead end. The 
length of each dead end path is 0.5 cm. The maze forms a closed loop, meaning start and end 
points are the same. There are four equal versions and a practice square. Subjects were 
instructed to close their eyes and find their way in the maze and make as many loops as 
possible in two minutes. They started with a practice maze for 30 seconds, then three trials 
with the maze and afterwards another trial with the rotated maze (subjects were told they had 
a new maze). This was done to control for a general increase in motor-speed instead of 
improved motor learning. 
7KHRXWFRPHPHDVXUHLVµQXPEHURIFRPSOHWHGORRSV¶LQWZRPLQXWHV 
 
Pursuit task  
To measure implicit procedural learning a computerized version of the rotor pursuit task was 
used. This test is based on the classical rotary pursuit task (Ammons 1947;Siegel 1990). It is a 
continuous motor task. Subjects had to follow the movement of a large target stimulus on the 
computer screen with a cursor by moving the pen over the XY-tablet. The speed of the target 
gradually increases when the cursor is contained within the target but slows down quite 
quickly when it is not. The target follows a spatially predictable circular path over the screen. 
The outcome measures for procedural learniQJDUHWKHµWRWDOQXPEHURIURWDWLRQV¶DQGµ7LPH
SHUORRS¶LHRQHGHJUHHWUDFNLQJRIWKHWDUJHWIRUWKHILUVWORRSV 
 
Visuospatial, information processing tests (without learning) 
Tangle 
 
 
Figure 3: Example of a simple trial in the Tangle test. 
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The Tangle task is a purely visual task, requiring high concentration for visually tracking a 
particular line winding through two to four other lines.  
The tangled lines were presented on the screen. The line that had to be visually traced to the 
end was indicated by a yellow square. On subsequent trials the tangles increased in 
complexity; they got longer and made more 90-degree turns. The paper form had a start area 
and five target areas, numbered 1 to 5, which reflect the maximum target areas on the screen, 
VWDUWLQJZLWKRQO\WKUHHWDUJHWDUHD¶VDVLQWKHH[DPSOHLQ)LJXUH 
7KLVWHVWLVPRGHOOHGDIWHUWKHYLVXDOLVDWLRQWHVWIURPWKH³NLWIRUIDFWRUUHIHUHQFHGFRJQLWLYH
WHVWV´RI)UHQFK	(NVWURP,WZDVVHOHFWHGE\WKH861$9<WRVWXG\
environmental and other time-course effects and has good task stability and reliability 
(Bittner, Carter et al. 1986a;Bittner, Carter et al. 1983). The outcome measure is the number 
of correct trials in two minutes. 
 
Symbol Digit Substitution Test (SDST)  
This test is a variant of the subtest from the WAIS (Wechsler Adult Intelligence Scale) 
(Wechsler 1981) . Subjects have to substitute the symbols for the digits 1-9 on the basis of a 
given key. The outcome measure is the total number of digits completed in 90 seconds.  
According to Hege et al. (1997) and Lezak (1994) this task measures many cognitive 
components like visuospatial scanning, intermediate memory, perceptual motor speed and 
speed of cognitive processing. Therefore, subsequent analyses were performed to attempt to 
disentangle these cognitive processes. Based on pen pressure, movement trajectories were 
defined as either pen-up periods or pen-down periods. This allowed for subsequent analysis of 
matching times and movement (writing) times in the symbol digit substitution test. For the 
motor component, the mean writing times were computed. For the more cognitive component, 
the mean matching times were computed. These analyses have been previously performed by 
(Jogems-Kosterman, Zitman et al. 2001;Sabbe, Hulstijn et al. 1999b;van Hoof, Jogems-
Kosterman et al. 1998b).  
Control measures: Sedation tests and adverse events 
Before dose and sixty minutes after drug administration subjects performed several tests 
measuring various aspects of sedation.  
Neurophysiological sedation  
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The measure Saccadic Eye Movements (SEM) was chosen as neurophysiologic measure for 
sedation. For the saccadic test, subjects were presented with sudden changes of target position 
at random intervals. The target consists of an array of light emitting diodes on a bar fixed at 
50 cm in front of the head support. The size of the steps was fixed at 30 degrees (15 from 
middle to left-right). The outcome measure is the overall mean peak velocity. 
Behavioral sedation  
As behavioural measures a Simple (SRT) and Choice Reaction Time Test (CRT) were 
chosen. In the SRT a yellow square was presented on the monitor at random intervals (0.5-1.5 
seconds). Subjects were instructed to press the response button on the response module as fast 
as possible following the detection of the target. There are 20 targets in the trial and the 
RXWFRPHPHDVXUHLVWKHPHDQUHDFWLRQWLPH,QWKH&57WKHZRUGVµOHIW¶DQGµULJKW¶ZHUH
presented randomly on the monitor and subjects had to press the corresponding buttons on the 
response module as fast as possible. There are 20 targets in the trial and the outcome measure 
is the mean reaction time. 
 
Subjective sedation 
As a measure for subjective sedation a Visual Analogue Scale (VAS) was added (Bond and 
Lader 1974). The VAS is a questionnaire of 16 visual analogue scales from which three 
factors are derived that assesses subjective in subjective alertness, calmness and contentment. 
Another subjective control measure was the reported adverse events. Whenever subjects 
reported an adverse event, this was recorded by MedDRA (6.1) coding. 
 
Statistical Analyses 
Statistical evaluation (using SPSS 11 for Windows) was performed with GLM Repeated 
0HDVXUHV$QDO\VLVRI9DULDQFH$129$ZLWKµGUXJV¶DVZLWKLQ-subject factor for all tests. 
For the Verbal Memory Test and SDRT, also the results for the within-VXEMHFWIDFWRUµWULDO¶
DQGWKHLQWHUDFWLRQEHWZHHQµWULDO¶DQGµGUXJV¶ZHUHDQDO\]HG2QO\WKHUHVXOWVRIWKHSODQQHG
contrasts, placebo versus biperiden and placebo versus rivastigmine, will be reported in the 
results section.  
 
Results 
Table 2:  Means and standard deviations per task and drug condition. M = Mean, SD = 
standard deviations. N-EDFNµ7'0¶ PRYHPHQWWLPHWRUHDFKWDUJHWDQGµ7&0¶ 
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distance covered to reach target. SDRT: STM = Short Term Memory trial, LTM = 
Long Term Memory trial. RT = Response Time. 
 
    Placebo  Biperiden  Rivastigmine 
  M  SD   M SD   M  SD 
Picture Memory Task        
 part 1 6.75 2.24  6.31 2.47  5.75 2.65 
 part 2 5.25 1.53  4.63 1.41  4.25 1.69 
Pursuit             
 
Number of 
rotations 10.56 2.94  9.60 3.70  11.45 3.65 
N-back          
 1-back TDM 0.70 0.13  0.77 0.14  0.70 0.14 
 1-back TCM 3.68 0.55  4.26 0.85  3.65 0.54 
          
 2-back TDM 0.74 0.23  0.79 0.16  0.72 0.17 
 2-back TCM 4.69 2.19  4.63 2.00  4.21 1.14 
SDRT          
 STM (correct) 1.94 1.65  2.69 1.54  3.25 1.69 
 STM (RT) 3.54 0.72  4.08 1.16  3.49 0.70 
 LTM (correct) 2.19 1.56  1.75 1.57  2.06 1.29 
 LTM (RT) 3.16 0.67  3.71 1.04  3.23 1.03 
Tangle             
 number correct 12.56 1.32  12.50 1.46  13.13 1.15 
SDST          
 number correct 40.69 9.54  36.50 9.45  43.06 10.09 
 matching time 1.72 0.51  2.02 0.57  1.62 0.57 
 writing time 0.63 0.17  0.61 0.12  0.61 0.20 
 
  
The descriptive statistics of the tests are presented in Table 2 and the results of the analysis 
are presented in Table 3. 
 
Episodic memory 
Verbal Memory Test 
As can be seen in Figure 4, test scores gradually increased from trial 1 to 3 (trial1 to 3: 
F(2,14) = 55.47, p <.001) however, from trial 1 to 3 this increase was significantly lower for 
biperiden compared to placebo. Rivastigmine scores did not improve learning compared to 
placebo scores on trial 1, 2, or 3. 
 
Chapter 5  92 
²²²²²²²²²²²²²²²²²²²²²²²²²²²²²²²²²²²²²²²²²²²²² 
 
 
 
 
 
Figure 4: Results on the Verbal Memory Test (VMT). Immediate recall results are to the left 
(ir trial 1, 2, 3). Delayed recall trials (dr trial 4, 5) and recognition trial (rc trial 6) are 
to the right. 
 
In the delayed recall trials test scores declined from trial 4 to trial 5 (F(1,15) = 23.13, p 
<.001). In both trials the biperiden performance was lower compared to placebo. Again 
rivastigmine did not improve recall; rather the reverse was marginally significant. 
In the delayed recognition trial (trial 6) the test scores approximately returned to the level of 
trial 3. Biperiden scores, and also rivastigmine scores were significantly decreased compared 
to placebo.  
 
Picture Memory  
The visual recognition of pictures was not significantly decreased by biperiden in part 1 
(simple visual memory) or in part 2 (self-ordered retrieval). 
As in the verbal memory test, rivastigmine did not improve but rather impaired performance 
in both recognition measures.  
 
Working memory 
N-back task 
Working memory as assessed by the N-back task showed significant larger movements by 
biperiden in the simple condition, but not in the more difficult condition. Furthermore a trend 
of impaired performance was found on the movement times in the more difficult, but not the 
simple condition. Rivastigmine had no effect on either measure. 
 
SDRT  
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7KHPHDVXUHµQXPEHUFRUUHFW¶VKRZHGa trend of improvement for biperiden. For rivastigmine 
also a small but significant improvement was found compared to placebo. 
7KHPHDVXUHµUHVSRQVHWLPH¶ZDVLPSDLUHGE\ELSHULGHQZKHUHDVULYDVWLJPLQHGLGQRWVKRZ
any effect. 
 
Table 3:  F and p values per task and drug condition. Verbal Memory Test: IR = Immediate 
Recall; DR = Delayed recall; RC = ReCognition. N-back: TDM = movement time to 
reach target and TCM = distance covered to reach target. SDRT: STM = Short Term 
Memory trial, LTM = Long Term Memory trial. Significance markers: 
#
 <.10 * <.05 
** <.01 *** < .001. 
 Placebo vs Biperiden   Placebo vs Rivastigmine  
  df(1,15)  df(1,15) 
Verbal Memory Test    
 IR (trial 1 vs 3 x Drugs) 12.16**  <  
 DR (trial 4 vs 5 x Drugs) 18.52***  3.45
#
 
 RC trial 6 5.12*  5.77* 
Picture Memory Task    
 part 1 <   4.80* 
 part 2 2.250  7.06* 
N-back    
 1-back TDM 2.28  <1 
 1-back TCM 6.37*  <1 
 2-back TDM 4.32
#
  <1 
 2-back TCM <1  <1 
SDRT    
 STM (number correct) 3.29
#
  9.10** 
 STM (response time) 7.05*  <1 
 LTM (number correct) <1  <1 
 LTM (response time) 5.72*  <1 
Maze learning    
 Trial (1-3) x Drugs <1  4.93* 
 Trial (3-4) x Drugs 1.15  5.21* 
Pursuit    
 number of rotations 2.88  3.49
#
 
 time per loop 6.15*  <1 
Tangle    
 number correct <1  4.23
#
 
SDST    
 number correct 3.52#  5.34* 
 matching time 6.96*  2.53 
 writing time <1  <1 
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Motor learning 
Maze learning task 
 
 
Figure 5: Results for Maze learning test on trial 1, 2, 3 and the new maze for Placebo, 
Biperiden and Rivastigmine. 
 
As can be seen in Figure 5, the number of completed loops gradually increased from trial 1 to 
3 (trial 1 to 3: F(1,15) = 11.01, p = .006). The improvement in performance over trials was 
markedly stronger for rivastigmine than for placebo. No effects were found for biperiden. 
To test whether the results of rivastigmine reflect improved motor-speed instead of improved 
learning the results of the new maze were compared to the trials of the old maze. If only 
motor-speed was improved by rivastigmine, these performances should also have been 
improved. However, there was no interaction between Trial (new versus old) x Drug (F(3,10) 
< 1), which indicates that it appears justified to conclude that rivastigmine improved motor 
learning in this task.  
 
Pursuit test 
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Figure 6: Results for the Pursuit test. Time to perform a loop for the first five loops is 
depicted here. 
 
7KHPHDVXUHµWRWDOQXPEHURIURWDWLRQVµDSSHDUHGWRVKRZGHWHULRUDWLRQLQSHUIRUPDQFHIRU
biperiden, however this effect did not reach significance. There was a trend of improvement 
in performance for rivastigmine. 
7KHUHVXOWVRIWKHSURFHGXUDOOHDUQLQJPHDVXUHµ7LPHSHUORRS¶FDQEHVHHQLQ)LJXUH7KH
time per loop was decreased for biperiden compared to placebo, no effects were found for 
rivastigmine. There was no interaction between drug * loop (1-5), indicating that the 
difference between biperiden and placebo was constant over loops. 
 
Visuospatial processes 
Tangle 
Visuospatial processes, as measured by the number of correctly solved tangles, were not 
affected by biperiden and tended to be improved after rivastigmine intake.  
 
SDST 
7KHRXWFRPHPHDVXUHµQXPEHUFRUUHFW¶VKRZHGDWUHQGRILPSDLUHGSHUIRUPDQFHIRUELSHULGHQ
and a significant improved performance for rivastigmine. Subsequent analyses showed a 
significant increase in matching time for biperiden and no effects in writing time. 
Rivastigmine showed a non-significant improvement in both matching and writing time.  
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Controlmeasures: Sedation tests, adverse events and sources of individual variation 
 
As can be seen in Table 5, sedation as assessed by the peak velocity of the SEM and the ERT 
and CRT tests did not differ between drug conditions, neither did the subjective feelings as 
measured by the VAS. 
The adverse events are displayed in Table 5. To assess WKHLPSDFWRIWKHUHSRUWHG$(¶VLQWKH
drug conditions, all analyses were repeated with AE (yes or no) as a between subject factor. 
This was repeated for only the nausea complaints on rivastigmine performance. No significant 
negative effects were found for either measurement. 
 
Table 4: Overview of results of control measures.  
M = Mean, SD = standard deviations. The reported F-values are Drug x Time 
interactions, 
#
 = p < .10. T0 is the Baseline measurement. Tmax is the measurement of 
the drug effects at the time of maximum efficacy. SEMpv: peak velocity in degrees 
SHUVHFRQG(57	&57WLPHLQPLOOLVHFRQGV9$6LQFHQWLPHWUHVµPRUH-OHVV¶
indicate the scaling of the VAS items: 0 indicates more alertness and 100 indicate less 
alertness.  
 
  Placebo Biperiden Rivastigmine 
  M SD M SD F M SD F 
SEMpv T0 349 37 353 41  343 37  
 Tmax 336 29 332 26 1.14 334 35 < 1 
          
ERT T0 290 25 288 28  288 32  
 Tmax 297 44 305 51 1.13 301 50 < 1 
          
CRT T0 375 51 370 42  372 47  
 Tmax 375 53 375 56 < 1 374 57 < 1 
          
VAS T0 43.75 13.20 47.56 12.56  45.00 12.50  
Alertness Tmax 47.00 18.96 53.93 8.54 < 1 58.56 12.54 1.64 
(more ± less)          
VAS T0 39.81 15.05 39.38 14.24  40.44 13.24  
Calmness Tmax 41.81 14.96 41.81 14.64 < 1 40.19 15.14 < 1 
(more ± less)          
VAS T0 38.94 17.56 42.06 11.45  39.19 17.18  
Contendednes Tmax 38.44 16.66 41.88 14.57 < 1 49.13 6.09 4.10
#
 
(more ± less)          
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To control for the effect of sources of individual variation, additional analysis were performed 
with Age and MMSE scores as covariates. The effect of age and MMSE scores were very 
limited and could not explain the current group findings for both drugs.  
 
 
Table 5: Overview of adverse events (AE) 
 Total number of 
subjects with 
AEs 
Number of AEs 
 
 
 
 
 
Somnolence Dizziness Nausea (vomiting) 
Placebo 5 5 0 0 
Biperiden 7 4 3 0 
Rivastigmine  9 4 1 4 (3) 
 
 
 
Discussion 
To our knowledge this is the first study to show that rivastigmine improves visuospatial 
processes, besides some aspects memory in healthy elderly subjects. 
The present study found that the M1 antagonist biperiden caused clear-cut negative effects on 
measures of episodic memory and working memory, whereas the negative effects on 
visuospatial measures were less strong and less clear. For rivastigmine marked positive 
effects were found on motor learning and visuospatial processes, and no positive, but even 
negative effects on measures of episodic memory.   
 
Modulation of Cognitive Processes: Memory  
First we summarize the results concerning the effects of the drugs on memory: For biperiden 
clear negative effects were found on the measures for episodic memory in immediate recall, 
delayed recall and recognition of verbal material. Visual recognition performance was 
unaffected. For rivastigmine no positive effects were found in measures of episodic memory, 
and surprisingly, a negative effect was found in the recognition of both verbal and visual 
material. Working memory, measured by the N-back task, showed moderate negative effects 
on accuracy and response speed for biperiden, whereas rivastigmine did not affect 
performance. In short-term memory (SDRT) biperiden showed again negative effects, as it 
did on other memory tasks, it prolonged response times, and in this test rivastigmine showed 
improved accuracy on the same measure. However, this effect is very small and in contrast to 
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the other memory tasks, therefore it is not unlikely to be an accidental finding. In motor 
learning biperiden impaired movement time over all trials in the pursuit task, however as this 
was equal over all loops, it is more likely that attentional impairments caused this decrement 
than impaired learning processes. For rivastigmine, interestingly, positive effects were found 
that actually did affect motor learning. In the maze task a relative increase in number of loops 
was found over consecutive trials, while performance dropped to baseline when a new maze 
was offered. 
Overall biperiden showed results that are in agreement with the literature on other 
anticholinergic drugs in humans as it impaired episodic memory performance (Mintzer and 
Griffiths 2003). These findings have relevance for clinical practice because this drug is 
commonly prescribed to alleviate extra-pyramidal side effects caused by antipsychotic 
medication, we therefore suggest to use caution in choosing the dose as it clearly impairs 
cognitive functioning.  
Our results of a negative impact of rivastigmine on episodic memory on the other 
hand, are in sharp contrast to most of the literature on the effects of the same or other ChEi in 
the AD populations and healthy volunteers, where generally positive results have been found 
(Bentley, Vuilleumier et al. 2003; Birks, Grimley Evans et al. 2003). In AD patients this 
positive effect is mostly measured by a change in ADAS-cog score. The ADAS-cog is a test-
battery used to measure changes in the core features of the cognitive impairments in AD, and 
has a memory, praxis and language domain.  
There are a few other studies that failed to find positive effects of AChE inhibitors, but 
they were performed in other populations than AD patients. One of those studies found that in 
patients with schizotypical personality disorder, administration of physostigmine did not 
improve performance in a verbal learning test, but only improved performance in a spatial 
performance test (Kirrane et al, 2001). Another study that could not find positive effects used 
a tone-shock conditioning reinforcement paradigm with physostigmine. The author suggested 
that an overactive cholinergic system leads to increased processing of behaviourally irrelevant 
stimuli and thereby did not improve conditioning (Thiel, Bentley et al. 2002). 
What also should be taken into consideration when trying to find an explanation for 
differential results between the effects of ACh in AD patients versus our healthy volunteers is 
that the CNS cholinergic pathways work differently in both groups. Evidence was found in a 
study by Nordberg (1989) that tacrine (an early ChEi) enhanced ACh release in AD brain 
tissue whereas it decreased ACh release in normal control tissue in post-mortem brains. These 
results were attributed to the normal working of negative feedback mechanisms (mediated via 
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presynaptic muscarinic autoreceptors) that is defective in AD brains. It could be that this 
mechanism is responsible for the neutral and negative effects that were found in the current 
study, although it does not explain the positive effects found on visuospatial performance.  
Another possible explanation might be that acetylcholinesterase inhibitors have an 
inverted U-shape function on cognitive performance, as dopaminergic compounds (Cohen, 
Braver et al. 2002). In that case, subjects would only respond in a positive manner if they 
would receive the right dose of rivastigmine. Subjects might have had the optimum dose at 
the beginning and end of the test battery as the positive results at those time points indicate. 
However, the dose might have been too high between 90 and 110 minutes after drug 
administration, when the tests were performed where negative results were found. An 
µRYHUGRVH¶FRXOGWKHQKDYHFDXVHGWKHLPSDLUPHQWVLQWKHWZRHSLVRGLFPHPRU\WHVWV
Unfortunately we have no serum concentrations to control for individual differences in 
absorption or metabolism, which might substantiate this explanation. 
 
Modulation of Cognitive Processes: Visuospatial abilities 
Improved visuospatial performance was found for rivastigmine, as it tended to 
increase the number of correct scores in the Tangles task. No impairment was found for 
biperiden on this PHDVXUH7KH6'67PHDVXUHVµQXPEHUFRUUHFW¶DQGµPDWFKLQJWLPH¶KDYH
next to intermediate memory aspects, a strong visuospatial scanning component. Results on 
these measures showed impaired performance for biperiden and improved performance for 
rivastigmine. The results of the other tests with (visuo-) spatial components, like the Tangle, 
Pursuit and the Maze learning task all showed at least a tendency of improved performance 
after rivastigmine. This suggests that the results on the SDST were more likely to be caused 
by the modulation of visuospatial processes than by changes in memory processes. This idea 
is supported by the findings that the direction of effects in the visual memory tests (both drugs 
either impair or have no effect) is different from the direction of effects on the SDST 
(biperiden impairs performance and rivastigmine enhances it). Following this interpretation, 
the negative effects of biperiden and the positive trends and effects of rivastigmine can be 
attributed to changes in visuospatial scanning performance.  
In general the data regarding the cholinergic modulation of the visuospatial 
performance are in line with the results of the few other human studies that looked into the 
effects of other cholinergic drugs on similar processes. In one study scopolamine impaired 
performance on visuospatial tasks, although mixed effects were found on measures of 
visuospatial memory (Meador, Moore et al. 1993). Other studies showed that physostigmine 
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generally increased reaction times and accuracy performance in spatial attention tasks 
(Bentley, Husain et al. 2004; Bentley, Vuilleumier et al. 2003; Witte, Davidson et al. 1997) . 
The positive results on motor learning and visuospatial performance are also in line with the 
results of animal experiments, for reviews see Gold (2003) and Power et al. (2003). 
Are the effects of Rivastigmine dependent on type of neural pathway? 
Overall there seems to be a division in type of tests where rivastigmine showed 
positive results versus negative results on cognitive performance. The tests showing positive 
effect all hold a visuospatial component, while the tests that showed a negative impact all 
KROGDUHFRJQLWLRQPHPRU\FRPSRQHQW7KLVPLJKWKDYHDUHODWLRQWRWKHµWZR-systems theory 
RIYLVXDOSHUFHSWLRQ¶ZKLFKLVDQDGDSWDWLRQIURPWKHWKHRU\DERXWµZKDWDQGZKHUH-
SDWKZD\V¶LQWKHEUDLQ7KHRULJLQDOWKHRU\ZDVSRVWXODWHGE\8QJHUOHLGHUDQG0LVKNLQ
(1982), and started with the finding that the outputs from the primary visual cortex follow two 
general pathways. The first projects to the inferior temporal cortex, a region associated with 
object recognition (the ventral pathway). The other projects to the posterior parietal cortex, a 
region associated with spatial perception (the dorsal pathway). The authors proposed that 
these paths process fundamentally different types of information. The ventral path is 
associated with object perception and recognition. The dorsal path is implicated in identifying 
WKHORFDWLRQRIDQREMHFW7KHPRUHUHFHQWYHUVLRQRIWKHµWZR-systems theory of visual 
SHUFHSWLRQ¶DOVRPDNHVDGLYLVLRQQRZEHWZHHQDZKDW-path and a how-path in information 
processing. The what-path processes information that is needed to consciously identify 
objects (e.g form, color), whereas the how-path processes information that is needed for 
online movement control (e.g. location in space) and is assumed not to be consciously 
accessible (Bridgeman 2000; Knoblich and Kircher 2004). It appears that the negative results 
on recognition of words and pictures fit in the what-path processing and the positive results 
on motor-learning and visuospatial performance in the how-path processing. This would 
imply that how-path processing would be more sensitive to increased levels of ACh than the 
what-path processing. The question remains whether this theory offers an explanation for 
ACh modulation in total or of specifically the effects of ACh increase in visual information 
processing because it cannot explain the findings of biperiden nor the results found for non-
visual (in this case verbal) material.  
 
Limitations 
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It should be noted that the present study has some limitations. It might be argued that the 
memory tests were too difficult for this age-group. Usually wordlists of ten items are used in 
neuropsychological research in elderly subjects (Bouma, Mulder et al. 1998; Lezak 1995).  
We used eighteen-item wordlists and a set of sixteen pictures. This was done on the one hand 
to make learning more difficult, as it is in dementia, and on the other hand to prevent possible 
ceiling effects.   
Furthermore, there were no specific attentional tests in the test-battery, so we could 
not control for specific changes in attention. From other studies using drugs with well-known 
effects on attention next to memory, we know that impaired attention shows up on tests of 
sedation (see the review of Buffett-Jerrott (2002) on benzodiazepines). We tried to control for 
this by looking at several sedation measures and since these did not show any effects of 
cholinergic modulation, we thought it safe to conclude that no big attentional effects were 
present in our study.    
Another issue is that in this study only one dose of each drug was used. A multiple-
dose study would give more insight, as the chosen doses may have been too low or too high to 
find the effects on the tests used in this study. It should be noted however that we did choose 
dosages that are known to have a clinical relevant effect.  
 
Conclusion 
In summary, the results of the present study demonstrated that a single dose of 2 mg biperiden 
showed clear negative effects on both episodic and working memory and that a single dose of 
3 mg rivastigmine showed both positive and negative effects on memory measures and only 
positive effects on visuospatial performance in healthy elderly volunteers.  
The conclusion that can be drawn from these findings is that the modulation of 
visuospatial processes in humans does not totally resemble the animal findings, which might 
result from the many differences between rat and human neurophysiology. It did point us in 
the direction of a new topic in ACh research: the modulation of visuospatial processes. We 
therefore advise further research into this specific cognitive domain with ACh inhibitors in 
AD patients, as it may be expected to find the most positive effects in that domain. 
To finish, we would like to repeat our concern about the use of biperiden to alleviate 
extra pyramidal side effects in clinical practice, due to its impairing cognitive effects we 
suggest to be careful in choosing the dose. 
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Abstract  
Introduction: Ampakines act as positive allosteric modulators of AMPA-type glutamate 
receptors and facilitate hippocampal long-term potentiation (LTP), a mechanism associated 
with memory storage and consolidation. The present study investigated the acute effects of 
farampator, 1-(benzofurazan-5-ylcarbonyl) piperidine, on memory and information processes 
in healthy elderly volunteers.  
Methods: A double-blind, placebo-controlled, randomized, cross-over study was performed 
in 16 healthy, elderly volunteers (8 male, 8 female; mean age 66.1, sd 4.5 years). All subjects 
received farampator (500 mg) and placebo. Testing took place one hour after drug intake, 
which was around Tmax for farampator. Subjects performed tasks assessing episodic memory 
(wordlist learning and picture memory), working and short-term memory (N-back, symbol 
recall) and motor learning (maze task, pursuit rotor). Information processing was assessed 
with a tangled lines task, the symbol digit substitution test (SDST) and the continuous trail 
making test (CTMT). 
Results: Farampator (500 mg) unequivocally improved short-term memory but appeared to 
impair episodic memory. Furthermore, it tended to decrease the number of switching errors in 
the CTMT. Drug-induced side effects (SEs) included headache, somnolence and nausea. 
Subjects with SEs had significantly higher plasma levels of farampator than subjects without 
SEs. Additional analyses revealed that in the farampator condition the group without SEs 
showed a significantly superior memory performance relative to the group with SEs.  
Conclusions: The positive results on short-term memory and the favorable trends in the trail 
making test (CTMT) are interesting in view of the development of ampakines in the treatment 
RI$O]KHLPHU¶VGLVHase and schizophrenia. 
 
Introduction 
Ampakines act as positive allosteric modulators of AMPA-type glutamate receptors (Arai, 
Kessler et al. 1994;Yamada 1998). In animals the drugs have been shown to facilitate 
hippocampal long-term potentiation (LTP), a mechanism associated with memory storage and 
formation (Lynch 1998; Staubli, Perez et al. 1994; Staubli, Rogers et al. 1994a).  
 Animal experiments have also demonstrated that ampakines improve performance in a 
variety of memory tasks like odor discrimination (Larson, Lieu et al. 1995; Staubli, Perez et 
al. 1994), spatial mazes (Granger, Staubli et al. 1993; Staubli, Perez et al. 1994), a spatial 
delayed-non-match-to-sample task (Hampson, Rogers et al. 1998), eye-blink conditioning 
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(Shors, Servatius et al. 1995) and learned fear (Lebrun, Pilliere et al. 2000). Ampakines have 
also been shown to be effective in reducing age-associated memory deficits in rats (Granger, 
Deadwyler et al. 1996). Furthermore, ampakines appear to be involved in other processes 
besides memory. Larson et al (1996) showed that the ampakine BPD-29 suppressed 
methamphetamine-induced stereotyped behavior. Next, Johnson et al (1999) found that the 
effects of very small doses of antipsychotics were greatly enhanced by the ampakine CX516. 
These ILQGLQJVOHGWRWKHGHYHORSPHQWRIDPSDNLQHVIRUWKHWUHDWPHQWRIERWK$O]KHLPHU¶V
Disease (AD) and schizophrenia. 
The current knowledge about the effects of ampakines on human memory and other 
cognitive processes is, however, still rather limited. In healthy young adults 300mg CX516 
improved the picture association, recognition of scent sequence and visuospatial maze 
performance although it only tended to enhance the recall of playing cards (Ingvar, 
AmbrosIngerson et al. 1997). In another study with young volunteers 600-1200 mg CX516 
was found to augment the delayed recall of nonsense syllables relative to baseline, whereas 
doses of 75-300mg CX516 and placebo did not enhance performance (Lynch, Kessler et al. 
1996). In healthy elderly subjects (age range 65-75 years) 900 mg CX516 caused a twofold 
increase in the recall of nonsense syllables (Lynch, Granger et al. 1997). In neither studies did 
(Lynch 2004) find any changes in tests assessing psychomotor performance, heart rate or 
mood. 
To date, only two small-scale studies have been published that investigated ampakines 
in patients with schizophrenia. One was a double-blind placebo-controlled trial in which 
CX516 was added to clozapine treatment for four weeks ((19 patients in total: 12 were 
allocated to CX516 treatment and 7 to the placebo treatment group)(Goff, Leahy et al. 2001). 
The ampakine group showed moderate to large improvements compared to the placebo group 
on attention and memory performance and showed a reduction of negative symptoms. It 
should be noted, however, that the ampakine group was substantially more impaired at 
baseline than the placebo group and that the small sample size prohibited any statistical 
analyses. In the second study (Marenco, Egan et al. 2002) administered CX516 to four 
patients with schizophrenia as a stand-alone antipsychotic treatment (in one patient as a 
single-blind treatment and in three patients as a double-blind treatment) for two to four weeks; 
two of the four patients receiving placebo dropped out. The study failed to yield any 
noticeable improvements in psychotic symptoms or cognitive processes.  
The present study is an exploratory phase I study and looks into the acute effects of 
farampator (1-(benzofurazan-5-ylcarbonyl) piperidine), a specific positive allosteric 
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modulator of the alpha-amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid (AMPA)-type 
glutamate receptors. This so-called ampakine is chemically distinct from CX516 and is being 
developed for the treatment of schizophrenia with emphasis on the improvement of negative 
symptoms and cognitive dysfunction. The basis for this lies in the glutamate balance theory 
for schizophrenia in which the potentiation of glutamatergic transmission is seen as having a 
potentially antipsychotic effect (Johnson et al, 1999). Evidence for glutaminergic involvement 
in schizophrenia comes from imaging and post-mortem studies that have found abnormalities 
in brain regions that are connected by glutaminergic circuits. Reduced excitatory 
(glutamatergic) activity might underlie some of the symptoms. This is substantiated by the 
finding that drugs like ketamine and phencyclidine, antagonists of NDMA type glutamate 
receptors exacerbate symptomps in patients and produce psychotic symptoms in healthy 
individuals. Drugs that enhance glutamatergic transmission on the other hand, might correct 
the imbalance in this system in the schizophrenic patients. 
AMPA receptors are the most abundant glutamate receptors in the brain and mediate 
fast excitatory neurotransmission as well as activation of co-localized NMDA receptors 
through partial depolarization of the postsynaptic membrane. Enhancement of AMPA 
receptor activity is anticipated to upregulate glutamatergic function through both AMPA and 
NMDA receptors. Using whole-cell patch-clamp recordings in rat cultured hippocampal 
neurons, farampator has been shown to increase glutamate-induced steady state currents with 
DQ(&YDOXHRIȝ0FRPSDUHGWRȝ0IRUWKHDPSDNLQH&;XQSXEOLVKHGILQGLQJV
Farampator was also more potent than CX516 in increasing the slope of field excitatory 
postsynaptic potentials (fEPSPs) in rat hippocampal slices. The effects of farampator were 
blocked by NBQX. These preliminary results indicate that farampator is an allosteric 
modulators of AMPA receptor function in hippocampal neurones and that it is as such more 
potent than CX516.  
 Farampator, at micromolar concentrations, potentiates AMPA receptor mediated 
responses in a number of in vitro assay systems and enhances hippocampal longterm 
potentiation (Shahid et al, unpublished), suggestive that farampator may, apart from 
antipsychotic properties, also have cognitive enhancing effects.  
As farampator is developed primarily as a putative antipsychotic, and since a large number of 
cognitive domains can be disturbed in schizophrenia (Green, Nuechterlein et al. 2004; 
Heinrichs and Zakzanis 1998; Nuechterlein, Barch et al. 2004), the present study was 
designed to look into the effects of the drug on tests of memory, as well as information 
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processing (with components of speed of processing, visuospatial processing, and set-shifting) 
in healthy elderly volunteers. 
 
Materials and methods 
Participants 
The study was approved by the local medical ethics committee and has been carried out in 
accordance with the Declaration of Helsinki. Prior to the trial, all participants gave their 
written informed consent. 
Enhancing cognitive performance in young healthy volunteers is rather difficult because they 
perform close to their optimum (Foster, Lidder et al. 1998). To circumvent this ceiling effect, 
we decided to choose eldery subjects, in which a age related cognitive decline may  be 
expected (Grady and Craik 2000). 
Sixteen healthy elderly volunteers participated in the trial: eight men and eight women 
with a mean age of 66.1 (sd 4.46; range 60-75 years). Their medical histories indicated they 
were in good physical and mental health and this was verified by a medical examination, 
ECG, laboratory examination and the mini mental state examination (MMSE), the scores of 
which fell within the normal range (MMSE mean = 28.13, sd = 1.73, range 25-30). Fifteen 
volunteers were right-handed and one was ambidextrous. Their educational level varied from 
primary education to academic schooling (primary n=3, lower n=2, intermediate n=3, higher 
n=6, academic n=2).  
 
Drug administration 
 
The study was done according to a double-blind, placebo-controlled, randomized, four-way 
crossover design with placebo, 500 mg farampator and 2 mg biperiden and 3 mg rivastigmine 
as drug conditions. Farampator reaches peak plasma concentrations around an hour after 
dosing and has a terminal half-life, which is less than 10 hours. A safe and well-tolerated dose 
of 500 mg farampator was selected on the basis of a double-blind, placebo-controlled phase-I 
study in healthy young (mean age of 31.3 yr) volunteers (n=29) in which a dose range from 
15 to 1100 mg was investigated and shown to be devoid of serious or severe adverse events 
(Dogterom et al, unpublished). For biperiden peak plasma concentrations are reached 1 to 2 
hours after single dose administration followed by a rapid initial decline of the concentrations 
to 12% of the peak values after 6 hours, and subsequently followed by a slow terminal 
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elimination phase with concentrations close to or below detection limit at 48 hours (Hollman 
et al 1987).  For rivastigmine the time to reach maximum plasma concentration ranges from 
0.8 to 1.2 hours. In elderly healthy volunteers, the plasma elimination half-life is 0.9 to 1.3 
KRXUV5HQDOHOLPLQDWLRQRIWKHGUXJ¶VPHWDEROLWHVLVUDSLGDnd essentially complete after 24 
hours. Inhibition of ChEi activity  (in CSF) is significant by 1.2 hours, reaches a peak by 2.4 
hours and declines slowly until approx. 8.5 hours.   
Randomisation of treatments over the drugs was done according to a balanced latin-
square design (repeated four times). There was a wash-out of a week and therefore no drug 
interaction or carry over effects are to be expected, because of the short elimination half times 
of the drugs and the unlikelihood of lasting effects after a single dose.   
Testing took place one hour after drug-intake, which is around Tmax. The data for biperiden 
and rivastigmine have been reported elsewhere (Wezenberg, Verkes et al. 2005).  
 
Tests, apparatus and procedure 
The tests employed during the study formed part of a more comprehensive cognitive and 
psychomotor test battery (Wezenberg, Hulstijn et al. 2004). All tests were computerized and 
were run on a laptop computer for stimulus presentation, while data were recorded using a 
digitizing tablet (WACOM UD-1218-RE) and a pressure sensitive pen, which could also be 
used as a cursor. The x and y coordinates of the pen tip on and up to 5 mm above the digitizer 
were sampled with a frequency of 200 Hz and a spatial accuracy of 0.2 mm (de Jong, Hulstijn 
et al. 1996).  
To allow them to familiarize themselves with tests and procedures, the participants 
were invited to the hospital to perform a practice session during the week preceding the actual 
trial. For all tests there were five comparable versions for four test days and one practice day. 
The order of testversion administration was counterbalanced across subjects. In an 
unpublished pilot study we have assessed possible practice effects, and after an adequate 
practice these are minimal.  
  
Assessment of short-term memory and working memory 
Symbol Digit Recall Test (SDRT)  
The SDRT is based on the extended procedure of the Symbol Digit Substitution Test (SDST) 
- which will be discussed in the last paragraph of this section -  as developed by Kaplan et al 
(1991) to measure incidental learning and follows directly after the SDST. In the present 
study it was used to assess short-term memory. As soon as the participants had completed the 
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SDST they were again presented with the same symbols from the SDST, now shown one at 
the time, and asked to point out the corresponding numbers (short-term memory or STM). 
After an interval of 30 minutes they were again to identify the correct numbers for the 
symbols (long-term memory or LTM). The outcome measures are the number of correctly 
identified symbols and the response times. 
 
N-back task  
To evaluate working memory an N-back task was chosen, a task widely used in schizophrenia 
research for the detection of deficits in working memory (Meyer-Lindenberg, Poline et al. 
2001;Weinberger, Mattay et al. 1996). In the present version the participants were presented 
with a sheet of paper depicting a start circle and six potential target circles that surround the 
start circle. As soon as a stimulus target circle appeared on the computer monitor, the 
participants needed to draw a line from the start circle towards and ending inside the 
corresponding target circle. In the 1-back condition, they had to respond to the stimulus that 
was presented in the previous trial and in the 2-back condition to the stimulus that was 
presented two trials before. Both conditions were performed twice and lasted a maximum of 2 
minutes after which the number of correct trials was counted. Alternatively, the condition 
ended as soon as the participant had produced 25 correct trials. The outcome measure is 
µPRYHPHQWWLPHWRUHDFKWDUJHW¶ZKLFKLVIDVWHUZKHQZRUNLQJPHPRU\LVHQKDQFHGDQG
VORZHUZKHQLWLVLPSDLUHG7KHPHDVXUHµGLVWDQFHFRYHUHGWRUHDFKWDUJHW¶ZDVDGGHGDVD
control variable because movement time is dependent on the distance covered. One 
participant did not take this test. 
 
 
Assessment of episodic memory  
Verbal Memory Test (VMT) 
We tested verbal memory with a modified version of the classical Auditory Verbal Learning 
Test (Vakil and Blachstein 1993b), which originally comprises 15 words that are presented 
verbally three times in the present study. Under normal circumstances subjects remember 
more words after each trial. In order to prevent ceiling effects, and to make the test more 
challenging especially because in elderly people the learning of word lists is compromised, 
we developed a series of four equivalent lists of 18 words. Immediately after each 
presentation and after a 5-minute and a 30-minute delay our participants were asked to recall 
as many words as they could. After the latter delayed recall trial they were presented with a 
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list of 36 words from which they were asked to identify the 18 words from the original list. 
The supplementary words were distracters and resembled the correct words in a semantic or 
phonological manner. The outcome measures are the sum of the number of correct scores for 
the three immediate recall trials (total direct recall), the two delayed recall trials and the 
delayed recognition trial.  
 
Picture Memory Task  
 
 
Figure 1: Example of the picture memory task. The left panel depicts the sixteen symbols that 
needed to be memorized; the right panel shows the collection from which the sixteen 
correct symbols needed to be recognized. 
 
Visual memory or picture memory, has been used widely as a measure of both immediate and 
delayed recall for the detection of cognitive changes in a wide range of conditions. The 
picture memory task used in this study (for an example, see Figure 1) was modeled after a 
task Petrides and Milner (1982) developed for the detection and localization of brain damage. 
That visual memory tests are also sensitive for drug effects has been shown by numerous 
studies (Peretti, Danion et al. 1997;Rammsayer, Rodewald et al. 2000;Robbins, Semple et al. 
1997).  
In the first part of our test (immediate visual recognition) the participants were shown 
a matrix of 16 abstract pictographs or symbols that they were instructed to memorize. Next, 
they were presented with a matrix of 48 symbols from which they needed to identify the 16 
original designs by pointing them out. The second part of the test started with the presentation 
of another matrix of 48 symbols, containing the earlier correctly remembered symbols. The 
participants were again asked to commit these designs to memory. They were subsequently 
asked to pick out the correctly identified symbols, but now only one at the time from several 
matrixes: after each choice the matrix was scrambled (using the same symbols) after which 
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they had to point out the next correct symbol. The test ended when all symbols had been 
recognized or when two consecutive mistakes had been made. With this test visual 
recognition and self-ordered retrieval were evaluated and the outcome measures of both test 
components were the number of correct responses. 
 
Assessment of motor learning 
Maze learning task  
To study the effect of glutaminergic modulation on motor learning we used the Maze learning 
task developed by Van Mier et al (1993). 
 
 
Figure 2: Example of the maze test. 
 
In several studies (among which a PET study) it was shown that the maze task assesses motor 
learning unaided by sight (van Mier, Tempel et al. 1998;Wezenberg, Verkes et al. 2005). The 
mazes (for an example, see Figure 2) are cut-out structures, creating an enclosed path for the 
pen to traverse. Each maze design has a 0.5-cm wide and 0.15-cm deep path with a total 
length of 24 cm that consists of 8 segments. To simplify decision-making, the maze features 
straight stretches with 90-degree turns. At each intersection subjects need to choose between 
two opposite directions, one of which leads to a dead end after 0.5 cm. The maze forms a 
closed loop, i.e. start and end points are the same. We used four comparable versions and a 
practice maze in the shape of a square. The participants were instructed to close their eyes and 
find their way through the maze and make as many loops as possible within two minutes. 
During the first 30 seconds they were presented with the practice maze after which they 
performed three trials with the actual maze followed by a trial with what they had been told 
was a new maze. This latter maze was effectively a rotated version of the original. The 
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procedure was adopted to control for a general increase in motor-speed that might otherwise 
have masked signs RILPSURYHGPRWRUVNLOO7KHRXWFRPHPHDVXUHZDVµWKHQXPEHURI
FRPSOHWHGORRSV¶ZLWKLQWZRPLQXWHV 
 
Pursuit task 
To measure implicit procedural learning a computerized version of the rotor pursuit task was 
used. This test is based on the classical rotary pursuit task (Ammons, 1951; Siegel, 1996). It is 
a continuous motor task. Subjects had to follow the movement of a large target stimulus on 
the computer screen with a cursor by moving the pen over the XY-tablet. The speed of the 
target gradually increases when the cursor is contained within the target but slows down quite 
quickly when it is not. The target follows a spatially predictable circular path over the screen. 
7KHRXWFRPHPHDVXUHVIRUSURFHGXUDOOHDUQLQJDUHWKHµWRWDOQXPEHURIURWDWLRQV¶DQGµ7ime 
SHUORRS¶LHRQHGHJUHHWUDFNLQJRIWKHWDUJHWIRUWKHILUVWORRSV 
 
 
Assessment of information processing 
Tangle  
The tangle task is a purely visual task requiring high concentration. Subjects are instructed to 
visually track a particular line that winds through two to four other lines. Our test was 
modHOHGDIWHUWKHYLVXDOL]DWLRQWHVWIURPWKHµNLWIRUIDFWRU-UHIHUHQFHGFRJQLWLYHWHVWV¶GHYLVHG
by French and Ekstrom (Ekstrom, French et al. 1976;French 1954). It was selected by the US 
NAVY to study environmental and other time-course effects and has good task stability and 
reliability (Bittner, Carter et al. 1986;Bittner, Carter et al. 1983). The tangled lines were 
presented on the laptop screen. The target line was indicated by a yellow square. On 
subsequent trials the tangles increased in complexity: they increased in length and included 
more 90-degree turns. The paper form depicted a start area and five target areas (numbered 1 
to 5), which reflected the potential maximum target areas on the screen. The outcome measure 
is the number of correct trials within two minutes. 
 
Symbol Digit Substitution Test (SDST)  
The SDST is a modification of the subtest from the WAIS (Wechsler Adult Intelligence 
Scale;(Wechsler 1981). Subjects have to substitute symbols for the digits 1-9 on the basis of a 
given key. The outcome measure is the total number of correct digits completed in 90 
seconds.  
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According to Hege et al (1997) and Lezak (1995) the test measures a multitude of cognitive 
components among which visuospatial scanning, intermediate memory, perceptual motor 
speed and speed of cognitive processing. In an attempt to disentangle these cognitive 
components we conducted additional analyses of the output data. Based on pen pressure, 
movement trajectories were defined as either pen-up or pen-down periods to allow the 
computation of matching times and movement (writing) times. For the motor component, the 
mean writing times were calculated and for the more cognitive component the mean matching 
times were derived. For more details of the method of analysis we refer to earlier publications 
(Jogems-Kosterman, Zitman et al. 2001;Sabbe, Hulstijn et al. 1999;van Hoof, Jogems-
Kosterman et al. 1998;Wezenberg, Verkes et al. 2005). 
 
Continuous Trail Making Test (CTMT)  
7KH&707ZDVGHYHORSEDVHGRQ5HLWDQ¶V5HLWDQWUDLOPDNLQJWHVW3DUW$WKH
simplest section of the test, is used to measure visual scanning, motor speed and agility while 
the more complex part B assesses executive performance, i.e. set-shifting, working memory 
and divided attention. Numerous studies have proven the test to be sensitive to various 
neuropsychiatric conditions, e.g. schizophrenia (Lezak 1995;Reitan and Wolfson 1995). 
In Part A subjects have to connect as many letters in alphabetical order as they can in 120 
seconds. In Part B, they have to connect as many numbers to their corresponding letters in the 
alphabet by alternating between the two sequences, for example 1A2B etc, in 120 seconds. 
7KHRXWFRPHPHDVXUHVDUHµWRWDOQXPEHUFRQQHFWHG¶µWRWDOQXPEHURIHUURUV¶DQGµW\SHRI
HUURUV¶,QSDUW%RQHFDQHUURQHRXVO\FRQQHFWQXPEHUVWRQXPEHUVRUOHWWHUVWROHWWHUV
(NNLL) instead of numbers to letters. One can also commit so-called switching errors by 
connecting the numbers to the wrong letters or letters to the wrong numbers by connecting 
numbers to letters or vice versa in the wrong order, for example 1B2C  instead of 1A2B 
(NLLN). 
 
Control measures 
Serum concentrations  
For each volunteer blood samples were taken at 55, 210 and 345 minutes after drug intake. In 
one female participant the last blood sampling did not succeed.  
  The farampator concentrations in the serum samples were determined by means of a 
liquid chromatographic assay with mass spectrometric detection (LC-MS) after solid phase 
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extraction. Bioanalyses were performed at the Department of Clinical Pharmacology and 
Kinetics of N.V. Organon (Oss, the Netherlands). 
 
Side effects 
All participants were monitored for side effects (SEs) by the research nurse and physician. 
The reported SEs were coded using MedDRA (6.1).  
 
Alertness measures  
To control for possible alterations in alertness as a confounder for memory improvements, 
subjects performed several tests measuring various aspects of alertness before dosing and 
sixty minutes after drug administration.  
Measurements of saccadic eye movements (SEM) were chosen as the (neuro)physiological 
measure for alertness. Subjects need to visually follow a target that changes position suddenly 
and at random intervals. The target consists of an array of light-emitting diodes on a bar fixed 
at 50 cm in front of the head support. The size of the target shifts was fixed at 30 degrees (15 
from middle to left-right). The outcome measure is the overall mean peak velocity.  
A simple (SRT) and a choice reaction time test (CRT) were used to assess behavioral 
alertness. In the SRT a yellow square was presented on the monitor at random intervals (0.5-
1.5 seconds). Subjects were instructed to press the response button on the response module as 
fast as possible after detection of the target. The trial consisted of 20 targets with mean 
UHDFWLRQWLPHDVWKHRXWFRPHPHDVXUH,QWKH&57WKHZRUGVµOHIW¶DQGµULJKW¶ZHUHSUHVHQWHG
randomly on the monitor and subjects had to press the corresponding buttons on the response 
module as fast as possible. Again, per trial 20 targets were presented with the outcome 
measure mean reaction time.  
For the assessment of subjective alertness the participants completed a mood rating scale 
(MRS;(Bond and Lader 1974b). The three factors subjective alertness, calmness and 
contentment were derived from the self-report questionnaire comprising 16 visual analogue 
scales.  
 
Statistical Analyses 
Statistical evaluation (using SPSS 11 for Windows) was performed with GLM Repeated 
Measures $QDO\VLVRI9DULDQFH$129$ZLWKµGUXJV¶DVZLWKLQ-subject factor for all tests. 
For the verbal memory test, maze learning task and SDRT, also the results for the within-
VXEMHFWIDFWRUµWULDO¶DQGWKHLQWHUDFWLRQEHWZHHQµWULDO¶DQGµGUXJV¶ZHUHDQDO\]HG 
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Subsequently, univariate ANOVAs were performed with the grouping factor side effects 
(SEs: yes / no) for the farampator condition and the placebo condition separately. 
 
Results 
Plasma levels 
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Figure 3: The left graph (3a) depicts the mean plasma levels and standard error bars of 
farampator and the right graph (3b) the level of farampator for participants with and 
without side effects. 
 
Figure 3a presents the mean plasma levels of farampator. The highest concentrations were 
found in the first blood sample taken at 55 minutes after drug intake although it should be 
noted that the variation in plasma levels was very high at this time point. In the subsequent 
serum samples farampator concentrations steadily declined and showed less variation. As 
only three blood samples were taken, it cannot be ruled out that the true peak concentrations 
occurred at another time (slightly earlier or later) than at the first measurement.  
 
 
Memory and Information processing 
Both the descriptive statistics and F-statistics of the test performance for the farampator and 
placebo conditions are presented in Table 1.  
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Table 1: Descriptive statistics and F-statistics  
    Placebo  Farampator  F-statistics  
    M  SD   M SD   
Drug-Placebo 
df (1,15) 
SDRT        
 STM (correct) 1.9 1.7  3.2 1.7  8.72** 
 LTM (correct) 2.2 1.6  2.6 1.9  < 1 
 STM (RT) 3.54 0.72  3.76 0.84  1.09 
 LTM (RT) 3.16 0.67  3.22 0.77  < 1 
n-back 1        
 Movement time 0.71 0.13  0.72 0.11  < 1 
 Distance covered 3.63 0.53  3.75 1.22  < 1 
n-back 2        
 Movement time 0.77 0.26  0.76 0.36  < 1 
 Distance covered 4.56 2.08  4.29 2.30  < 1 
verbal memory test        
 Immediate Recall 21.9 2.2  21.7 2.1  < 1 
 Delayed Recall 7.2 3.6  6.2 3.5  3.36
#
 
 Recognition 10.1 3.1  8.06 3.8  5.77* 
picture memory task        
 Part 1 6.8 2.2  6.6 3.2  < 1 
 Part 2 5.3 1.5  4.4 2.2  3.30
#
 
maze learning task        
 
Mean number of loops for 
trials 1,2,3 10.4 5.0  11.1 5.9  < 1 
 Number of loops for trial 4 9.2 4.6  8.9 4.4  < 1 
 
Mean number of errors for 
trials 1,2,3 2.7 1.6  2.8 1.5  < 1 
 Number of errors for trial 4 3.2 1.5  3.4 1.1  < 1 
pursuit Rotor        
 Number of rotations 10.6 2.9  10.7 3.5  < 1 
 Mean loop time 5.97 2.84  6.13 2.71  < 1 
tangle          
 Number correct 12.6 1.3  12.9 2.1  < 1 
SDST        
 Number correct 40.7 9.5  41.0 8.9  < 1 
 Matching time 1.72 0.51  1.71 0.47  < 1 
 Writing time 0.63 0.17  0.59 0.12  1.05 
CTMT        
 Number correct 37.4 7.8  39.9 8.0  1.6 
 Total errors 1.8 1.5  1.0 1.6  2.6 
 Errors NNLL 1.2 1.0  0.9 1.5  < 1 
 Errors NLLN 0.6 0.9  0.1 0.5  4.29
#
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Figure 4: The effect of farampator on the performance measures of the SDRT in terms of the 
number of correctly identified symbol-digit pairs during the short-term memory trials 
(STM) and the long-term memory trials (LTM). 
  
As can be seen in Figure 4, farampator significantly improved the performance on the STM 
trial of the SDRT by enhancing the number of correctly remembered symbols. The 
improvement in the LTM trial did not reach significance. 
Neither the 1-back nor the 2-back trials of the N-back task generated differences between 
placebo and farampator for the parameters movement time (MT) and distance covered. 
 
Episodic memory 
In the three immediate recall trials of the verbal memory test all participants showed equal 
increases in the number of words they managed to recall in both conditions. Surprisingly, 
farampator tended to impair the performance in the delayed recall trials and significantly 
impaired the recognition performance relative to placebo. 
  In the picture memory test no significant effects were found for simple drug-placebo 
comparisons although farampator tended to impair performance in the second part of the test. 
 
Motor Learning  
The number of completed loops increased non-significantly from trial 1 to 3 in the maze 
learning task. However, no significant differences were found in the performance between 
placebo and farampator. From trial 3 (learned maze) to trial 4 (the new / rotated maze) the 
number of completed loops decreased significantly, which suggests that the performance 
measures indeed reflect motor learning rather than motor speed. Again, the outcomes were 
comparable for the two conditions.  
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Similarly, no differences were found between placebo and farampator in the pursuit task for 
the drug-SODFHERFRPSDULVRQVLQWKHSDUDPHWHUVµQXPEHURIURWDWLRQV¶DQGµPHDQORRSWLPH¶ 
 
Information processing speed  
Neither the SDST nor the tangle task revealed any drug-placebo differences. Also in the 
CTMT no significant drug-placebo effects were found for the number of correctly connected 
symbols or the total number of errors, although the participants did tend to make fewer 
switching errors (NLLN) in the farampator condition. 
 
Control Measures 
Side effects 
 
Table 2: Overview of the reported side effects (SEs) for placebo and farampator. 
 
Total number of 
subjects with SEs 
 
Number of SEs 
 
Headache Somnolence Nausea (vomiting) 
Placebo 6 2 5 0 
Farampator 10 6 5 4 (1) 
 
Table 2 lists the reported SEs. Only the SEs that were reported more than once are listed. In 
the farampator condition more participants experienced headache and nausea than in the 
placebo condition.  A high degree of somnolence was reported by almost one third of the 
participants, but to the same degree in both the drug and the placebo condition. All SEs were 
transient and self-limiting. 
Figure 3b shows the differences in plasma levels of farampator relative to the presence and 
absence of SEs. A one-way ANOVA revealed significantly higher concentrations of 
farampator in the first serum sample (after 55 minutes) in participants that reported to 
experience SEs than in participants that did not (F(1,14)  = 6.59, p =  .022). This difference 
disappeared in the subsequent samples (after 210 and 345 minutes). The group differences in 
plasma levels for the specific SEs did not reach significance. 
 
Alertness measures  
Table 3 lists the descriptive statistics and F-statistics for the alertness measures. 
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Table 3: Overview of the drug effects for the alertness measures at baseline and 55 minutes 
after drug administration. CM = centimeter, msec = milliseconds, pv = peak velocity. 
M = mean, SD = standard deviation. # p < .1 
  
Placebo 
 
Farampator 
 
F-statistics  
drug * time 
  M SD M SD df (1,15) 
MRS (cm) Baseline 48 5 46 4 < 1 
 55 min 46 5 45 4  
SRT (msec) Baseline 290 25 292 30 1.36 
 55 min 290 37 301 38  
CRT (msec) Baseline 376 51 374 51 < 1 
 55 min 362 35 369 45  
SEM (pv) Baseline 349 37 340 32 3.95
#
 
 55 min 343 34 347 29  
 
No significant effects were found although the drug tended to interact (non-significantly) with 
time on the SEM: in the placebo condition peak velocity marginally decreased, whereas after 
farampator peak velocity appeared to increase over baseline. 
 
Additional analyses: The relationship between drug effects on memory, information 
processing and SEs  
In view of the differences in plasma levels of farampator for the participants with and without 
SEs additional analyses were performed. Univariate ANOVAs were performed to reanalyze 
test performance with the grouping factor SE (yes / no), separately for placebo and for 
farampator SEs on placebo or farampator performance. No drug-placebo comparisons were 
made for the SE and SE-free groups, since the subjects who had SEs under the two conditions 
were not the same and because of sample-size considerations (N is too small). Table 4 
presents the effect of the SEs on test performance 
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Table 4: Mean group effects  for memory performance and information processing 
proportionate to the presence (SE) or absence (no SEs) of side effects for the placebo 
and farampator condition. # p <.1, * p < .05, ** p < .01  
 Means placebo  F-statistics Means farampator F-statistics  
    no SE SE df (1,15) no SE SE df (1,15) 
SDRT       
 STM correct 1.9 2.0 < 1 4.3 2.5 5.92* 
 LTM correct 2.2 2.2 < 1 3.3 2.1 1.73 
n-back 1             
 Movement time 0.7 0.7 < 1 0.7 0.7 2.29 
 Distance covered 3.4 3.9 3.94# 3.3 4.0 1.23 
n-back 2       
 Movement time 0.7 0.9 3.32# 0.7 0.8 < 1 
  Distance covered 4.0 5.6 2.38 3.7 4.6 < 1 
verbal memory test       
 Immediate Recall 21.6 22.3 < 1 25.5 19.4 5.68* 
 DR STM 7.8 7.2 < 1 9.3 4.7 9.6** 
 DR LTM 6.9 6.8 < 1 9.0 4.0 17.74*** 
  Recognition 10.8 9.0 1.33 8.7 7.7 < 1 
picture memory task        
 Part 1 7.4 5.7 2.48 8.5 5.4 4.21# 
 Part 2 5.6 4.7 1.44 5.5 3.7 2.95 
maze learning task            
 Trials 1,2,3 10,11,12 9,11,10 < 1 10,12,13 10,12,11 < 1 
  Trial 4 (- 3) 9 (12) 9 (10) 1.48 9 (13) 9 (11) 12.47** 
pursuit rotor       
 Number of rotations 10.5 9.3 < 1 11.2 9.5 < 1 
  Mean loop time 5.5 6.7 < 1 5.2 6.7 1.27 
tangle       
 Number correct 12.70 12.33 < 1 12.83 13.00 < 1 
SDST             
 Number correct 41 41 < 1 45 39 2.27 
 Matching time 1.750 1.678 < 1 1.429 1.873 4.07# 
  Writing time 0.642 0.598 < 1 0.638 0.568 1.39 
CTMT       
 Number correct 37.3 37.7 < 1 44.7 37.0 4.22# 
 Total errors 1.5 2.3 < 1 0.8 1.1 < 1 
 Errors NNLL 1.2 1.2 < 1 0.8 0.9 < 1 
  Errors NLLN 0.3 1.2 4.41# 0.0 0.2 < 1 
 
Short-term and working memory 
Whereas placebo-related SEs did not affect SDRT performance, the presence of drug-induced 
SEs did so significantly: although the performance of both groups was superior throughout the 
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farampator condition, the participants without SEs showed significantly more improvement 
than the group with SEs.  
Neither the presence of placebo-related nor drug-induced SEs affected performance in the N-
back task.  
 
Episodic memory  
In the verbal memory test, the placebo-related side effects had no effect on performance. The 
farampator-induced SEs on the other hand did affect performance: participants experiencing 
SEs performed worse than participants who did not. This applied to the immediate recall trials 
and both delayed recall trials (STM and LTM), but not to the recognition trial. The result for 
the delayed recall trials is depicted in Figure 5. 
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Figure 5: The effect (number of words recalled) of SEs on the VMT performance in the two 
delayed recall conditions (DR) for the placebo and farampator conditions; 
LMT=Long-Term Memory Trial approximately 30 minutes after learning the words. 
 
In the picture memory task no significant effects were found for the placebo-related SEs. For 
the farampator-induced SEs a trend was found in the first trial: participants with SEs tended to 
perform worse than participants without SEs. No effects were found in the second trial. 
 
Motor learning 
No effects were found for the SEs reported in the placebo condition on the maze-learning 
task. There was an interaction between Trial (4 -3) and Group for the farampator-induced 
SEs: in the group of participants that did not report any SEs performance steadily improved 
from trial 1 to trail 3 and then dropped sharply in the new (rotated) maze in trial 4. In the 
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group that did report SEs the performance enhancement was halted after the second trial, 
making the drop in trial 4 less severe. 
The performance on the pursuit task was not affected by the presence or absence of either 
placebo-related or drug-induced SEs.  
 
Information processing 
No effects were found for the placebo-related SEs in the SDST, tangle task or CTMT and in 
the tangle task the drug-induced SEs also did not affect performance. 
Farampator-induced SEs did affect SDST and CTMT performance to some extent. In both 
tasks the group without SEs showed a clearly superior performance than the group with SEs, 
but this was only marginally significant in the matching times in the SDST and the number of 
correctly connected pairs in the CTMT. 
 
Discussion 
This is the first study to show effects of the ampakine farampator on memory and information 
processing. The results revealed that 500 mg farampator caused a clear-cut improvement in 
the short-term memory of healthy elderly volunteers, but  appeared to impair  episodic 
memory. In addition, it was found that the plasma levels of participants that reported SEs was 
higher than the levels found for the participants that did not experience any SEs. Post-hoc 
analyses revealed that in contrast to placebo, farampator had selectively improved the 
memory performance in the group without SEs and not in the group with SEs.  
 
Modulation of Cognitive Processes 
Memory  
Short-term memory was clearly enhanced after farampator: in the SDRT the drug always led 
to a superior performance, irrespective of the presence or absence of SEs, although the 
participants without SEs performed significantly better than the group with SEs.  
Initially, the analyses of the episodic memory data generated negative effects of farampator 
both in the delayed recall conditions and in the recognition of verbal material. Supplementary 
analyses, however, revealed that the impairments predominantly occurred in the delayed free 
recall of the verbal material in the subjects that had reported drug-induced SEs; the effect was 
not found in the word recognition condition.  
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Analysis of the motor learning data initially yielded comparable results in that no effects were 
found when farampator was compared to placebo. Post-hoc analyses demonstrated, however, 
that the presence of SEs had negatively affected maze learning in the farampator condition. 
The group without SEs showed a gradual increase in the number of loops they produced in the 
course of the test, indicating normal learning, whereas the group that had reported SEs did not 
show such progress in their performance. 
The positive effects of farampator on memory are in line with the results for CX516 in 
human volunteers reported in the literature (Lynch 2004). More important, although perhaps 
not surprising, was our finding that performance improvements tended to be dependent on the 
absence or presence of (subjective) side effects. Earlier studies had demonstrated that 
distractions (e.g. feeling unwell) could negatively affect performance because they tend to 
decrease concentration or divide attention (Carver 1994;Lezak 1995;Meyer, Thornby et al. 
2000;Schmidt and Lee 1999). The adverse drug reactions that were reported in a study using 
high doses (900-1200 mg) of CX516 included mild headache, salivation and/or swallowing 
reactions and spontaneous leg movements (Lynch, Kessler et al. 1996). Hence, barring 
headache, the adverse reactions our participants reported after farampator appear new, 
although it needs to be noted that to date reports on adverse reactions to ampakines are scarce. 
Our experimental setting, i.e. the long test days, the number of tests, the double-blind 
treatment and strange hospital environment, was likely to induce some tiredness and anxiety 
and perhaps even somnolence, headache or nausea. To exclude the study environment as a 
cause for the SEs, the effects of the SEs reported for placebo were analyzed carefully. Apart 
from a few minor non-significant effects, they proved not to have affected performance. 
Although we did not explicitly check for the nature of placebo-related SEs, nor the intensity, 
time of onset and duration on performance, it is likely that they persisted less long and were 
less intense to have caused any effect on performance.  
The overall lack of a positive effect of farampator on the episodic memory measures 
used in this study was unexpected. It was especially surprising for the verbal memory test as 
in other studies using the ampakine CX516, it had been a nonsense syllable test that had 
generated the strongest effects (Lynch, Granger et al. 1997;Lynch, Kessler et al. 1996). It 
should be noted, however, that only those participants that had experienced SEs had shown a 
decrement in their performance. Moreover, this group proved to have higher plasma levels, 
which may imply that the beneficial effects on memory of ampakines are non-linear, or that 
WKH\DUHFRXQWHUDFWHGE\WKHDSSHDUDQFHRI6(¶VDWKLJKHUSODVPDOHYHOV7KLVPD\PHDQWKDW
improvements in performance are only induced by an optimal plasma level of farampator and 
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that the dose of farampator may have been too high for some of the elderly subjects in this 
study. 
Another tentative explanation for the negative results is that our memory tests may 
have been too difficult for this age-group. We opted for eighteen-item word lists and a set of 
sixteen pictographs to prevent ceiling effects and to create a state of pseudo-dementia. 
However, lists comprising a maximum of ten items are more common in neuropsychological 
research in elderly subjects (Bouma, Mulder et al. 1998;Lezak 1995). It should be noted, 
though, that all the participants did show the expected learning curves in both the placebo and 
the drug conditions of the memory tasks. 
 
Information processing 
The effects of farampator on information processing are somewhat more subtle than its effects 
on memory. No significant effects were found in the first drug-placebo comparisons, although 
in the CTMT there was a trend indicating a decrease in the number of switching errors. This 
effect will be discussed in more detail in the section on ampakines for the treatment of 
schizophrenia. 
The post-hoc analyses also did not generate significant effects for the SDST, although 
it did reveal a trend: the participants without SEs were faster in matching the correct numbers 
to the symbols in the farampator condition than those with SEs. 
For the tangle task, measuring more visuospatial processes, our extra analyses failed to detect 
a difference between the participants with or without SEs. Also in the CTMT, which requires 
matching as well as set-shifting skills, no significant effects were found although in the group 
without SEs the number of correctly connected letters and numbers proved to have increased 
noticeably in the farampator condition. 
As ours are the first data reflecting the effects of an ampakine on information 
processing, it is not possible to compare the present results with other data from literature. To 
date, attention has mainly been focused on memory tests to examine cognitive effects of 
ampakines. One study did assess psychomotor performance with a finger tapping test and a 
digit cancellation test (Ingvar, AmbrosIngerson et al. 1997) but could not report any effects. 
The tests applied in the present study contained more prominent cognitive components than 
motor-speed components.  
 
Ampakines and schizophrenia 
Acute effects of the ampakine farampator on memory and information processing in healthy elderly volunteers  129 
²²²²²²²²²²²²²²²²²²²²²²²²²²²²²²²²²²²²²²²²²²²²² 
 
The positive results on short-term memory and the favorable trends in the trail making test 
(CTMT) are of interest in view of the development of farampator for schizophrenia. Memory 
is one of the cognitive domains that are found to be frequently impaired in schizophrenia 
(Nuchterlein et al 2004). Although the CTMT version we used is considered as a test for 
processing speed (Nuechterlein, Barch et al. 2004), it also measures another process due to the 
necessity to shift continuously between numbers and letters. It is well known that set-shifting 
is also often disturbed in schizophrenia (Donohoe and Robertson 2003;Pantelis, Barber et al. 
1999) and it has even been identified as a predictor of relapse in first-episode schizophrenia 
(Chen, Hui et al. 2005). 
Interestingly, in animal research it has been established that AMPA and NMDA 
receptors are essential in facilitating working memory and set-shifting. Schmitt et al (2005) 
demonstrated that gene-targeted mice lacking the AMPA receptor subunit GluR-A have 
deficits in hippocampal long-term potentiation (LTP) and spatial working memory deficits. In 
their study Stefani et al (2003) showed that blockage of AMPA receptors in the medial 
prefrontal cortex impaired set shifting in a maze-based task where rats were required to switch 
between brightness and texture discrimination strategies. 
 
Suggestions for future research 
The present study compared farampator with placebo at a single-dose level. It would be 
interesting to see whether future research will replicate these findings at other doses, with 
special emphasis on the lower doses, as the present findings indicate that impairments are 
more likely to occur at the higher plasma levels of farampator, which also induce side effects. 
It would also be worthwhile to study the effects of ampakines in other age-groups than the 
healthy elderly subjects of the current study. It is known that aging causes neurobiological 
changes, including metabolic and neurochemical changes, as well as changes in functional 
circuitry (Li and Dinse 2002). Possibly, the interaction of side effects with drug-condition is 
partly caused for a large part by the slower metabolic processes in older age. 
 As farampator was developed to ameliorate the cognitive deficits seen in 
schizophrenia, the experimental results of the present study using healthy volunteers need to 
be compared with the findings from randomized controlled studies with patients. 
 
Conclusion 
Farampator has a significant, positive effect on short-term memory functioning in healthy, 
elderly volunteers, regardless of plasma level or side effects. In addition, a modest reduction 
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of errors was found in a set-switching task. In the participants that did experience side effects, 
episodic memory was impaired, but in subjects that did not experience side effects memory 
processes tended to be enhanced, though this did not reach the significance level.  
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Memory is one of the most essential of human cognitive functions, crucial for everyday life 
and critical for our identity as individuals in that it determines how we remember and 
interpret past experiences, act upon them and anticipate present and future experiences 
(Curran and Mintzer 2006). With the rising number of elderly citizens in our western 
societies, age-related memory loss and dementia place mounting demands on our health-care 
systems. It is also increasingly recognised that frequently psychiatric populations are suffering 
from memory impairments, which deficits have been related to the core symptoms of their 
diseases, like in schizophrenia and depression, and impede the patients even further in their 
daily functioning. In schizophrenia memory deficiencies have even been linked to the 
functional outcome of the disease (Green 1996). Paradoxically, pharmacological interventions 
LQWHQGHGWRDOOHYLDWHDSDWLHQW¶VV\PSWRPVPD\FDXVHHYHQIXUWKHr increments in memory 
deficits. Especially benzodiazepines and agents with anticholinergic properties are known to 
have adverse effects on memory. 
To foster drug development and patient care, we need to be able to distinguish 
EHWZHHQDGUXJ¶VFRJQLWLYHVLde effects, i.e. to be able to separate its effects on memory from 
its effects on alertness. Both effects may occur simultaneously, which is undesirable as in 
most cases sedation is sought, for instance to calm anxious or agitated patients, but not the 
adverse effects on memory as these may render the patient incapable of fully benefiting from 
other therapies. Based on these arguments, we decided to make memory the key topic of this 
thesis and posed the following two questions:  
 
1. &DQZHVHSDUDWHDGUXJ¶VGLminishing effects on alertness (desired sedation)1 from those 
on memory (undesired impairments)? 
2. What is the relationship between increased alertness (arousal) and memory? 
 
As with the increasing elderly population the need to find compounds that significantly 
LPSURYHPHPRU\IXQFWLRQLQJLQ$O]KHLPHU¶V'LVHDVH$'DQGRWKHUQHXURSV\FKLDWULF
syndromes has gained urgency and given that many of the currently available 
psychopharmacological treatment options are not altogether effective, memory research of 
pharmacological compounds has also gained in importance. The second part of the thesis 
                                                 
1
 The terms diminished alertness and sedation are used to indicate one and the same effect as are increased 
alertness and arousal 
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accordingly focused on the effects of two memory-enhancing drugs: rivastigmine, a 
cholinesterase inhibitor, and farampator, an ampakine. Here, our questions read: 
3. Which memory systems improve by the use of memory-enhancing drugs?  
4. Do memory-enhancing drugs exclusively boost memory or do they also have an effect 
on other cognitive functions like information processing or attention? 
 
The chapters of this thesis and the research they describe were based on three randomized 
four-way cross-over studies conducted to investigate the acute effects of clinically relevant 
(neuro)psychiatric drugs with most having an effect on memory performance. The first two 
studies examined various well-known drugs in healthy volunteers (18-40 years of age). Study 
1 evaluated the effects of 2.5mg lorazepam, 15mg mirtazapine, 15mg d-amphetamine and 
placebo in 16 subjects and in Study 2 we compared 2.5mg haloperidol, 10mg olanzapine, 
20mg paroxetine and placebo in 15 adults. In the third study we analyzed drugs with a 
specific effect on memory in 16 healthy elderly volunteers (60-75 years of age): 2mg 
biperiden, 3mg rivastigmine, 500mg farampator and placebo. 
 One of the original goals of these first three studies was to evaluate a test battery for 
the benefit of pharmacological research that was to assess cognitive as well as psychomotor 
effects. An explanation of the development of this test battery, a list detailing the constituent 
tests and the test descriptions can be found in Appendix I. Because the initial studies 
generated striking results on memory performance, we felt strengthened in our choice of 
PHPRU\PRGXODWLRQDVWKHFHQWUDOWKHPHRIWKLVWKHVLVZLWKWKHGUXJV¶HIIHFWVRQ
psychomotor processes being awarded a less prominent role.  
Table 1 in Appendix 2 provides an overview of the research conducted and 
summarizes the main data of all the studies presented in the chapters of this thesis. In the 
sections below per chapter the results are described in brief and discussed in the light of our 
main research questions.  
  
Memory and sedation ± Can we tell drug-effect patterns for sedation and memory 
functions apart? 
The first part of the thesis investigated whether cognitive reactions to the drugs under study 
could be separated out into sedative and amnesic effects. This is relevant because memory 
performance is dependent on more than memory processes alone. In a verbal memory test 
(VMT), for example, the immediate and delayed free recall of words as well as word 
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recognition are evaluated. As during the free recall trials subjects are sensitive to distractions 
and fluctuations in alertness and attention, inferior performance does not necessarily indicate 
impaired memory capacity. Recognition performance, on the other hand, is less sensitive to 
such fluctuations and is therefore compared to the delayed free recall condition. Although 
impaired free recall in the absence of impaired recognition may still indicate a memory 
problem, i.e. deficient retrieval, it might also reflect deficient arousal or attention, functions 
that are vital in retrieval (Baddeley 1998; Lezak 2006).   
To disentangle memory from alertness effects we need to be able to establish that 
drug-induced effects in a memory test are not due to sedation but to an explicit effect on 
memory. This is a complicated mission as most drugs affecting memory also have sedative 
side effects ((Curran et al. 1998; Curran and Birch 1991; Fluck et al. 1998; Huron et al. 2002; 
Lucchesi et al. 2003). Curran et al. (1998) and Ghoneim ((1998; 2004) proposed several 
methods for this purpose, two of which were used in this thesis. The first makes use of a 
statistical method (covariation) to control for sedative effects when analyzing drug-placebo 
effects RQPHPRU\PHDVXUHVZKHQWKHGUXJ¶VHIIHFWVRQWKHPHPRU\PHDVXUHUHPDLQ
significant after covarying for sedation, a dissociation between memory and sedation has been 
proven. The second method proposes direct comparisons of several drugs with both sedative 
and amnesic effects on both memory and sedation measures: when for a particular agent 
similar effects are found for one type of measure (e.g. the sedation measures) but not for the 
other (e.g. the memory tests), a dissociation between the two effects has been established. The 
results of these two approaches are described below. It is noteworthy that in the studies 
presented in this thesis we evaluated more categories of drugs and tests than earlier studies, 
which mainly focused on the effects of benzodiazepines in one or two tests.  
In Chapter 2 we looked into the cognitive effects of antipsychotic drugs and found 
that 2.5mg haloperidol was not associated with sedative nor with impairing effects on verbal 
memory. In contrast, 10mg olanzapine caused significant sedative effects. In addition, the 
subjects displayed a significant impairment on all measures of verbal memory and 
psychomotor functioning and analyses of covariance, moreover, showed that the observed 
amnesic effects occurred independently from the dUXJ¶VVHGDWLYHHIIHFWV 
In Chapter 3 the results of two double-blind, placebo-controlled, crossover studies 
were compared to evaluate the sedative and amnesic effects of four drugs, i.e. 2.5mg 
haloperidol, 10mg olanzapine, 2.5mg lorazepam and 15mg mirtazapine, on a wide range of 
sedation measures and an episodic memory task. We wished to establish whether the drugs 
would show similar effect patterns on the sedation measures and contrasted their patterns on 
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the sedation and memory performance measures to determine whether the sedative effects 
could be differentiated from the memory effects. To compare the results across studies, 
standardized scores, reflecting effect sizes, were computed. Apart from haloperidol, all drugs 
proved to impair performance on all five sedation indices. Contrary to the outcomes on the 
self-assessment scales (VAS), the effect sizes of the objective sedation measures, reaction-
time tasks, the Symbol Digit Substitution Test (SDST) and saccadic eye movements (SEM), 
yielded different response profiles. We subsequently compared the drugs-placebo effects on 
the sedation and memory tests to see whether we could distinguish between the two types of 
performance decrements. Two drugs indeed showed different effect patterns for the two 
variables: whereas the sedation tests indicated all drugs to impair performance, olanzapine 
proved not to have impeded word recognition on the VMT  and mirtazapine had not affected 
any of the memory measures. 
We subsequently rearranged the sedation and memory conditions according to their 
mental load, i.e. from those requiring the least to those requiring the greatest cognitive effort. 
The new categorization revealed different patterns of effect sizes for the various drugs, which 
are listed in Table 1 below. The cognitive demands increase from SEM to ERT to CRT to 
SDST to the VMT. The effects of lorazepam and olanzapine proved to become stronger with 
incremental task demands (increasing cognitive effort). The effect of mirtazapine, on the other 
hand, was strongest in the simplest alertness task and, relative to the effects of the other drugs, 
diminished when task demands increased. 
The results of Chapters 2 and 3 demonstrated that, as Curran (1998) and Ghoneim 
KDGVXJJHVWHGZHZHUHDEOHWRVHSDUDWHWKHGUXJV¶VHGDWLYHIURPWKHLUDPQHVLFHIIHFWV
using two of the methods they had proposed. It also showed that their principles do not only 
work for benzodiazepines but also for other drugs that concurrently induce sedation and 
memory impairments.  
In sum, in the dosages used, lorazepam, olanzapine and mirtazapine all impaired 
performance on the sedation measures while olanzapine did not impede VMT word 
recognition and mirtazapine none of the memory measures. 
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Table 1.6WUHQJWKRIWKHGUXJV¶HIIHFWVSURSRUWLRQDWHWRWKHFRJQLWLYHGHPDQGVRIWKHWHVWV
applied. 
 
Tests arranged 
according to 
cognitive load  
(least to highest)  
Strength of drug effects 
SEM MIR > LOR > OLA 
ERT MIR >  LOR =  OLA 
CRT LOR =  MIR > OLA 
SDST LOR > MIR = OLA 
VMT RC LOR > MIR = OLA 
VMT IR LOR > OLA >  MIR 
VMT DR LOR > OLA > MIR 
 
MIR = mirtazapine 15mg; LOR = Lorazepam 2.5mg; OLA = olanzapine 10mg. 
SEM = Saccadic Eye Movements; ERT = Elementary Reaction Time Task; CRT = Choice Reaction Time Task; 
SDST = Symbol Digit Substitution Test; VMT = Verbal Memory Test; IR = Immediate Recall; DR = Delayed 
Recall; RC = Delayed Recognition.  
 
Furthermore, as the different drugs showed different types of effects on the various 
sedation and memory measures, we underpinned the notion that to accurately assess the level 
and nature of drug-related effects, we need to administer different types of measures for both 
sedation and memory. Our data also revealed that it is advisable to also test psychomotor 
responses and information-processing speed to supplement any subjective outcomes, and for 
memory, to not only assess recognition but also immediate and delayed free recall. 
 
Memory and arousal ± Does heightened arousal enhance memory? 
If diminished alertness impairs memory performance, does increased alertness enhance it?  
Chapter 4 evaluated the effects of 15mg d-amphetamine on tasks assessing alertness, 
memory, psychomotor performance and information processing. D-amphetamine was found 
to improve psychomotor speed but not speed of information processing. Two of the four 
µDOHUWQHVV¶WHVWVVKRZHGSRVLWLYHHIIHFWVDIWHUGUXJLQWDNHEXWWKHPHPRU\PHDVXUHVVKRZHG
no change in performance. Thus, d-amphetamine generated a different pattern of effects than 
the patterns observed in Chapter 3 and reported in earlier studies (Curran et al. 1998) where 
both sedative and memory impairments were seen to occur concurrently. As mentioned in the 
introduction, the Yerkes-Dodson Law (Yerkes and Dodson 1908) explains that arousal has an 
inverted U-shape effect on performance. Hence, since the subjects in our studies were all 
healthy, relatively young volunteers, their alertness levels may already have been at an 
Summary and general discussion              139 
²²²²²²²²²²²²²²²²²²²²²²²²²²²²²²²²²²²²²²²²²²²²² 
 
 
optimum, making it difficult for a drug to improve their performance even further. 
Nevertheless, our results demonstrate that the effects of increased arousal are less strong than 
assumed and do not (exactly) mirror the effects of diminished arousal (sedation) on memory. 
 
Can we improve memory? 
Many (neuro)psychiatric and or (neuro)degenerative disorders cause deficiencies in cognitive 
IXQFWLRQVDQGPRUHVSHFLILFDOO\PHPRU\SURFHVVHVDQGWRGD\¶VSKDUPDFHXWLFDOLQGXVWU\DQG
pharmacological research institutes are eagerly searching for effective memory-enhancing 
drugs for this extensive patient population. The second part of the thesis was therefore 
dedicated to two such agents: the cholinesterase inhibitor rivastigmine and the ampakine 
farampator.  
 Most human memory research exploring the role of the cholinergic system has focused 
on learning and memory by looking into the modulatory effects of cholinergic drugs. The 
discovery that anticholinergic agents negatively affect memory led to the idea that 
cholinesterase inhibitors (ChEi) might improve memory. The anticholinergic drug 
scopolamine was most commonly used to investigate impairments and the ChEi 
physostigmine to investigate improvements in memory performance. Imaging studies in 
humans have shown that cholinergic modulation in combination with memory performance 
causes activational changes in two types of functional anatomical areas: the learning- and 
memory-related areas such as the hippocampus, inferior temporal cortex, prefrontal cortex 
and anterior cingulate, but also the stimulus-processing regions like the fusiform gyrus and 
other extrastriate areas (Ernst et al. 2001; Furey et al. 2000; Furey et al. 1997; Rosier et al. 
1999; Sperling et al. 2002). In animal studies, the focus has shifted from memory to attention 
as new highly selective toxins for the cholinergic system often did not affect memory but did 
selectively impair attention and visuospatial performance (Baxter and Gallagher 1996; De 
Rosa et al. 2001; Everitt and Robbins 1997; Gutierrez et al. 1999; Torres et al. 1994). 
In view of these findings, in Chapter 5 we studied the effects of two drugs with an 
opposing effect on the central cholinergic system: the cholinesterase inhibitor (ChEi) 
rivastigmine (3 mg), an anti-Alzheimer drug assumed to enhance memory, and biperiden 
(2mg), an anticholinergic drug prescribed to alleviate extrapyramidal symptoms caused by 
antipsychotic agents and assumed to deteriorate memory. We wished to find out whether in 
healthy humans selective cholinergic drugs, as opposed to non-selective cholinergic drugs 
(i.e. scopolamine and physostigmine), would show similar results as had been reported for the 
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distinctly selective cholinergic lesioning methods in animals when compared to the non-
selective methods, in other words whether they would affect memory less and attention and 
visuospatial processing more. We found that episodic memory was indeed impaired by 
biperiden but, surprisingly, also by rivastigmine as far as word recognition was concerned. 
Working memory was non-significantly impaired by biperiden and not affected by 
rivastigmine. However, rivastigmine did enhance both motor learning and visuospatial 
processes, which were also impaired by biperiden. Selective cholinergic drugs thus yielded 
similar results as they had done in studies with rats, confirming acetylcholine as a modulator 
not only of memory but also of visuospatial functions and motor learning. 
 
As cognitive and amnesic problems affect both patients with a dementia and those with a 
(neuro)psychiatric illness, e.g. schizophrenia, and since more effective pharmacological 
treatments are urgently desired, a generally approved new line of drug development research 
is focused on ampakines (National Institute of Mental Health). Ampakines act as positive 
allosteric modulators of AMPA-type glutamate receptors and have been shown to facilitate 
hippocampal long-term potentiation (LTP), a mechanism associated with memory storage and 
formation. In Chapter 6 we therefore investigated the effects of the ampakine farampator 
(500mg) on memory and information processing and found that the agent unequivocally 
improved short-term memory in the symbol-digit recall task but at the same time impaired 
episodic memory. Furthermore, it tended to decrease the number of switching errors in a 
Continuous Trail Making Test (CTMT), a task assessing set shifting. The drug-induced side 
effects included headache, somnolence and nausea. The subjects exhibiting these adverse 
reactions had significantly higher plasma levels of farampator than those that did not report 
the effects. Additional analyses revealed that in the farampator condition the group without 
side effects showed a significantly superior memory performance than the group experiencing 
adverse effects. The positive results on short-term memory and the favourable trends in the 
CTMT thus look promising in view of the further development of ampakines. 
 
Of the studies described in the last three chapters, the results of the latter two indicated that 
we can indeed improve memory to some extent. Whereas d-amphetamine (15mg) had no 
specific effects on memory, rivastigmine (3mg) and farampator (500mg) had. Rivastigmine 
enhanced both short-term memory and motor learning and farampator boosted short-term 
memory in all subjects and the delayed recall of words in those subjects that did not report 
any drug-related adverse effects. Nevertheless, not all tasks yielded a positive outcome and 
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the enhancements were not as strong as anticipated or hoped for. Our observations once more 
emphasize how difficult it is to enhance memory functions in healthy subjects. 
Surprisingly, rivastigmine and farampator also generated negative effects, for which 
several explanations can be offered. That rivastigmine impeded episodic memory (word 
UHFRJQLWLRQPLJKWEHDWWULEXWHGWRDSRVVLEOHµRYHUGRVH¶RIWKHGUXJDW7-max, the time the 
tests showing the negative effects were performed. According to the Yerkes Dodson Law an 
excessive dose may cause over-arousal leading to a drop in performance. (Thiel et al. 2002) 
also attributed the absence of any positive effects for a cholinesterase inhibitor to an 
µRYHUGRVH¶WKH\FRQFOXGHGWKDWthe disproportionate dose might have induced their subjects to 
also pay more attention to the processing of irrelevant stimuli rather than just the relevant 
stimuli, which could thus have prevented improvement of the intended conditioning.  
An alternative explanation was offered by a post mortem study. (Nordberg et al. 1989) 
found that tacrine (an early cholinesterase inhibitor) had a different effect on neural pathways 
in human brain tissue obtained post mortem: it increased acetylcholine in AD patients but 
decreased it in healthy controls. The authors attributed this to the normal working of negative 
feedback mechanisms (mediated via presynaptic muscarinic autoreceptors) that is defective in 
AD brains but  intact in the normally functioning brains of healthy volunteers.  
For farampator, it appears that the experience of adverse effects, which in our study 
were related to higher plasma levels of farampator, tends to attenuate performance 
improvements. 
 
Memory and its relation to other cognitive processes 
As stated in the introduction, memory capacity is in part also dependent on attention and 
alertness levels. Earlier research (Curran et al. 1998; Curran and Birch 1991; Fluck et al. 
1998; Huron et al. 2002; Lucchesi et al. 2003) and our studies presented in Chapters 2 and 3 
have proven that for many sedative drugs these three processes tend to be all but 
interconnected. But how did memory and alertness correlate following the three performance-
enhancing drugs d-amphetamine, rivastigmine and farampator? D-amphetamine (15mg; see 
Chapter 4) was found to raise self-assessed alertness and saccadic peak velocity (EOG), but 
not memory, which thus precludes any relationship here. Our dose of 3mg rivastigmine  
(Chapter 5) enhanced performance on one alertness measure (SDST), but this effect was 
SUREDEO\PRUHDWWULEXWDEOHWRWKHVXEMHFWV¶LPSURYHGVSDWLDOVFDQQLQJDELOLWLHVDQGHQFRGLQJ
than increased arousal, as none of the other alertness measures were affected. Finally, EOG 
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measurements showed that 500mg farampator tended to improve the saccadic peak velocity 
whereas it did not affect any of the other alertness measures (Chapter 6). We can accordingly 
conclude that the association between increased alertness and enhanced memory is not as 
straightforward as the association between diminished alertness (sedation) and impaired 
memory.  
The latter two memory-enhancing drugs clearly did not only boost memory but other 
cognitive processes as well. Rivastigmine affected most tests with a spatial component and 
therefore appears to modulate (visuo)spatial processes in addition to memory functions. 
Farampator, on the other hand, affected information-processing tasks involving set shifting. 
Based on these findings we can surmise that memory drugs do not selectively target memory 
processes but have an impact on cognitive functions in general. 
 
Some methodological reflections and suggestions for further research 
Because in our investigations of the relationship between memory and sedation we only 
explored T-max effects of single doses, we cannot make any claims as to the effects different 
doses and plasma levels the drugs under study might have. It would be interesting to see 
whether the tests we conducted would show similar or different results when performed after 
administration of other doses. We know, for example, that in benzodiazepines the dose is 
indeed relevant as Weingartner et al. (1995) showed that high doses of triazolam revealed 
strong associations between different sedation measures (i.e. VAS and the Digit Symbol 
Substitution Test, a psychomotor measure), which were not present in moderate or low doses 
of the same drug. 
Dose-response relationships are also important topics for the further study of the 
memory-enhancing drugs we evaluated, especially since we found that, besides the desired 
positive effects, both rivastigmine and farampator also elicited adverse effects on some of our 
memory measures that we assumed could be associated with overdoses. A study design that 
includes comparisons of different doses of the same agents might prove or refute this 
assumption. 
It would, moreover, be interesting to compare our results, which were all obtained in 
healthy participants, with the effects the various memory-enhancing agents would cause in 
various patient populations. It is plausible that drugs not only affect patients differently than 
they do healthy adults, but that they also elicit different effects in different types of patients. 
In their recent fMRI study Goekoop et al. (2006), for instance, examined the effects of the 
cholinesterase inhibitor galantamine on recognition memory in patients with AD and patients 
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with mild cognitive impairment (MCI) and found differential activation changes for these two 
groups. In the MCI patients the changes involved both cortical (posterior cingulate, prefrontal, 
lateral temporal) and subcortical areas, but not the hippocampal areas. In contrast, in the AD 
group the galantamine-induced changes mainly involved hippocampal regions. The authors 
attributed these disparate findings to the different disease stages of the two patient groups, 
which, if confirmed, would indeed prove that the same drugs can affect patients differentially 
and requires further investigation. 
In addition, a replication of our studies with extended drug exposure will have to 
demonstrate the long-term usefulness of the various agents. In their recent review Birks et al. 
(2006) state that for cholinesterase inhibitors to show beneficial effects in patient populations 
requires prolonged (several weeks) titration. As the ampakine farampator has only recently 
been introduced on the market, no data to their titration are yet available.  
 Lastly, as the drug administration always preceded the memory tests, it is difficult to 
pinpoint exactly which parts of the memory processes, i.e. the encoding, consolidation and/or 
the retrieval stages, were affected by the drugs we tested in this thesis. Some memory studies 
with benzodiazepines used different dosing schedules and compared performance results 
obtained with drug-intake before and after the participants had memorised a word list. 
(Buffett-Jerrott et al. 1998) revealed that no amnesia occurred when the drug was taken after 
the list had been memorized, thereby proving an effect of benzodiazepines on encoding. In 
view of these findings, we recommend similar studies for the other drugs we have currently 
evaluated in which drug-administration times are manipulated in relation to the learning 
material.  
 
Conclusions 
The studies gathered in this thesis have yielded new insights into the effects the drugs 
investigated have on memory-related and associated cognitive processes. 
Firstly, sedation effects can be separated from amnesic effects by the use of a 
combination of different assessment methods and paradigms, which we demonstrated were 
successful for both benzodiazepines and other agents. In the dosages used, lorazepam, 
olanzapine and mirtazapine all impaired performance on each of the sedation tests 
administered, while olanzapine did not impede word recognition and mirtazapine did not 
affect any of the memory measures. Our studies showed that to accurately assess the level and 
nature of sedation and to differentiate sedation from memory impairments, different types of 
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sedation and memory measures need to be applied. In addition to the assessment of subjective 
effects, it is recommended to also test psychomotor responses and information-processing 
speed and to include not only recognition but also free immediate and delayed recall in the 
evaluation of memory functions. 
As to the relationship between arousal and memory, the effects of d-amphetamine, 
which were evaluated using the same set of tests as used to study the relationship between 
sedation and memory, did not show the reversed pattern of the sedation-memory association: 
despite the evidence of an increment in arousal, d-amphetamine did not improve memory 
performance. 
The memory-enhancing drugs rivastigmine and farampator proved to improve more 
than memory alone in our healthy volunteers. Rivastigmine tended to augment performance 
on most tests with a spatial component and therefore appears to modulate visuospatial 
processes as well. Farampator, conversely, improved information processing as reflected by 
enhanced performance on the tasks involving set shifting. 
  
To conclude, memory performance can be said to also in part depend on other cognitive 
processes and that when studying the effects of (psycho)pharmacological agents, we need to 
take all beneficial and detrimental effects on these various aspects into account. To us all, 
memory is crucial as it determines who we are and how we function, how we remember and 
interpret ourselves and the outside world and how we react to and anticipate events. Even 
though the progress in finding truly effective palliative, let alone curative treatments for such 
QHXURGHJHQHUDWLYHDQGSV\FKLDWULFGLVHDVHVOLNH$O]KHLPHU¶V3DUNLQVRQ¶V'LVHDVHRU
schizophrenia, has been slow, we hope that with the accelerated development of new drugs 
that help enhance their cognitive functioning, and with the increasing refinement of our 
techniques to test their effects, as highlighted in this thesis, the many patients and their 
families and relatives will feel a new sense of hope.  
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Het oorspronkelijke doel van de onderzoeken die beschreven zijn in dit proefschrift was het 
valideren van een cognitieve en psychomotorische testbatterij voor psychofarmacologisch 
onderzoek. Deze testbatterij bevatte o.a. testen voor geheugen, snelheid van 
informatieverwerking, psychomotoriek, planning en probleemoplossend vermogen. In alle 
onderzoeken is er gekeken naar de werking van klinische relevante (neuro)psychiatrische 
middelen bij gezonde vrijwilligers. Hieruit bleek dat de meeste middelen een direct of indirect 
effect hadden op het geheugen, waardoor dat het centrale thema van dit proefschrift is 
geworden. 
Voor de ontwikkeling van medicijnen is het van belang om de cognitieve bijwerkingen 
op geheugen en alertheid, die vaak samen voorkomen, in kaart te brengen en te kunnen 
onderscheiden. Meestal is één van deze (bij)werkingen gewenst, zoals een kalmerende 
werking bij zeer angstige patiënten, maar wil men bijkomende geheugenproblemen vermijden 
omdat dat interfereert bij het volgen van andere vormen van therapie. Het eerste deel van dit 
proefschrift richt zich daarom op de vraag of twee effecten van veelgebruikte psychofarmaca, 
te weten verminderde alertheid*
1
 en geheugenstoornissen van elkaar onderscheiden kunnen 
worden. 
 Het tweede deel van dit proefschrift richt zich op psychofarmaca die ontwikkeld zijn om 
specifiek het geheugen te verbeteren van patiënten met neurodegeneratieve of psychiatrische 
aandoeningen zoals de ziekte van Alzheimer en schizofrenie. Er wordt gekeken naar welke 
geheugensystemen worden verbeterd door deze middelen en of de effecten selectief zijn voor 
het geheugen of ook aanwezig zijn op andere cognitieve gebieden, zoals visuospatiële 
informatieverwerking en aandacht. 
 
In hoofdstuk 1 worden de vraagstellingen verder ingeleid en wordt de onderzoeksopzet 
besproken. De volgende hoofdstukken in dit proefschrift beschrijven drie gerandomiseerde 
µIRXU-way cross-RYHU¶RQGHU]RHNHQZDDULQGHDFXWHHIIHFWHQYDQNOLQLVFKHUHOHYDQWH
psychofarmaca centraal stonden. In de eerste twee onderzoeken zijn veel gebruikte 
psychofarmaca onderzocht in respectievelijk 16 en 15 gezonde jonge vrijwilligers (van 18-40 
jaar). In het eerste onderzoek was dit lorazepam (2,5mg), mirtazapine (15mg), d-amfetamine 
(15mg) en placebo. Het tweede onderzoek vergeleek haloperidol (2,5mg), olanzapine (10mg), 
paroxetine (20mg) en placebo. In het derde onderzoek werden middelen onderzocht met een 
                                                     
*1  de termen verminderde alertheid en sedatie worden in dit proefschrift door elkaar gebruikt en liggen op 
eenzelfde dimensie: hoe hoger de alertheid hoe minder sedatie. 
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specifiek effect op geheugen in 16 gezonde oudere vrijwilligers (60-75 jaar): dit betrof 
biperideen (2mg), rivastigmine (3mg), farampator (500mg) en placebo. 
De eerste vraag in het proefschrift betrof het onderwerp geheugen en sedatie: Is het 
mogelijk om de effecten van psychofarmaca die zowel verminderde alertheid veroorzaken als 
geheugenstoornissen van elkaar te scheiden? Centraal staat hierbij het gegeven dat 
geheugenprestaties afhankelijk zijn van zowel geheugenprocessen als alertheid. Het is 
moeilijk om deze twee effecten los te kunnen koppelen omdat de meeste medicatie die een 
negatief effect op het ene proces laten zien, dat ook op het ander proces doen. Curran & 
Ghoneim (1998, 2004) hebben vijf methoden voorgesteld om deze twee effecten te 
dissociëren, twee daarvan zijn toegepast in dit proefschrift. De eerste maakt gebruik van 
µFRYDULDQWLHDQDO\VH¶HHQVWDWLVWLVFKHPHWKRGHGLH de geheugeneffecten binnen een drug-
placebo vergelijking corrigeert voor de gelijktijdig aanwezige sedatieve effecten. De tweede 
methode vergelijkt verschillende psychofarmaca op beide typen processen. Wanneer 
vergelijkbare effecten op één type maat gevonden worden (bv sedatiematen), maar niet of 
minder sterk op de andere type maat (bv geheugen maten) is er een dissociatie aangetoond.  
Hoofdstuk 2 beschrijft een onderzoek naar de effecten van twee antipsychotica. 
Haloperidol 2,5 mg liet geen effecten op de sedatie testen of op een verbale geheugentaak 
zien. Daarentegen liet olanzapine 10mg wel significante effecten zien. De prestaties op de 
verbale geheugentaak en een psychomotorische taak waren significant verslechterd. 
Bovendien liet covariantie analyse zien dat de geheugeneffecten ook onafhankelijk van de 
sedatieve effecten aanwezig waren. 
In het derde hoofdstuk zijn de resultaten van de eerste twee onderzoeken 
gecombineerd om de effecten van vier psychofarmaca met sedatieve bijwerkingen te 
evalueren (haloperidol 2,5mg, olanzapine 10mg, lorazepam 2,5mg and mirtazapine 15mg). 
Om een vergelijking tussen de twee  onderzoeken mogelijk te maken zijn er 
gestandaardiseerde scores berekend die effectgroottes uitdrukken. Uit de resultaten bleek dat 
de prestatie op alle vijf de sedatietaken (visuele zelfbeoordelingschaal (VAS), simpele 
reactietijden taak (SRT), keuze reactie taak (CRT), symbool substitutie taak (SDST), 
saccadische oogbewegingen (SEM)) significant verstoord werd door zowel lorazepam, 
mirtazapine en olanzapine, maar niet door haloperidol. De effectgroottes lieten twee typen 
medicijneffecten zien: een verstoring van de responssnelheid (SRT & SEM) en een verstoring 
van de informatieverwerkingssnelheid (CRT en SDST). Daarnaast lijken de effecten van 
lorazepam en olanzapine sterker te worden naarmate het uitvoeren van de taken meer 
inspanning vraagt. Het effect van mirtazapine daarentegen, is het meest sterk in de taak die de 
Samenvatting  150 
 
             
minste inspanning vergt en lijkt juist af te nemen naarmate de cognitieve inspanning 
toeneemt.  
Een tweede vraag over de samenhang tussen geheugen en alertheid, gaat over de 
relatie tussen toegenomen alertheid en geheugen. Als het verminderen van alertheid een 
negatief effect heeft op geheugen, heeft dan een toename in alertheid een positief effect? Om 
deze vraag te beantwoorden is er in hoofdstuk 4 gekeken naar de effecten van d-amfetamine 
15mg op geheugen, psychomotorische snelheid en informatie verwerking en alertheid. D-
amfetamine gaf een significant verbetering van de psychomotorische snelheid en de snelheid 
van informatieverwerking. Verder liet het positieve effecten zien op twee van de vier 
alertheidtesten, maar er waren geen effecten op de geheugenmaten.  
Het tweede deel van het proefschrift kijkt als eerste naar de vraag welke geheugen 
systemen worden verbeterd door geheugenverbeterende middelen. De wetenschap dat 
anticholinerge medicatie een negatief effect heeft op geheugenprestaties heeft geleid tot de 
aanname dat de tegenhanger op de cholinerge as: de cholinesterase remmers (ChEi), mogelijk 
kunnen dienen als geheugenverbeteraars. In ratten en muizen studies, is de focus van 
geheugenonderzoek naar aandachtsonderzoek verschoven omdat het toepassen zeer specifieke 
laesie technieken in het centrale cholinerge systeem van ratten hersenen niet leidde tot 
geheugenstoornissen, maar tot selectieve stoornissen in de aandacht en de visuospatiële 
informatieverwerking. De vraag is of toepassing van meer selectieve medicatie i.t.t. niet 
selectieve medicatie bij mensen tot eenzelfde resultaat zal leiden: minder effect op geheugen 
en meer op aandacht en visuospatiële informatieverwerking. 
In hoofdstuk 5 zijn de effecten van de ChEi, rivastigmine (een anti-Alzheimer 
middel) vergeleken met de effecten van een anticholinergicum, biperideen (een middel dat 
gebruikt wordt tegen extrapiramidale bijwerkingen van antipsychotica). Biperideen had een 
negatief effect op het episodisch geheugen, maar geheel onverwacht had rivastigmine ook een 
negatief effect op de herkenningsconditie. Er werd een niet-significante verslechtering van het 
werkgeheugen gevonden na biperideen, maar rivastigmine had geen effect op deze taken. 
Rivastigmine had significant positieve effecten op motorisch leren en niet-significant 
positieve effecten op taken die visuospatiële informatieverwerking meten, welke negatief 
werden beïnvloed door biperideen. Hierdoor kon de conclusie getrokken worden dat 
selectieve cholinerge middelen inderdaad eenzelfde patroon van effecten laten zien als de 
selectieve laesie methoden in rattenstudies. Deze resultaten impliceren acetylcholine als een 
modulator van niet alleen geheugen, maar ook van visuospatiële processen. 
Samenvatting  151 
 
             
Ampakines werken als positieve modulatoren van AMPA A type glutamate receptoren 
HQYHUVWHUNHQGHVLJQDDORYHUGUDFKWGHµORQJ-term potentiaWLRQ¶/73LQGHKLSSRFDPSXVHHQ
mechanisme dat geassocieerd wordt met het formeren en opslaan van geheugen. In hoofdstuk 
6 worden de effecten van de ampakine farampator (500mg) op het geheugen en 
informatieverwerking beschreven. Farampator liet een heel duidelijk positief effect zien op 
het korte termijn geheugen (SDST recall: een symbool-cijfer herinneringstaak), maar had het 
een negatief effect op het episodisch geheugen (verbale geheugentaak (VMT). Verder leek 
farampator het aantal switching fouten te verminderen in een continue trail making test 
(CTMT), die o.a. het vermogen om te wisselen van concepten meet. De bijwerkingen van 
farampator waren hoofdpijn, slaperigheid en misselijkheid. Vrijwilligers met die bijwerkingen 
hadden significant hogere plasma spiegels dan vrijwilligers de geen bijwerkingen hadden. 
Post hoc analyses lieten zien dat in de farampator conditie de groep vrijwilligers zonder 
bijwerkingen veel betere geheugenprestaties lieten zien met farampator i.v.m. placebo, dan de 
groep die wel bijwerkingen had.  
In hoofdstuk 7, het laatste hoofdstuk wordt een samenvatting gecombineerd met een 
discussie over de bijdrage van de verschillende hoofdstukken in antwoord op de vraag of het 
geheugen verbeterbaar is en uit welke geheugensystemen dat blijkt. Hier komt naar voren dat 
d-ampfetamine geen effecten op geheugen liet zien, maar rivastigmine en farampator wel. 
Rivastigmine verbeterde het korte termijn geheugen en het motorisch leren. Farampator 
verbeterde eveneens het korte termijn geheugen en de uitgestelde herinnering van woorden in 
vrijwilligers die geen last hadden van bijwerkingen. Maar er werden niet alleen positieve 
effecten van deze psychofarmaca gevonden en de gevonden effecten waren niet zo sterk als 
gehoopt. Er wordt geconcludeerd dat geheugenmedicatie niet alleen een effect heeft op 
geheugenprocessen, maar ook op andere cognitieve processen. Dan worden nog verklaringen 
voor de verschillende werkingen van de geheugenverbeterende medicijnen besproken. De 
effecten zijn zeer genuanceerd en soms afhankelijk van bijwerkingen, al dan niet gerelateerd 
aan plasma spiegels. Ook kunnen de effecten individueel verschillen op grond van een 
µLQYHUWHG-U-VKDSH¶HIIHFWGLHZDDUVFKLMQOLMNZHHUYHUVFKLOWYRRUJH]RQGHEUHLQHQYDQGHGRRU
ziekte aangetaste breinen.  
 
Conclusie 
Naar aanleiding van de resultaten van dit proefschrift kunnen we concluderen dat veel 
gebruikte psychofarmaca, zoals lorazepam, mirtazapine en olanzapine het leren belemmeren 
waardoor patiënten mogelijk minder baat hebben bij het volgen van niet-farmacologische 
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interventies zoals bv. psychotherapie. Deze negatieve effecten op het geheugen kunnen  
veroorzaakt worden enerzijds door het optreden van sedatie waardoor minder snel en volledig 
de aandacht opgebracht kan worden om te leren en anderzijds door een werkelijk verminderde 
opslagcapaciteit. Beide processen kunnen ook gelijktijdig optreden. De toepassing van 
PHHUGHUHRQGHU]RHNVSDUDGLJPD¶VHQGDDUELQQHQKHWJHEUXLNYDQPHHUGHUHVRRUWHQ
psychomotorische testen was nodig om tot deze inzichten te komen. 
Het tweede deel van dit proefschrift liet zien dat geheugenverbeterende middelen, 
zoals rivastigmine en farampator subtiele effecten hebben op verschillende 
geheugenprocessen van gezonde oudere vrijwilligers. Daarnaast hadden de middelen op meer 
dan alleen geheugenprocessen effect: rivastigmine verbeterde ook visuospatiële 
informatieverwerking en farampator het wisselen van concepten. Opmerkelijk was dat het 
effect van deze middelen mede bepaald werd door inverted-U-shape curves en de 
aanwezigheid van bijwerkingen. Hier zal nog veel meer onderzoek naar gedaan moeten 
worden: allereerst om te bekijken of de effecten gelijk blijven bij andere doseringen en bij 
langdurige behandeling. Bovendien het is ook de vraag hoe de effecten van de middelen 
zullen zijn in niet-gezonde vrijwilligers aangezien ziekteprocessen ook de werking van 
neurotransmitters beïnvloeden. We hopen dat de daaruit voortvloeiende resultaten zullen 
bijdragen aan de kennis die nodig is om psychofarmaca te ontwikkelen die 
neurodegeneratieve en psychiatrische aandoeningen zoals de ziekte van Alzheimer en 
schizofrenie kunnen behandelen.  
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Appendix I 
 
The orgabat testbattery 
The study of cognitive functions has become a major topic in psychiatry for at least two 
reasons. First, psychomotor and cognitive disturbances are important symptoms in many 
neuropsychLDWULFGLVRUGHUVVXFKDV$O]KHLPHU¶VGLVHDVH0DUFRV3DUNLQVRQ¶VGLVHDVH
(Basset 2005), schizophrenia (Andreasen 1999; Wagner et al. 2005) and depression (Steffens 
2006; Mayberg 2000; Sobin and Sackheim 1997). Secondly, substantial psychomotor and 
cognitive changes may occur during treatment with antipsychotic (Stip, 2000; Green, 1996), 
antidepressant (Sobin & Sackeim, 1997), sedative, hypnotic and anti-anxiety therapeutic 
agents (Curran et al. 1991), or with anti-Alzheimer drugs (Lane 2004).  Most older central 
nervous system (CNS) drugs are know to have negative side effects on cognition due to for 
example sedation or memory impairments and one of the targets in drug development is to 
produce drugs without such impact on cognition. Therefore it is logical to test new drugs in 
early phases for their effects on cognitive performance (Wesnes, 2000).  
Organon in collaboration with Nijmeegs Institute of Cognition and Information 
(NICI), Klingental Drug Development Consultancy in Basel (KDDC) and Kikosoftware 
developed a cognitive screening testbattery named Orgabat, which was added as a standard 
phase I measure to the vital signs, laboratory parameters and pharmaco-EEG. The tests 
comprising this battery were selected from those tests, described in the literature to be 
sensitive to drug effects and to give abnormal results in conditions like depression and 
schizophrenia. The Orgabat includes routine functional tests of attention, concentration, 
reaction speed, learning, memory, problem solving, planning and several other aspects of 
neuropsychological functioning, for an overview of the specific tests see Table 1, a more 
extensive explanation of all tests is offered below.  
Although the Orgabat psychometric test battery had frequently been used at Organon 
in Phase I studies with novel psychotropic agents, the data could not be evaluated properly 
and their value for the rest of the drug development process is difficult to judge, since data for 
reference pharmacologic and therapeutic agents were still lacking. That is why the Orgabat 
project was setup: to validate this cognitive screening testbattery.  
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Tabel 1: Overview of Orgabat tests  
Test name Short testdescription Part of study 
Memory   
VMT Verbal memory  I, II, III 
PMT Visual memory I, II, III 
SDRT Short term memory I, II, III 
Mazes  Procedural memory III 
N-back Working memory III 
Information processing  
SDST Visual scanning, psychomotor speed, attention I, II, III 
CTMT A/B Visual scanning, psychomotor speed, divided attention I, II, III 
Visuospatial   
Tangle Visual scanning, visuospatial abilities I, II, III 
Pursuit 1 Psychomotor speed, visuo-motor coordination, attention I, II, III 
Pursuit 2 Psychomotor speed, visuo-motor coordination, attention, 
action monitoring and adaptation abilities 
I, II, III 
Psychomotor   
Point Visuo-motor coordination, attention I, II, III 
Line cop Psychomotor speed I, II, III 
Fig cop Psychomotor speed, working memory I, II, III 
Fitts Psychomotor speed, visuo-motor coordination, attention I, II 
Track Visuo-motor coordination, attention, visual scanning I, II 
VMT = verbal memory test, PMT = picture memory test, SDRT = symbol digit recall test: stm = short term 
memory ltm = long term memory, Mazes = maze learning task 1-3 is trials 1 through 3 and 4 is a new maze, 
SDST = symbol digit substitution test: n = number correct, mt = matching times, wt = writing times, CTMT = 
continuous trail making test: n = number correct, e = errors. Tangle = Tangled lines task, Pursuit = rotor pursuit 
task, 1 = without acceleration and 2 = with acceleration, n = number of rotations, t = mean time to complete a 
rotation. Point = hold pen still above point task. Line cop = line copying task: it = initiation times. Fig cop = 
Figure copying task. Fitts = Fitts task: n= number of lines completed, e = errors. Track = track a ball through a 
maze without touching walls - task. 
 
 
Verbal memory test (VMT) 
Contrary to the classical Auditory Verbal Learning Test (1974) on which it was founded, our 
VMT consisted of 18 words instead of the original 15 words to prevent ceiling effects. The 
words were read out to the participants three times with the instruction to memorize as many 
words as possible each time. Under normal circumstances an increasing number of words will 
be recalled after each presentation. The participants were asked to recite the words they could 
recollect immediately following each presentation (immediate recall) and after an interval of 
20 minutes (delayed recall). Immediately following the delayed-recall condition a list of 36 
words was read out from which they were asked to identify the 18 words of the test list (word 
recognition). The other 18 words were distracters that resembled the correct words 
semantically or phonologically. The outcome measures for the five separate recall conditions 
were the number of correctly recollected words.  
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Picture Memory Task  
Visual memory or picture memory, has been used widely as a measure of both immediate and 
delayed recall for the detection of cognitive changes in a wide range of conditions. The 
picture memory task used in this study (for an example, see Figure 1) was modeled after a 
task Petrides and Milner (1982) developed for the detection and localization of brain damage. 
That visual memory tests are also sensitive for drug effects has been shown by numerous 
studies (Peretti et al. 1997; Rammsayer et al. 2000; Robbins et al. 1997).  
In the first part of our test (immediate visual recognition) the participants were shown a 
matrix of 16 abstract pictographs or symbols that they were instructed to memorize. Next, 
they were presented with a matrix of 48 symbols from which they needed to identify the 16 
original designs by pointing them out. The second part of the test started with the presentation 
of another matrix of 48 symbols, containing the earlier correctly remembered symbols. The 
participants were again asked to commit these designs to memory. They were subsequently 
asked to pick out the correctly identified symbols, but now only one at the time from several 
matrixes: after each choice the matrix was scrambled (using the same symbols) after which 
they had to point out the next correct symbol. The test ended when all symbols had been 
recognized or when two consecutive mistakes had been made. With this test visual 
recognition and self-ordered retrieval were evaluated and the outcome measures of both test 
components were the number of correct responses. 
 
SDRT 
The SDRT is based on the extended procedure of the Symbol Digit Substitution Test (SDST) 
- which will be discussed in the last paragraph of this section -  as developed by Kaplan et al 
(1991) to measure incidental learning and follows directly after the SDST. In the present 
study it was used to assess short-term memory. As soon as the participants had completed the 
SDST they were again presented with the same symbols from the SDST, now shown one at 
the time, and asked to point out the corresponding numbers (short-term memory or STM, or 
after a longer interval: long-term memory or LTM). The outcome measures are the number of 
correctly identified symbols and the response times. 
 
Maze learning task  
To study the effect of glutaminergic modulation on motor learning we used the Maze learning 
task developed by Van Mier et al (1993). 
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In several studies (among which a PET study) it was shown that the maze task assesses motor 
learning unaided by sight (van Mier et al. 1998; Wezenberg et al. 2005). The mazes (for an 
example, see Figure 2) are cut-out structures, creating an enclosed path for the pen to traverse. 
Each maze design has a 0.5-cm wide and 0.15-cm deep path with a total length of 24 cm that 
consists of 8 segments. To simplify decision-making, the maze features straight stretches with 
90-degree turns. At each intersection subjects need to choose between two opposite 
directions, one of which leads to a dead end after 0.5 cm. The maze forms a closed loop, i.e. 
start and end points are the same. We used four comparable versions and a practice maze in 
the shape of a square. The participants were instructed to close their eyes and find their way 
through the maze and make as many loops as possible within two minutes. During the first 30 
seconds they were presented with the practice maze after which they performed three trials 
with the actual maze followed by a trial with what they had been told was a new maze. This 
latter maze was effectively a rotated version of the original. The procedure was adopted to 
control for a general increase in motor-speed that might otherwise have masked signs of 
improved motor skill. The outcome measure ZDVµWKHQXPEHURIFRPSOHWHGORRSV¶ZLWKLQWZR
minutes. 
 
N-back task  
To evaluate working memory an N-back task was chosen, a task widely used in schizophrenia 
research for the detection of deficits in working memory (Meyer-Lindenberg et al. 2001; 
Weinberger et al. 1996). In the present version the participants were presented with a sheet of 
paper depicting a start circle and six potential target circles that surround the start circle. As 
soon as a stimulus target circle appeared on the computer monitor, the participants needed to 
draw a line from the start circle towards and ending inside the corresponding target circle. In 
the 1-back condition, they had to respond to the stimulus that was presented in the previous 
trial and in the 2-back condition to the stimulus that was presented two trials before. Both 
conditions were performed twice and lasted a maximum of 2 minutes after which the number 
of correct trials was counted. Alternatively, the condition ended as soon as the participant had 
produced 25 correcWWULDOV7KHRXWFRPHPHDVXUHLVµPRYHPHQWWLPHWRUHDFKWDUJHW¶ZKLFKLV
faster when working memory is enhanced and slower when it is impaired. The measure 
µGLVWDQFHFRYHUHGWRUHDFKWDUJHW¶ZDVDGGHGDVDFRQWUROYDULDEOHEHFDXVHPRYHPHQWWLPHLV
dependent on the distance covered.  
 
Symbol Digit Substitution Test (SDST)  
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The SDST is a modification of the subtest from the WAIS (Wechsler Adult Intelligence 
Scale;(Wechsler 1981). Subjects have to substitute symbols for the digits 1-9 on the basis of a 
given key. The outcome measure is the total number of correct digits completed in 90 
seconds.  
According to Hege et al (1997) and Lezak (1995) the test measures a multitude of cognitive 
components among which visuospatial scanning, intermediate memory, perceptual motor 
speed and speed of cognitive processing. In an attempt to disentangle these cognitive 
components we conducted additional analyses of the output data. Based on pen pressure, 
movement trajectories were defined as either pen-up or pen-down periods to allow the 
computation of matching times and movement (writing) times. For the motor component, the 
mean writing times were calculated and for the more cognitive component the mean matching 
times were derived. For more details of the method of analysis we refer to earlier publications 
(Jogems-Kosterman et al. 2001; Sabbe et al. 1999; van Hoof et al. 1998; Wezenberg et al. 
2005). 
 
Continuous Trail Making Test (CTMT)  
7KH&707ZDVGHYHORSEDVHGRQ5HLWDQ¶V5HLWDQWUDLOPDNLQJWHVW3DUW$WKH
simplest section of the test, is used to measure visual scanning, motor speed and agility while 
the more complex part B assesses executive performance, i.e. set-shifting, working memory 
and divided attention. Numerous studies have proven the test to be sensitive to various 
neuropsychiatric conditions, e.g. schizophrenia (Lezak 1995; Reitan and Wolfson 1995). 
In Part A subjects have to connect as many letters in alphabetical order as they can in 120 
seconds. In Part B, they have to connect as many numbers to their corresponding letters in the 
alphabet by alternating between the two sequences, for example 1A2B etc, in 120 seconds. 
7KHRXWFRPHPHDVXUHVDUHµWRWDOQXPEHUFRQQHFWHG¶µWRWDOQXPEHURIHUURUV¶DQGµW\SHRI
HUURUV¶,QSDUW%RQHFDQHUURQHRXVO\FRQQHFWQumbers to numbers or letters to letters 
(NNLL) instead of numbers to letters. One can also commit so-called switching errors by 
connecting the numbers to the wrong letters or letters to the wrong numbers by connecting 
numbers to letters or vice versa in the wrong order, for example 1B2C  instead of 1A2B 
(NLLN). 
 
Tangle  
The tangle task is a purely visual task requiring high concentration. Subjects are instructed to 
visually track a particular line that winds through two to four other lines. Our test was 
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modHOHGDIWHUWKHYLVXDOL]DWLRQWHVWIURPWKHµNLWIRUIDFWRU-UHIHUHQFHGFRJQLWLYHWHVWV¶GHYLVHG
by French and Ekstrom (Ekstrom et al. 1976; French 1954). It was selected by the US NAVY 
to study environmental and other time-course effects and has good task stability and 
reliability (Bittner et al. 1983; Bittner et al. 1986). The tangled lines were presented on the 
laptop screen. The target line was indicated by a yellow square. On subsequent trials the 
tangles increased in complexity: they increased in length and included more 90-degree turns. 
The paper form depicted a start area and five target areas (numbered 1 to 5), which reflected 
the potential maximum target areas on the screen. The outcome measure is the number of 
correct trials within two minutes. 
 
Pursuit task 1 
For this continuous motor task we used a computerized version of the classical rotary pursuit 
task (Ammons 1947; Siegel 1990). Subjects had to track the movements of a large target 
stimulus that followed a spatially predictable circular path across the computer screen with a 
cursor by moving the pen across an XY-tablet. The pursuit-1 outcome measure was 
percentage of time on target.  
 
Pursuit task 2  
In this second pursuit task, whose format was identical to that of pursuit task 1, attention load 
was manipulated in that the target speed gradually increased when the cursor was kept within 
the confines of the target and rapidly slowed down again when it was not. The pursuit-2 
outcome measure was the total number of rotations.  
This task can be used for measuring implicit procedural learning as well. The outcome 
PHDVXUHVIRUSURFHGXUDOOHDUQLQJLVµ7LPHSHUORRS¶LHRQHGHJUHHWUDFNLQJRIWKHWDUJHW
for the first 5 loops.  
 
Pointing task 
In this simple motor-coordination test subjects have to hold a normally shaped, electronic 
ballpoint pen closely above a target dot on a sheet of paper that is placed on a digitizer and to 
WU\QRWWRPRYHWKHSHQIRUVHFRQGV:HXVHGWKLVµKDQG-VWDELOLW\¶WHVWZKLFKVRPHZKDW
resembles the body sway test that measures overall postural stability  (McClelland 1989), to 
FRQWUDVWWKHVXEMHFWV¶PRWRUFRRUGLQDWLRQWRWKHLUSHUIRUPDQFHRQWKHPRUHFRPSOH[SXUVXLW
tasks (see below). The pointing-WDVNRXWFRPHPHDVXUHLVWKHSHQ¶VPHGLDQGLVWDQFHWRWKH
target point. 
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Tracking task 
We based our eye-hand co-ordination test on a maze task that was shown to be sensitive to 
drug effects (MeyerLindenberg et al. 1997). The subject has to move a cursor along a curved 
path up to its end without touching the borders. If a border is touched, the trial has to be 
repeated. The level of difficulty is increased in that in consecutive trials the path becomes 
narrower and the number of curves rises. The tracking-task outcome measure is the number of 
mazes completed. 
 
Line copying task 
Subjects have to copy lines presented on a screen, as fast as possible on a piece of paper. The 
lines disappear of the screen as soon as the pen is put on the paper. There are straight lines in 
four different directions (vertical, horizontal, oblique to the left and oblique to the right), all 
are presented six times in a fixed random order. 
 
Figure copying task (FCT) 
The task requires subjects to copy 20 patterns containing two, three or four line segments that 
are presented in a fixed random order on a computer screen in the designated, preprinted 
boxes on a form sitting on the digitizer. They start the trial by putting the pen in a circle 
printed below and left of the relevant box. The stimulus patterns disappear as soon as the pen 
is put on the paper. Subjects end the trial by putting the pen in a circle printed above and right 
of the relevant box. The FCT outcome measures are the time taken to start drawing the 
pattern, denoted as RTD (reation time pen down), i.e., the time elapsed between the moment 
the pen is lifted from the start-trial cirlce and is first placed inside de designated copy box) 
and the time taken to complete drawing the pattern, which was denoted as MT (motion time), 
i.e., the time between RTD and the moment the pen is lifted from the copy box for placement 
in the end-trial circle. 
 
)LWWV¶WDVN 
7KH)LWWV¶WDVNZHXVHG0DJLOOUHTXLUHVSUHFLVHPRWRUSODQQLQJDQGSURJUDPPLQJ7KH
centers of three open circles that are placed in a triangle have to be connected in a clock-wise 
direction. 3HUWULDOPRYHPHQWDFFXUDF\ZDVPDQLSXODWHGE\YDU\LQJWKHFLUFOHV¶GLDPHWHUV
or 1 cm) and the between-circle distance (3.5 or 7 cm), resulting in four different trials (1 = 
big target/short distance, 2 = big target/long distance, 3 = small target/long distance, 4 = small 
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WDUJHWVKRUWGLVWDQFH7ULDOGXUDWLRQZDVVHFRQGV7KHWDVN¶VRXWFRPHPHDVXUHZDVWKH
number of completed lines per trial. 
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Appendix II 
 
Table 1. Drug-placebo effects for all studies. 
 
         Chapter 3 Chapter 2 
    
Chap.4 Chap.6 Chapter 5 
 
 
 
Lor 
 
Mir 
 
Ola 
 
Hal 
 
Par 
 
D-am 
 
Far 
 
Riv 
 
Bip 
Memory          
   VMT ir *** - ns *** - ns ns ns ns ns ** - 
   VMT dr *** - ns ** - ns ns ns # - # - *** - 
   VMT rc *** - # - ns ns ns ns * - *- *- 
   PMT 1 **- ns ns ns ns ns ns *- *- 
   PMT 2 *- ns ns ns ns ns # - *- *- 
   Nback 1       ns ns *- 
   Nback 2       ns ns *- 
   SDRT stm ns *- ns ns ns *- ** + ** + # + 
   SDRT ltm       ns ns ns 
   Mazes1-3       ns *+ ns 
   Mazes4       ns *+ ns 
Information processing         
   SDST n *** - ** - ** - ns ns ns ns *+ # - 
   SDST mt ***- #- ns ns ns # - ns ns *- 
   SDST wt **- #- ** - ns # - ns ns ns ns 
   CTMT n **- ns ***- ns ns ns ns ns *- 
   CTMT e *- ns **- ns ns ns # + ns ns 
Sedation ± arousal         
   EOG rt ***- **- #- ns ns # + ns ns ns 
   EOG pv *** - *** + *** - ns *+ *** + # + ns ns 
   EOG acc **- ***- ***- ns ns ns ns ns #- 
   ERT ** - ** - *** - # - ns ns ns ns ns 
   CRT ** - ** - *** - ns ns ns ns ns ns 
   VAS alert ** - *** - ** - ns ns ** + ns ns ns 
   VAS content ns ns ns ns ns * +  # - ns 
   VAS calm ns ns ns ns ns ns  ns ns 
Visuospatial           
   Tangle ***- ns *- ns ns ns ns # + ns 
   Pursuit2n ***- ns *** - * - ns * + ns # + ns  
   Pursuit2t        ns *- 
   Pursuit1 ***- *- ***- ns ns ns    
Psychomotor          
   Point ns *- ** - ns ns # + ns ns ns 
   Line cop IT **- ns *** - ns * - ns ns ns ns 
   Fig cop IT ***- ns ***- ns ns #+ *+ ns ns 
   Fitts n lines ***- ns ns ns ns ns    
   Fitts errors      # +    
   Track      # +    
p < .001 = ***, p < .01 = **, p < .05 = *, p < .1 = #, ns = not significant. - = negative effect and + = positive 
effect compared to placebo. Lor = Lorazepam 2,5mg, mir = mirtazepine 15mg, ola = olanzapine 10mg, hal = 
haloperidol 2,5mg, par = paroxetine 20mg, d-am = d-amphetamine 15mg, far = farampator 500mg, riv =  
rivastigmine 3mg, bip = biperiden 2mg. Grey results are not reported in the chapters. Empty fields  means no 
results available. VMT = verbal memory test, PMT = picture memory test, SDRT = symbol digit recall test: stm 
= short term memory ltm = long term memory, Mazes = maze learning task 1-3 is trials 1 through 3 and 4 is a 
new maze, SDST = symbol digit substitution test: n = number correct, mt = matching times, wt = writing times, 
CTMT = continuous trail making test: n = number correct, e = errors, EOG = electro ocular gram: rt = reaction 
time, pv = peak velocity, acc = accuracy. ERT =  elementary reaction time, CRT = choice reaction time.VAS = 
visual analogue scale. Tangle = Tangled lines task, Pursuit = rotor pursuit task, 1 = without acceleration and 2 = 
with acceleration, n = number of rotations, t = mean time to complete a rotation. Point = hold pen still above 
point task. Line cop = line copying task: it = initiation times. Fig cop = Figure copying task. Fitts = Fitts task: n= 
number of lines completed, e = errors. Track = track a ball through a maze without touching walls - task. 
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Allereerst wil ik mijn promotor Wouter Hulstijn bedanken. Beste Wouter mijn wens om 
onderzoek te gaan doen ontstond tijdens het schrijven van mijn afstudeer scriptie bij jou, dank 
zij jouw enthousiasme ben ik gegrepen geraakt door het onderzoeksvirus. Ik dank je daarvoor 
en voor de kans die je me met dit project gegeven hebt. Ook dank ik je voor je toewijding en 
geduld. We hebben de afgelopen jaren vele uren samen doorgebracht met meestal 
interessante, maar soms ook pittige discussies over de interpretatie van lastige data en het 
verzinnen van nieuwe ideeën, maar ook over vele dingen die buiten dit proefschrift vallen. Ik 
heb van jou veel geleerd: zoals niet te kort door de bocht te gaan met conclusies en niet te snel 
tevreden te zijn, dat goede ideeën lang niet altijd op gewenste tijden in te plannen zijn en dat 
haast hebben, te relativeren valt.  
Mijn tweede promotor, Bernard Sabbe, wil ik ook zeker bedanken voor zijn 
medewerking aan dit proefschrift. Beste Bernard, ook al was je niet heel veel aanwezig in 
Nijmegen toch heb je op de momenten dat je er wel was, of wanneer ik je aan de telefoon 
sprak, heel veel bijgedragen aan de totstandkoming van dit proefschrift. Vaak had je doordat 
je iets meer afstand had inhoudelijk een verfrissende kijk op de relevantie van onze 
bevindingen. Misschien was je van ons allemaal inhoudelijk het beste instaat om de kennis uit 
twee werelden te verenigen: de medische en cognitief psychologische. Ook dank ik je voor je 
motiverende rol, het af en toe inzetten van je humor en je uitstekende diplomatieke 
vaardigheden wanneer de onderlinge meningsverschillen binnen onze groep hoog opliepen.  
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voor onze samenwerking aan dit proefschrift. Beste Robbert Jan, ik was in bij aanvang van 
het project erg verrast over de mate van vertrouwen dat ik van je kreeg, dat ik het allemaal 
wel zou kunnen regelen terwijl ik nog geen ervaring had op dit terrein. Jij hebt me gelukkig in 
die periode en later wel veel bijgestaan en me wegwijs gemaakt in het doen en laten van 
psychofarmacologisch onderzoek. Ook denk ik graag terug aan de vele uurtjes waarin we de 
opzet en de uitvoering van het onderzoek bespraken en later naar de data keken en de teksten 
bespraken.  
Ge Ruigt, mede-bedenker en mede-auteur van de Orgabat studies en representant van 
de sponsor: Organon. Ge, bedankt voor het geduld dat je met ons had en jouw interesse en 
toewijding aan dit project. Je hebt me in het begin veel uitgelegd over procedures rondom 
clinical trials en heel goed bijgestaan in de onze. Ik verbaasde mij in het begin over de 
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snelheid waarmee je mailtjes kon beantwoorden, maar daardoor bleek zeker jouw 
betrokkenheid bij de diverse stadia van de studies.  
Ik wil ook natuurlijk mijn DQGHUH2UJDEDWFROOHJD¶VEHGDQNHQDOVHHUVWHQDWXXUOLMN-DQ
Leijtens, als research verpleegkundige bij alle studies betrokken. Je was een vaste gezicht 
voor zowel de vrijwilligers als voor ons, een pilaar om op te leunen, relativerend en (bijna) 
altijd in goed humeur. Het was een plezier om met je samen te werken. Ik wil ook Maurits 
Nijs en Sevla Cinar als verantwoordelijke artsen op dit onderzoek bedanken. Ellen de Bruijn 
wil ik bedanken voor haar aanwezigheid en hulp in de eerste studie en voor de hulp die ze 
later meer op de achtergrond gaf, zonder jou hadden we het EEG gedeelte van deze studie niet 
voor elkaar gekregen. Ook Christopher Miller dank ik voor zijn inzet op dit project. Manuel 
Morrens bedank ik voor de plezierige samenwerking aan hoofdstuk twee van dit proefschrift. 
Ook alle stagiaires dank ik voor hun medewerking, zonder hen was het praktisch niet 
mogelijk geweest deze studies uit te voeren: Marleen van der Linden, Jolanda Janson, Miriam 
Kos en Irma van Welij van tijdens de Orgabat, maar ook stagiaires van buiten Orgabat in die 
periode: Lianne Vermeeren (eigenlijk niet zozeer mijn stagiaire, maar ik was ook betrokken 
bij haar project) en Maike van Dartel. Allemaal ontzettend bedankt voor jullie inzet op de 
diverse projecten, maar ook voor de gezelligheid toen en bij de vele etentjes en borrels die we 
hebben gehouden ter afsluiting van de onderzoeken en van jullie studies. 
Ik wil ook alle vrijwilligers die aan de drie studies hebben deelgenomen zeer hartelijk 
bedanken voor hun inzet en doorzettingsvermogen om toch maar telkens vier hele dagen mee 
te doen aan alle experimenten ondanks de (bij)werkingen van de medicijnen.  
Geen onderzoek zonder techniek en geen techniek zonder problemen. Voor de 
technische ondersteuning wil ik als eerste Peter de Jong bedanken, de programmeur van 
Orgabat, we hebben met name in het begin heel veel contact gehad om alle programmatuur 
draaiende te krijgen, te houden en te verbeteren. Voor de andere technische onderdelen in de 
Orgabat studie, zoals de EEG en EOG metingen wil ik Jan van Proosdij en Jos Wittebrood 
bedanken. Ook Armand van Oosterwijck bedank ik voor het incidenteel oplossen van 
software problemen. 
Els van Bergen, hartstikke bedankt voor je incidentele secretariële ondersteuning, 
maar vooral ook voor alle gezellige gesprekken aan het begin van iedere werkdag tijdens de 
ochtend-koffie en voor het uitzicht op de mooie bloemen die je altijd uit eigen tuin meenam. 
2RNZLOLNDOPLMQOLHYHHQJH]HOOLJHRQGHU]RHNVFROOHJD¶V noemen: Koen en Frank uit 
de eerste dagen van het onderzoek, die ook nog wel eens hebben ingevallen wanneer een arts 
van mijn onderzoek afwezig was. Later kwamen Arnt en Barbara, waarvan de laatste lange 
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tijd mijn kamergenoot was, maar daarna ook nog mijn collega op de polikliniek. Nog weer 
later kwamen Gerard, Cathelijne, Maaike, Annemarie, Pieter, Guido, Fiona, Karin en Glenn. 
Sommigen hebben direct bijgedragen aan mijn proefschrift anderen meer op indirecte wijze: 
met interessante discussies, een luisterend oor, of peptalks en gezellig samenzijn tijdens 
lunches, borrels, weekendje weg, hulp bij verhuizen en schilderen, pogingen tot relatie 
bemiddeling, noem maar op. Wetenschap is zeker geen eenzame bezigheid. Ik dank jullie 
allemaal voor jullie gezelschap, waar ik niet zonder had gekund. 
Ik wil ook Jan Buitelaar als hoofd van de afdeling en de medewerkers van de afdeling 
Psychiatrie van het UMC St Radboud en bedanken voor het bieden van een zeer prettige en 
stimulerende werkomgeving voor onderzoekers. Hierbij noem ik ook in het bijzonder Monica 
Pop-Purceleanu met wie ik in dezelfde periode met heel veel plezier aan een ander onderzoek 
heb gewerkt en van wie ik veel steun en advies heb ontvangen. 
Gelukkig bestond er ook een leven buiten het onderzoek en daarvoor dank ik mijn 
lieve vrienden en familie. Zij hebben er om beurt voor gezorgd dat ik niet mijn hele sociale 
leven heb stil gelegd en de zaken in het juiste perspectief kon blijven zien.  
 
Voor iedereen die bij mijn onderzoek betrokken was: ik ga jullie missen, maar het is tijd voor 
iets nieuws. 
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Curriculum Vitae 
 
Elke Wezenberg werd geboren op 3 februari 1977 in Kampen. In 1996 behaalde zij haar 
VWO diploma aan de Koninklijke Scholen Gemeenschap in Apeldoorn. Daarna vertrok zij 
naar Nijmegen om psychologie te gaan studeren aan de toen nog Katholieke Universiteit 
Nijmegen, de huidige Radboud Universiteit Nijmegen. Begin 2001 studeerde zij af in de 
neuro-en revalidatiepsychologie. De interesse in de psychiatrie was toen gelegd met een 
scriptie over grafische planningsproblemen bij schizofrenie onder begeleiding van Prof. dr. 
W. Hulstijn. Hierna attendeerde hij haar op een project dat aan de basis heeft gelegen van dit 
proefschrift: het Orgabat project waaraan zij de eerste maanden begon als onderzoeksassistent 
op het NICI en de jaren daarna als junior onderzoeker op de afdeling Psychiatrie van het 
UMC St. Radboud. Na afloop van dit project heeft ze drie maanden in Apeldoorn gewerkt op 
de praktijk voor persoonlijkheidsstoornissen van het toenmalige SPATIE, huidig GGNet. 
Daarna heeft zij van 2006 en 2007 als psycholoog op de polikliniek van de afdeling 
psychiatrie van het UMC St. Radboud gewerkt binnen de zorglijnen ADHD & autisme en 
depressie en dit proefschrift afgerond. Nu is zij per januari 2008 als GZ psycholoog in 
opleiding begonnen op de afdeling Angst en Stemmingsstoornissen van GGNet in Zevenaar. 
 
 





